date generated: 2020-07-13
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## heart_ctrl_vs_acetate heart_ctrl_vs_hifibre spleen_ctrl_vs_acetate
## A2M 0.4967182 -0.27091788 0.6662719
## A4GALT 1.1055218 1.99263712 1.5792346
## AAAS 2.1498692 1.07279989 1.2886140
## AACS -0.8274404 -0.00214706 -1.1333351
## AAED1 1.1657765 -1.15426628 0.9638579
## AAGAB -1.5884609 -0.96778649 0.8245435
## spleen_ctrl_vs_hifibre
## A2M 1.45975674
## A4GALT 1.70760621
## AAAS -0.83461264
## AACS -2.73557983
## AAED1 0.02403748
## AAGAB 0.33001838
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genes_in_profile | 12665 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 7247 |
num_profile_genes_not_in_sets | 5418 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Here are some metrics about the gene sets used: GMT file of genesets: ReactomePathways.gmt
Gene sets metrics | |
---|---|
num_genesets | 2400 |
num_genesets_excluded | 1088 |
num_genesets_included | 1312 |
heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | Count | |
---|---|---|---|---|---|
1 | -1 | -1 | -1 | -1 | 1554 |
2 | 1 | -1 | -1 | -1 | 713 |
3 | -1 | 1 | -1 | -1 | 536 |
4 | 1 | 1 | -1 | -1 | 1318 |
5 | -1 | -1 | 0 | -1 | 1 |
6 | -1 | -1 | 1 | -1 | 1009 |
7 | 1 | -1 | 1 | -1 | 374 |
8 | -1 | 1 | 1 | -1 | 338 |
9 | 1 | 1 | 1 | -1 | 1018 |
10 | 1 | -1 | -1 | 0 | 1 |
11 | -1 | -1 | -1 | 1 | 541 |
12 | 1 | -1 | -1 | 1 | 230 |
13 | -1 | 1 | -1 | 1 | 271 |
14 | 1 | 1 | -1 | 1 | 655 |
15 | -1 | -1 | 1 | 1 | 1276 |
16 | 1 | -1 | 1 | 1 | 475 |
17 | 1 | 0 | 1 | 1 | 1 |
18 | -1 | 1 | 1 | 1 | 647 |
19 | 0 | 1 | 1 | 1 | 1 |
20 | 1 | 1 | 1 | 1 | 1706 |
s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | Count | |
---|---|---|---|---|---|
1 | -1 | -1 | -1 | -1 | 63 |
2 | 1 | -1 | -1 | -1 | 20 |
3 | -1 | 1 | -1 | -1 | 4 |
4 | 1 | 1 | -1 | -1 | 9 |
5 | -1 | -1 | 1 | -1 | 47 |
6 | 1 | -1 | 1 | -1 | 52 |
7 | -1 | 1 | 1 | -1 | 7 |
8 | 1 | 1 | 1 | -1 | 145 |
9 | -1 | -1 | -1 | 1 | 25 |
10 | -1 | 1 | -1 | 1 | 14 |
11 | 1 | 1 | -1 | 1 | 12 |
12 | -1 | -1 | 1 | 1 | 36 |
13 | 1 | -1 | 1 | 1 | 7 |
14 | -1 | 1 | 1 | 1 | 14 |
15 | 1 | 1 | 1 | 1 | 154 |
All sets with FDR<0.05. Try hovering over the points.
Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.
Top N= 50 gene sets
set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | p.heart_ctrl_vs_acetate | p.heart_ctrl_vs_hifibre | p.spleen_ctrl_vs_acetate | p.spleen_ctrl_vs_hifibre |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Classical antibody-mediated complement activation | 10 | 6.32e-09 | 4.74e-08 | 1.500 | 0.256 | 0.6840 | 0.896 | 0.9480 | 1.61e-01 | 1.78e-04 | 9.16e-07 | 2.05e-07 |
Unwinding of DNA | 12 | 1.21e-13 | 1.89e-12 | 1.340 | 0.705 | 0.7050 | 0.864 | -0.2310 | 2.32e-05 | 2.32e-05 | 2.19e-07 | 1.66e-01 |
Creation of C4 and C2 activators | 11 | 7.68e-08 | 4.50e-07 | 1.320 | 0.265 | 0.7100 | 0.742 | 0.7940 | 1.28e-01 | 4.55e-05 | 2.02e-05 | 5.13e-06 |
Initial triggering of complement | 18 | 3.07e-11 | 3.35e-10 | 1.270 | 0.349 | 0.6920 | 0.673 | 0.7470 | 1.03e-02 | 3.71e-07 | 7.58e-07 | 4.01e-08 |
Peptide chain elongation | 55 | 3.62e-26 | 2.07e-24 | 1.140 | 0.604 | 0.5730 | 0.549 | 0.5570 | 9.17e-15 | 1.92e-13 | 1.95e-12 | 9.38e-13 |
Viral mRNA Translation | 55 | 1.21e-25 | 6.60e-24 | 1.120 | 0.613 | 0.5450 | 0.523 | 0.5620 | 3.61e-15 | 2.61e-12 | 1.90e-11 | 5.45e-13 |
DNA strand elongation | 32 | 5.30e-28 | 3.31e-26 | 1.120 | 0.542 | 0.5380 | 0.791 | -0.2110 | 1.09e-07 | 1.41e-07 | 9.12e-15 | 3.94e-02 |
Selenocysteine synthesis | 58 | 5.52e-25 | 2.90e-23 | 1.090 | 0.571 | 0.5550 | 0.508 | 0.5430 | 5.14e-14 | 2.72e-13 | 2.23e-11 | 8.89e-13 |
Eukaryotic Translation Termination | 58 | 5.66e-24 | 2.32e-22 | 1.060 | 0.561 | 0.5060 | 0.524 | 0.5260 | 1.44e-13 | 2.60e-11 | 4.96e-12 | 4.11e-12 |
Eukaryotic Translation Elongation | 59 | 9.44e-24 | 3.75e-22 | 1.050 | 0.544 | 0.5170 | 0.525 | 0.5150 | 4.99e-13 | 6.59e-12 | 3.07e-12 | 7.85e-12 |
FCGR activation | 16 | 8.32e-07 | 4.21e-06 | 1.050 | 0.253 | 0.5050 | 0.544 | 0.6970 | 8.00e-02 | 4.65e-04 | 1.65e-04 | 1.36e-06 |
Processive synthesis on the lagging strand | 15 | 4.64e-11 | 4.84e-10 | 1.030 | 0.493 | 0.5090 | 0.716 | -0.2230 | 9.38e-04 | 6.50e-04 | 1.57e-06 | 1.34e-01 |
Activation of the pre-replicative complex | 31 | 1.53e-23 | 5.27e-22 | 1.030 | 0.586 | 0.4810 | 0.613 | -0.3250 | 1.66e-08 | 3.60e-06 | 3.44e-09 | 1.76e-03 |
SRP-dependent cotranslational protein targeting to membrane | 76 | 5.08e-30 | 3.92e-28 | 1.030 | 0.481 | 0.4450 | 0.521 | 0.5940 | 4.44e-13 | 2.10e-11 | 4.03e-15 | 3.22e-19 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 65 | 4.87e-24 | 2.06e-22 | 1.010 | 0.590 | 0.5530 | 0.440 | 0.4180 | 1.97e-16 | 1.31e-14 | 8.34e-10 | 5.69e-09 |
Formation of a pool of free 40S subunits | 65 | 2.18e-24 | 9.85e-23 | 1.010 | 0.503 | 0.4680 | 0.544 | 0.4970 | 2.24e-12 | 6.76e-11 | 3.34e-14 | 4.18e-12 |
Removal of the Flap Intermediate | 14 | 6.56e-10 | 5.90e-09 | 1.010 | 0.472 | 0.4810 | 0.714 | -0.2160 | 2.23e-03 | 1.84e-03 | 3.71e-06 | 1.62e-01 |
Lagging Strand Synthesis | 20 | 2.91e-14 | 4.84e-13 | 0.991 | 0.444 | 0.4360 | 0.746 | -0.1980 | 5.95e-04 | 7.37e-04 | 7.54e-09 | 1.26e-01 |
Leading Strand Synthesis | 14 | 7.29e-10 | 6.42e-09 | 0.984 | 0.407 | 0.3960 | 0.787 | -0.1630 | 8.34e-03 | 1.03e-02 | 3.40e-07 | 2.90e-01 |
Polymerase switching | 14 | 7.29e-10 | 6.42e-09 | 0.984 | 0.407 | 0.3960 | 0.787 | -0.1630 | 8.34e-03 | 1.03e-02 | 3.40e-07 | 2.90e-01 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 60 | 9.57e-21 | 2.85e-19 | 0.969 | 0.511 | 0.4580 | 0.504 | 0.4620 | 7.36e-12 | 8.92e-10 | 1.50e-11 | 5.90e-10 |
Condensation of Prometaphase Chromosomes | 11 | 1.54e-06 | 7.54e-06 | 0.953 | 0.531 | 0.5400 | 0.475 | -0.3300 | 2.29e-03 | 1.92e-03 | 6.34e-03 | 5.83e-02 |
Mucopolysaccharidoses | 11 | 2.12e-04 | 8.01e-04 | 0.952 | -0.232 | -0.0446 | 0.647 | 0.6560 | 1.83e-01 | 7.98e-01 | 2.01e-04 | 1.64e-04 |
G1/S-Specific Transcription | 26 | 4.52e-18 | 1.10e-16 | 0.950 | 0.454 | 0.4420 | 0.637 | -0.3090 | 6.18e-05 | 9.49e-05 | 1.85e-08 | 6.43e-03 |
Cholesterol biosynthesis | 23 | 1.53e-07 | 8.41e-07 | 0.949 | -0.333 | -0.5080 | -0.487 | -0.5440 | 5.77e-03 | 2.46e-05 | 5.34e-05 | 6.35e-06 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 1.18e-07 | 6.68e-07 | 0.934 | 0.443 | 0.4350 | 0.693 | -0.0805 | 4.11e-03 | 4.82e-03 | 7.08e-06 | 6.02e-01 |
L13a-mediated translational silencing of Ceruloplasmin expression | 73 | 1.21e-23 | 4.69e-22 | 0.933 | 0.480 | 0.4290 | 0.508 | 0.4440 | 1.32e-12 | 2.46e-10 | 5.94e-14 | 5.31e-11 |
Interferon alpha/beta signaling | 45 | 2.21e-14 | 3.73e-13 | 0.927 | 0.416 | 0.6190 | 0.345 | 0.4300 | 1.39e-06 | 6.72e-13 | 6.27e-05 | 6.11e-07 |
Polo-like kinase mediated events | 15 | 3.64e-09 | 2.83e-08 | 0.916 | 0.518 | 0.3920 | 0.578 | -0.2900 | 5.17e-04 | 8.61e-03 | 1.06e-04 | 5.20e-02 |
Condensation of Prophase Chromosomes | 13 | 9.05e-08 | 5.19e-07 | 0.912 | 0.535 | 0.4260 | 0.470 | -0.3780 | 8.37e-04 | 7.79e-03 | 3.37e-03 | 1.82e-02 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 75 | 5.04e-23 | 1.69e-21 | 0.911 | 0.473 | 0.4300 | 0.489 | 0.4270 | 1.38e-12 | 1.27e-10 | 2.51e-13 | 1.66e-10 |
Establishment of Sister Chromatid Cohesion | 10 | 7.19e-05 | 2.86e-04 | 0.905 | 0.719 | 0.3460 | 0.049 | -0.4240 | 8.17e-05 | 5.83e-02 | 7.88e-01 | 2.01e-02 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 1.86e-11 | 2.14e-10 | 0.904 | 0.442 | 0.4060 | 0.663 | -0.1310 | 4.51e-04 | 1.30e-03 | 1.46e-07 | 2.98e-01 |
Mitotic Telophase/Cytokinesis | 12 | 3.06e-06 | 1.46e-05 | 0.902 | 0.676 | 0.3470 | 0.142 | -0.4650 | 5.05e-05 | 3.73e-02 | 3.93e-01 | 5.31e-03 |
Selenoamino acid metabolism | 70 | 1.38e-20 | 4.03e-19 | 0.902 | 0.468 | 0.4530 | 0.446 | 0.4350 | 1.25e-11 | 5.82e-11 | 1.07e-10 | 3.02e-10 |
Formation of the ternary complex, and subsequently, the 43S complex | 39 | 1.83e-11 | 2.13e-10 | 0.893 | 0.439 | 0.4030 | 0.519 | 0.4160 | 2.13e-06 | 1.33e-05 | 2.05e-08 | 6.84e-06 |
G0 and Early G1 | 25 | 1.09e-14 | 1.91e-13 | 0.883 | 0.465 | 0.4330 | 0.496 | -0.3600 | 5.73e-05 | 1.80e-04 | 1.77e-05 | 1.82e-03 |
Cap-dependent Translation Initiation | 81 | 1.33e-23 | 4.73e-22 | 0.882 | 0.444 | 0.4060 | 0.504 | 0.4030 | 5.18e-12 | 2.81e-10 | 4.52e-15 | 3.59e-10 |
Eukaryotic Translation Initiation | 81 | 1.33e-23 | 4.73e-22 | 0.882 | 0.444 | 0.4060 | 0.504 | 0.4030 | 5.18e-12 | 2.81e-10 | 4.52e-15 | 3.59e-10 |
HDMs demethylate histones | 21 | 1.97e-06 | 9.56e-06 | 0.876 | -0.174 | -0.4100 | -0.446 | -0.6080 | 1.68e-01 | 1.14e-03 | 3.98e-04 | 1.40e-06 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 6.72e-08 | 3.95e-07 | 0.871 | 0.479 | 0.4020 | 0.558 | -0.2380 | 1.31e-03 | 7.07e-03 | 1.84e-04 | 1.11e-01 |
LGI-ADAM interactions | 11 | 1.67e-03 | 5.38e-03 | 0.864 | -0.470 | -0.6070 | -0.391 | -0.0678 | 6.97e-03 | 4.92e-04 | 2.49e-02 | 6.97e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 4.10e-06 | 1.91e-05 | 0.855 | 0.393 | 0.4260 | 0.627 | -0.0442 | 1.09e-02 | 5.76e-03 | 4.85e-05 | 7.75e-01 |
Trafficking and processing of endosomal TLR | 11 | 1.89e-03 | 5.97e-03 | 0.853 | 0.216 | 0.1160 | 0.492 | 0.6530 | 2.15e-01 | 5.07e-01 | 4.72e-03 | 1.78e-04 |
Activation of ATR in response to replication stress | 35 | 4.75e-17 | 9.74e-16 | 0.844 | 0.488 | 0.4090 | 0.499 | -0.2390 | 5.85e-07 | 2.89e-05 | 3.21e-07 | 1.44e-02 |
Transcription of E2F targets under negative control by DREAM complex | 18 | 4.75e-09 | 3.64e-08 | 0.825 | 0.410 | 0.4040 | 0.521 | -0.2800 | 2.62e-03 | 2.98e-03 | 1.32e-04 | 3.95e-02 |
Termination of translesion DNA synthesis | 29 | 2.03e-13 | 3.00e-12 | 0.822 | 0.409 | 0.4040 | 0.560 | -0.1760 | 1.37e-04 | 1.64e-04 | 1.81e-07 | 1.01e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 46 | 2.71e-11 | 2.98e-10 | 0.806 | 0.414 | 0.3620 | 0.482 | 0.3390 | 1.20e-06 | 2.23e-05 | 1.52e-08 | 7.00e-05 |
Presynaptic depolarization and calcium channel opening | 11 | 9.75e-03 | 2.45e-02 | 0.800 | -0.224 | -0.2790 | -0.565 | -0.4390 | 1.98e-01 | 1.09e-01 | 1.17e-03 | 1.17e-02 |
Regulation of IFNA signaling | 12 | 4.92e-03 | 1.38e-02 | 0.798 | 0.287 | 0.4820 | 0.279 | 0.4940 | 8.52e-02 | 3.83e-03 | 9.42e-02 | 3.02e-03 |
set | setSize | pMANOVA | p.adjustMANOVA | s.dist | s.heart_ctrl_vs_acetate | s.heart_ctrl_vs_hifibre | s.spleen_ctrl_vs_acetate | s.spleen_ctrl_vs_hifibre | p.heart_ctrl_vs_acetate | p.heart_ctrl_vs_hifibre | p.spleen_ctrl_vs_acetate | p.spleen_ctrl_vs_hifibre |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Classical antibody-mediated complement activation | 10 | 6.32e-09 | 4.74e-08 | 1.5000 | 0.256000 | 6.84e-01 | 0.896000 | 9.48e-01 | 1.61e-01 | 1.78e-04 | 9.16e-07 | 2.05e-07 |
Unwinding of DNA | 12 | 1.21e-13 | 1.89e-12 | 1.3400 | 0.705000 | 7.05e-01 | 0.864000 | -2.31e-01 | 2.32e-05 | 2.32e-05 | 2.19e-07 | 1.66e-01 |
Creation of C4 and C2 activators | 11 | 7.68e-08 | 4.50e-07 | 1.3200 | 0.265000 | 7.10e-01 | 0.742000 | 7.94e-01 | 1.28e-01 | 4.55e-05 | 2.02e-05 | 5.13e-06 |
Initial triggering of complement | 18 | 3.07e-11 | 3.35e-10 | 1.2700 | 0.349000 | 6.92e-01 | 0.673000 | 7.47e-01 | 1.03e-02 | 3.71e-07 | 7.58e-07 | 4.01e-08 |
Peptide chain elongation | 55 | 3.62e-26 | 2.07e-24 | 1.1400 | 0.604000 | 5.73e-01 | 0.549000 | 5.57e-01 | 9.17e-15 | 1.92e-13 | 1.95e-12 | 9.38e-13 |
Viral mRNA Translation | 55 | 1.21e-25 | 6.60e-24 | 1.1200 | 0.613000 | 5.45e-01 | 0.523000 | 5.62e-01 | 3.61e-15 | 2.61e-12 | 1.90e-11 | 5.45e-13 |
DNA strand elongation | 32 | 5.30e-28 | 3.31e-26 | 1.1200 | 0.542000 | 5.38e-01 | 0.791000 | -2.11e-01 | 1.09e-07 | 1.41e-07 | 9.12e-15 | 3.94e-02 |
Selenocysteine synthesis | 58 | 5.52e-25 | 2.90e-23 | 1.0900 | 0.571000 | 5.55e-01 | 0.508000 | 5.43e-01 | 5.14e-14 | 2.72e-13 | 2.23e-11 | 8.89e-13 |
Eukaryotic Translation Termination | 58 | 5.66e-24 | 2.32e-22 | 1.0600 | 0.561000 | 5.06e-01 | 0.524000 | 5.26e-01 | 1.44e-13 | 2.60e-11 | 4.96e-12 | 4.11e-12 |
Eukaryotic Translation Elongation | 59 | 9.44e-24 | 3.75e-22 | 1.0500 | 0.544000 | 5.17e-01 | 0.525000 | 5.15e-01 | 4.99e-13 | 6.59e-12 | 3.07e-12 | 7.85e-12 |
FCGR activation | 16 | 8.32e-07 | 4.21e-06 | 1.0500 | 0.253000 | 5.05e-01 | 0.544000 | 6.97e-01 | 8.00e-02 | 4.65e-04 | 1.65e-04 | 1.36e-06 |
Processive synthesis on the lagging strand | 15 | 4.64e-11 | 4.84e-10 | 1.0300 | 0.493000 | 5.09e-01 | 0.716000 | -2.23e-01 | 9.38e-04 | 6.50e-04 | 1.57e-06 | 1.34e-01 |
Activation of the pre-replicative complex | 31 | 1.53e-23 | 5.27e-22 | 1.0300 | 0.586000 | 4.81e-01 | 0.613000 | -3.25e-01 | 1.66e-08 | 3.60e-06 | 3.44e-09 | 1.76e-03 |
SRP-dependent cotranslational protein targeting to membrane | 76 | 5.08e-30 | 3.92e-28 | 1.0300 | 0.481000 | 4.45e-01 | 0.521000 | 5.94e-01 | 4.44e-13 | 2.10e-11 | 4.03e-15 | 3.22e-19 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 65 | 4.87e-24 | 2.06e-22 | 1.0100 | 0.590000 | 5.53e-01 | 0.440000 | 4.18e-01 | 1.97e-16 | 1.31e-14 | 8.34e-10 | 5.69e-09 |
Formation of a pool of free 40S subunits | 65 | 2.18e-24 | 9.85e-23 | 1.0100 | 0.503000 | 4.68e-01 | 0.544000 | 4.97e-01 | 2.24e-12 | 6.76e-11 | 3.34e-14 | 4.18e-12 |
Removal of the Flap Intermediate | 14 | 6.56e-10 | 5.90e-09 | 1.0100 | 0.472000 | 4.81e-01 | 0.714000 | -2.16e-01 | 2.23e-03 | 1.84e-03 | 3.71e-06 | 1.62e-01 |
Lagging Strand Synthesis | 20 | 2.91e-14 | 4.84e-13 | 0.9910 | 0.444000 | 4.36e-01 | 0.746000 | -1.98e-01 | 5.95e-04 | 7.37e-04 | 7.54e-09 | 1.26e-01 |
Leading Strand Synthesis | 14 | 7.29e-10 | 6.42e-09 | 0.9840 | 0.407000 | 3.96e-01 | 0.787000 | -1.63e-01 | 8.34e-03 | 1.03e-02 | 3.40e-07 | 2.90e-01 |
Polymerase switching | 14 | 7.29e-10 | 6.42e-09 | 0.9840 | 0.407000 | 3.96e-01 | 0.787000 | -1.63e-01 | 8.34e-03 | 1.03e-02 | 3.40e-07 | 2.90e-01 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 60 | 9.57e-21 | 2.85e-19 | 0.9690 | 0.511000 | 4.58e-01 | 0.504000 | 4.62e-01 | 7.36e-12 | 8.92e-10 | 1.50e-11 | 5.90e-10 |
Condensation of Prometaphase Chromosomes | 11 | 1.54e-06 | 7.54e-06 | 0.9530 | 0.531000 | 5.40e-01 | 0.475000 | -3.30e-01 | 2.29e-03 | 1.92e-03 | 6.34e-03 | 5.83e-02 |
Mucopolysaccharidoses | 11 | 2.12e-04 | 8.01e-04 | 0.9520 | -0.232000 | -4.46e-02 | 0.647000 | 6.56e-01 | 1.83e-01 | 7.98e-01 | 2.01e-04 | 1.64e-04 |
G1/S-Specific Transcription | 26 | 4.52e-18 | 1.10e-16 | 0.9500 | 0.454000 | 4.42e-01 | 0.637000 | -3.09e-01 | 6.18e-05 | 9.49e-05 | 1.85e-08 | 6.43e-03 |
Cholesterol biosynthesis | 23 | 1.53e-07 | 8.41e-07 | 0.9490 | -0.333000 | -5.08e-01 | -0.487000 | -5.44e-01 | 5.77e-03 | 2.46e-05 | 5.34e-05 | 6.35e-06 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 14 | 1.18e-07 | 6.68e-07 | 0.9340 | 0.443000 | 4.35e-01 | 0.693000 | -8.05e-02 | 4.11e-03 | 4.82e-03 | 7.08e-06 | 6.02e-01 |
L13a-mediated translational silencing of Ceruloplasmin expression | 73 | 1.21e-23 | 4.69e-22 | 0.9330 | 0.480000 | 4.29e-01 | 0.508000 | 4.44e-01 | 1.32e-12 | 2.46e-10 | 5.94e-14 | 5.31e-11 |
Interferon alpha/beta signaling | 45 | 2.21e-14 | 3.73e-13 | 0.9270 | 0.416000 | 6.19e-01 | 0.345000 | 4.30e-01 | 1.39e-06 | 6.72e-13 | 6.27e-05 | 6.11e-07 |
Polo-like kinase mediated events | 15 | 3.64e-09 | 2.83e-08 | 0.9160 | 0.518000 | 3.92e-01 | 0.578000 | -2.90e-01 | 5.17e-04 | 8.61e-03 | 1.06e-04 | 5.20e-02 |
Condensation of Prophase Chromosomes | 13 | 9.05e-08 | 5.19e-07 | 0.9120 | 0.535000 | 4.26e-01 | 0.470000 | -3.78e-01 | 8.37e-04 | 7.79e-03 | 3.37e-03 | 1.82e-02 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 75 | 5.04e-23 | 1.69e-21 | 0.9110 | 0.473000 | 4.30e-01 | 0.489000 | 4.27e-01 | 1.38e-12 | 1.27e-10 | 2.51e-13 | 1.66e-10 |
Establishment of Sister Chromatid Cohesion | 10 | 7.19e-05 | 2.86e-04 | 0.9050 | 0.719000 | 3.46e-01 | 0.049000 | -4.24e-01 | 8.17e-05 | 5.83e-02 | 7.88e-01 | 2.01e-02 |
PCNA-Dependent Long Patch Base Excision Repair | 21 | 1.86e-11 | 2.14e-10 | 0.9040 | 0.442000 | 4.06e-01 | 0.663000 | -1.31e-01 | 4.51e-04 | 1.30e-03 | 1.46e-07 | 2.98e-01 |
Mitotic Telophase/Cytokinesis | 12 | 3.06e-06 | 1.46e-05 | 0.9020 | 0.676000 | 3.47e-01 | 0.142000 | -4.65e-01 | 5.05e-05 | 3.73e-02 | 3.93e-01 | 5.31e-03 |
Selenoamino acid metabolism | 70 | 1.38e-20 | 4.03e-19 | 0.9020 | 0.468000 | 4.53e-01 | 0.446000 | 4.35e-01 | 1.25e-11 | 5.82e-11 | 1.07e-10 | 3.02e-10 |
Formation of the ternary complex, and subsequently, the 43S complex | 39 | 1.83e-11 | 2.13e-10 | 0.8930 | 0.439000 | 4.03e-01 | 0.519000 | 4.16e-01 | 2.13e-06 | 1.33e-05 | 2.05e-08 | 6.84e-06 |
G0 and Early G1 | 25 | 1.09e-14 | 1.91e-13 | 0.8830 | 0.465000 | 4.33e-01 | 0.496000 | -3.60e-01 | 5.73e-05 | 1.80e-04 | 1.77e-05 | 1.82e-03 |
Cap-dependent Translation Initiation | 81 | 1.33e-23 | 4.73e-22 | 0.8820 | 0.444000 | 4.06e-01 | 0.504000 | 4.03e-01 | 5.18e-12 | 2.81e-10 | 4.52e-15 | 3.59e-10 |
Eukaryotic Translation Initiation | 81 | 1.33e-23 | 4.73e-22 | 0.8820 | 0.444000 | 4.06e-01 | 0.504000 | 4.03e-01 | 5.18e-12 | 2.81e-10 | 4.52e-15 | 3.59e-10 |
HDMs demethylate histones | 21 | 1.97e-06 | 9.56e-06 | 0.8760 | -0.174000 | -4.10e-01 | -0.446000 | -6.08e-01 | 1.68e-01 | 1.14e-03 | 3.98e-04 | 1.40e-06 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 6.72e-08 | 3.95e-07 | 0.8710 | 0.479000 | 4.02e-01 | 0.558000 | -2.38e-01 | 1.31e-03 | 7.07e-03 | 1.84e-04 | 1.11e-01 |
LGI-ADAM interactions | 11 | 1.67e-03 | 5.38e-03 | 0.8640 | -0.470000 | -6.07e-01 | -0.391000 | -6.78e-02 | 6.97e-03 | 4.92e-04 | 2.49e-02 | 6.97e-01 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 14 | 4.10e-06 | 1.91e-05 | 0.8550 | 0.393000 | 4.26e-01 | 0.627000 | -4.42e-02 | 1.09e-02 | 5.76e-03 | 4.85e-05 | 7.75e-01 |
Trafficking and processing of endosomal TLR | 11 | 1.89e-03 | 5.97e-03 | 0.8530 | 0.216000 | 1.16e-01 | 0.492000 | 6.53e-01 | 2.15e-01 | 5.07e-01 | 4.72e-03 | 1.78e-04 |
Activation of ATR in response to replication stress | 35 | 4.75e-17 | 9.74e-16 | 0.8440 | 0.488000 | 4.09e-01 | 0.499000 | -2.39e-01 | 5.85e-07 | 2.89e-05 | 3.21e-07 | 1.44e-02 |
Transcription of E2F targets under negative control by DREAM complex | 18 | 4.75e-09 | 3.64e-08 | 0.8250 | 0.410000 | 4.04e-01 | 0.521000 | -2.80e-01 | 2.62e-03 | 2.98e-03 | 1.32e-04 | 3.95e-02 |
Termination of translesion DNA synthesis | 29 | 2.03e-13 | 3.00e-12 | 0.8220 | 0.409000 | 4.04e-01 | 0.560000 | -1.76e-01 | 1.37e-04 | 1.64e-04 | 1.81e-07 | 1.01e-01 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 46 | 2.71e-11 | 2.98e-10 | 0.8060 | 0.414000 | 3.62e-01 | 0.482000 | 3.39e-01 | 1.20e-06 | 2.23e-05 | 1.52e-08 | 7.00e-05 |
Presynaptic depolarization and calcium channel opening | 11 | 9.75e-03 | 2.45e-02 | 0.8000 | -0.224000 | -2.79e-01 | -0.565000 | -4.39e-01 | 1.98e-01 | 1.09e-01 | 1.17e-03 | 1.17e-02 |
Regulation of IFNA signaling | 12 | 4.92e-03 | 1.38e-02 | 0.7980 | 0.287000 | 4.82e-01 | 0.279000 | 4.94e-01 | 8.52e-02 | 3.83e-03 | 9.42e-02 | 3.02e-03 |
Mismatch Repair | 15 | 2.83e-06 | 1.36e-05 | 0.7980 | 0.358000 | 3.81e-01 | 0.594000 | -1.06e-01 | 1.65e-02 | 1.07e-02 | 6.89e-05 | 4.77e-01 |
Translation initiation complex formation | 45 | 9.41e-11 | 9.73e-10 | 0.7970 | 0.402000 | 3.48e-01 | 0.478000 | 3.52e-01 | 3.02e-06 | 5.52e-05 | 2.96e-08 | 4.47e-05 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 23 | 2.78e-10 | 2.70e-09 | 0.7960 | 0.380000 | 3.53e-01 | 0.582000 | -1.62e-01 | 1.63e-03 | 3.38e-03 | 1.38e-06 | 1.79e-01 |
Phosphorylation of CD3 and TCR zeta chains | 11 | 1.39e-03 | 4.54e-03 | 0.7900 | 0.374000 | 6.30e-01 | -0.295000 | -1.66e-02 | 3.17e-02 | 2.95e-04 | 8.99e-02 | 9.24e-01 |
Ribosomal scanning and start codon recognition | 46 | 1.11e-10 | 1.13e-09 | 0.7850 | 0.413000 | 3.55e-01 | 0.461000 | 3.29e-01 | 1.28e-06 | 3.20e-05 | 6.55e-08 | 1.13e-04 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 24 | 2.46e-10 | 2.41e-09 | 0.7830 | 0.379000 | 3.19e-01 | 0.592000 | -1.34e-01 | 1.32e-03 | 6.86e-03 | 5.19e-07 | 2.58e-01 |
DNA Replication Pre-Initiation | 77 | 6.37e-29 | 4.64e-27 | 0.7810 | 0.366000 | 3.53e-01 | 0.592000 | -1.68e-02 | 2.79e-08 | 8.81e-08 | 2.55e-19 | 7.99e-01 |
Recognition of DNA damage by PCNA-containing replication complex | 28 | 2.13e-12 | 2.72e-11 | 0.7750 | 0.459000 | 2.74e-01 | 0.528000 | -1.91e-01 | 2.67e-05 | 1.22e-02 | 1.33e-06 | 8.08e-02 |
E2F mediated regulation of DNA replication | 20 | 1.21e-09 | 1.02e-08 | 0.7730 | 0.408000 | 2.11e-01 | 0.587000 | -2.03e-01 | 1.60e-03 | 1.03e-01 | 5.41e-06 | 1.17e-01 |
Phase 2 - plateau phase | 16 | 5.28e-04 | 1.84e-03 | 0.7720 | -0.247000 | -2.85e-01 | -0.597000 | -3.13e-01 | 8.73e-02 | 4.83e-02 | 3.59e-05 | 3.03e-02 |
Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 12 | 1.51e-06 | 7.47e-06 | 0.7700 | 0.286000 | 1.11e-01 | 0.663000 | -2.42e-01 | 8.67e-02 | 5.04e-01 | 7.00e-05 | 1.46e-01 |
Orc1 removal from chromatin | 63 | 9.26e-20 | 2.59e-18 | 0.7660 | 0.358000 | 3.59e-01 | 0.570000 | 7.18e-02 | 9.23e-07 | 8.48e-07 | 5.25e-15 | 3.25e-01 |
Striated Muscle Contraction | 28 | 7.73e-09 | 5.66e-08 | 0.7600 | -0.039100 | 1.88e-01 | -0.615000 | -4.03e-01 | 7.21e-01 | 8.54e-02 | 1.78e-08 | 2.23e-04 |
Assembly of the pre-replicative complex | 61 | 1.62e-19 | 4.42e-18 | 0.7580 | 0.318000 | 3.31e-01 | 0.598000 | 7.61e-02 | 1.75e-05 | 7.94e-06 | 6.18e-16 | 3.05e-01 |
G1/S Transition | 119 | 4.04e-44 | 7.58e-42 | 0.7580 | 0.378000 | 3.56e-01 | 0.547000 | -7.12e-02 | 1.10e-12 | 2.01e-11 | 6.53e-25 | 1.81e-01 |
Cyclin A/B1/B2 associated events during G2/M transition | 22 | 1.84e-08 | 1.23e-07 | 0.7550 | 0.514000 | 2.89e-01 | 0.434000 | -1.81e-01 | 2.97e-05 | 1.88e-02 | 4.23e-04 | 1.42e-01 |
Cross-presentation of soluble exogenous antigens (endosomes) | 45 | 3.39e-11 | 3.67e-10 | 0.7530 | 0.256000 | 3.02e-01 | 0.584000 | 2.65e-01 | 2.98e-03 | 4.64e-04 | 1.24e-11 | 2.13e-03 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 80 | 1.30e-16 | 2.50e-15 | 0.7520 | 0.444000 | 3.88e-01 | 0.364000 | 2.94e-01 | 7.02e-12 | 1.97e-09 | 1.94e-08 | 5.78e-06 |
Nonsense-Mediated Decay (NMD) | 80 | 1.30e-16 | 2.50e-15 | 0.7520 | 0.444000 | 3.88e-01 | 0.364000 | 2.94e-01 | 7.02e-12 | 1.97e-09 | 1.94e-08 | 5.78e-06 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 21 | 3.61e-04 | 1.30e-03 | 0.7470 | -0.312000 | -3.43e-01 | -0.424000 | -4.05e-01 | 1.33e-02 | 6.57e-03 | 7.73e-04 | 1.31e-03 |
Regulation of expression of SLITs and ROBOs | 120 | 7.26e-25 | 3.67e-23 | 0.7430 | 0.362000 | 3.53e-01 | 0.438000 | 3.23e-01 | 7.89e-12 | 2.48e-11 | 1.18e-16 | 1.03e-09 |
Telomere C-strand (Lagging Strand) Synthesis | 33 | 1.27e-14 | 2.19e-13 | 0.7430 | 0.293000 | 3.52e-01 | 0.534000 | -2.38e-01 | 3.59e-03 | 4.71e-04 | 1.12e-07 | 1.79e-02 |
Activation of gene expression by SREBF (SREBP) | 41 | 1.86e-08 | 1.24e-07 | 0.7350 | -0.174000 | -3.31e-01 | -0.404000 | -4.87e-01 | 5.34e-02 | 2.43e-04 | 7.70e-06 | 6.95e-08 |
HSF1-dependent transactivation | 31 | 3.91e-06 | 1.84e-05 | 0.7340 | -0.495000 | -4.62e-01 | -0.103000 | -2.64e-01 | 1.88e-06 | 8.63e-06 | 3.19e-01 | 1.11e-02 |
Synthesis of DNA | 112 | 3.21e-38 | 3.83e-36 | 0.7260 | 0.352000 | 3.02e-01 | 0.557000 | -3.64e-02 | 1.31e-10 | 3.35e-08 | 2.13e-24 | 5.07e-01 |
DNA Replication | 119 | 1.41e-41 | 2.31e-39 | 0.7240 | 0.353000 | 2.99e-01 | 0.554000 | -5.73e-02 | 3.21e-11 | 1.82e-08 | 1.62e-25 | 2.82e-01 |
tRNA processing in the mitochondrion | 16 | 8.47e-04 | 2.87e-03 | 0.7210 | 0.105000 | 1.47e-01 | -0.527000 | -4.57e-01 | 4.67e-01 | 3.08e-01 | 2.61e-04 | 1.57e-03 |
Polymerase switching on the C-strand of the telomere | 25 | 1.14e-09 | 9.70e-09 | 0.7180 | 0.290000 | 3.55e-01 | 0.521000 | -1.86e-01 | 1.20e-02 | 2.14e-03 | 6.62e-06 | 1.08e-01 |
Mitotic G1 phase and G1/S transition | 135 | 1.37e-44 | 3.37e-42 | 0.7160 | 0.381000 | 3.45e-01 | 0.490000 | -9.15e-02 | 2.39e-14 | 4.50e-12 | 9.21e-23 | 6.72e-02 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 46 | 2.59e-11 | 2.88e-10 | 0.7070 | 0.199000 | 2.86e-01 | 0.584000 | 1.96e-01 | 1.99e-02 | 7.86e-04 | 7.44e-12 | 2.16e-02 |
p53-Independent DNA Damage Response | 46 | 2.59e-11 | 2.88e-10 | 0.7070 | 0.199000 | 2.86e-01 | 0.584000 | 1.96e-01 | 1.99e-02 | 7.86e-04 | 7.44e-12 | 2.16e-02 |
p53-Independent G1/S DNA damage checkpoint | 46 | 2.59e-11 | 2.88e-10 | 0.7070 | 0.199000 | 2.86e-01 | 0.584000 | 1.96e-01 | 1.99e-02 | 7.86e-04 | 7.44e-12 | 2.16e-02 |
CDC6 association with the ORC:origin complex | 10 | 1.34e-03 | 4.39e-03 | 0.7070 | 0.450000 | 2.48e-01 | 0.449000 | -1.83e-01 | 1.37e-02 | 1.74e-01 | 1.39e-02 | 3.16e-01 |
Metabolism of polyamines | 52 | 7.76e-12 | 9.42e-11 | 0.7040 | 0.248000 | 2.97e-01 | 0.550000 | 2.08e-01 | 1.95e-03 | 2.14e-04 | 6.88e-12 | 9.41e-03 |
Deposition of new CENPA-containing nucleosomes at the centromere | 22 | 1.27e-08 | 8.93e-08 | 0.7040 | 0.337000 | 2.24e-01 | 0.547000 | -1.80e-01 | 6.30e-03 | 6.91e-02 | 8.84e-06 | 1.44e-01 |
Nucleosome assembly | 22 | 1.27e-08 | 8.93e-08 | 0.7040 | 0.337000 | 2.24e-01 | 0.547000 | -1.80e-01 | 6.30e-03 | 6.91e-02 | 8.84e-06 | 1.44e-01 |
CDT1 association with the CDC6:ORC:origin complex | 52 | 4.35e-13 | 6.20e-12 | 0.7020 | 0.269000 | 2.70e-01 | 0.571000 | 1.49e-01 | 8.09e-04 | 7.73e-04 | 1.04e-12 | 6.37e-02 |
SCF(Skp2)-mediated degradation of p27/p21 | 52 | 4.45e-13 | 6.28e-12 | 0.7010 | 0.257000 | 3.32e-01 | 0.547000 | 1.23e-01 | 1.35e-03 | 3.45e-05 | 8.54e-12 | 1.25e-01 |
Processive synthesis on the C-strand of the telomere | 19 | 4.70e-07 | 2.46e-06 | 0.6980 | 0.283000 | 4.17e-01 | 0.402000 | -2.68e-01 | 3.30e-02 | 1.64e-03 | 2.42e-03 | 4.33e-02 |
Ubiquitin-dependent degradation of Cyclin D | 46 | 4.82e-10 | 4.46e-09 | 0.6980 | 0.212000 | 2.69e-01 | 0.557000 | 2.44e-01 | 1.29e-02 | 1.59e-03 | 6.54e-11 | 4.26e-03 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 44 | 1.03e-09 | 8.83e-09 | 0.6890 | 0.223000 | 2.71e-01 | 0.555000 | 2.11e-01 | 1.06e-02 | 1.88e-03 | 1.96e-10 | 1.54e-02 |
Glycogen storage diseases | 11 | 2.71e-02 | 5.65e-02 | 0.6870 | -0.431000 | -5.13e-01 | 0.043500 | 1.41e-01 | 1.32e-02 | 3.20e-03 | 8.03e-01 | 4.18e-01 |
Regulation of Complement cascade | 31 | 1.06e-05 | 4.75e-05 | 0.6860 | 0.239000 | 3.64e-01 | 0.254000 | 4.65e-01 | 2.12e-02 | 4.57e-04 | 1.45e-02 | 7.49e-06 |
Regulation of ornithine decarboxylase (ODC) | 46 | 1.65e-10 | 1.64e-09 | 0.6800 | 0.222000 | 2.34e-01 | 0.569000 | 1.87e-01 | 9.23e-03 | 6.05e-03 | 2.47e-11 | 2.87e-02 |
Removal of the Flap Intermediate from the C-strand | 17 | 1.23e-05 | 5.47e-05 | 0.6780 | 0.283000 | 4.36e-01 | 0.363000 | -2.41e-01 | 4.37e-02 | 1.88e-03 | 9.65e-03 | 8.49e-02 |
Vif-mediated degradation of APOBEC3G | 45 | 1.50e-09 | 1.23e-08 | 0.6780 | 0.221000 | 2.56e-01 | 0.547000 | 2.14e-01 | 1.02e-02 | 3.01e-03 | 2.21e-10 | 1.31e-02 |
Translesion synthesis by POLI | 15 | 4.53e-05 | 1.88e-04 | 0.6760 | 0.321000 | 2.50e-01 | 0.520000 | -1.46e-01 | 3.12e-02 | 9.38e-02 | 4.91e-04 | 3.28e-01 |
Negative regulation of NOTCH4 signaling | 48 | 1.36e-09 | 1.13e-08 | 0.6760 | 0.257000 | 2.87e-01 | 0.511000 | 2.16e-01 | 2.07e-03 | 5.76e-04 | 9.01e-10 | 9.76e-03 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 35 | 1.23e-11 | 1.47e-10 | 0.6730 | 0.327000 | 3.01e-01 | 0.474000 | -1.76e-01 | 8.22e-04 | 2.07e-03 | 1.21e-06 | 7.15e-02 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 12 | 9.80e-03 | 2.46e-02 | 0.6720 | 0.401000 | 4.51e-01 | 0.283000 | -9.10e-02 | 1.62e-02 | 6.85e-03 | 9.00e-02 | 5.85e-01 |
Laminin interactions | 22 | 1.74e-05 | 7.60e-05 | 0.6720 | -0.222000 | -2.85e-02 | -0.582000 | -2.51e-01 | 7.14e-02 | 8.17e-01 | 2.27e-06 | 4.16e-02 |
S Phase | 152 | 1.54e-44 | 3.37e-42 | 0.6720 | 0.366000 | 2.96e-01 | 0.474000 | -7.21e-02 | 6.93e-15 | 3.16e-10 | 6.87e-24 | 1.26e-01 |
Generation of second messenger molecules | 22 | 5.74e-06 | 2.65e-05 | 0.6720 | 0.238000 | 4.64e-01 | -0.417000 | -7.16e-02 | 5.37e-02 | 1.63e-04 | 7.12e-04 | 5.61e-01 |
Translesion synthesis by REV1 | 14 | 6.15e-05 | 2.47e-04 | 0.6710 | 0.329000 | 2.42e-01 | 0.490000 | -2.05e-01 | 3.29e-02 | 1.17e-01 | 1.49e-03 | 1.84e-01 |
Hyaluronan uptake and degradation | 11 | 4.06e-02 | 7.77e-02 | 0.6650 | 0.242000 | 2.03e-01 | 0.502000 | 3.02e-01 | 1.65e-01 | 2.44e-01 | 3.93e-03 | 8.31e-02 |
PI-3K cascade:FGFR2 | 12 | 7.19e-04 | 2.46e-03 | 0.6640 | -0.012500 | -5.60e-01 | -0.269000 | -2.35e-01 | 9.40e-01 | 7.91e-04 | 1.06e-01 | 1.58e-01 |
SCF-beta-TrCP mediated degradation of Emi1 | 49 | 3.53e-11 | 3.77e-10 | 0.6640 | 0.212000 | 2.45e-01 | 0.560000 | 1.51e-01 | 1.03e-02 | 3.02e-03 | 1.22e-11 | 6.78e-02 |
Extension of Telomeres | 48 | 2.15e-17 | 4.56e-16 | 0.6620 | 0.262000 | 3.13e-01 | 0.462000 | -2.40e-01 | 1.71e-03 | 1.75e-04 | 3.01e-08 | 4.02e-03 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 48 | 2.85e-08 | 1.81e-07 | 0.6610 | 0.285000 | 3.89e-01 | 0.183000 | 4.13e-01 | 6.46e-04 | 3.12e-06 | 2.86e-02 | 7.41e-07 |
DNA Damage Bypass | 44 | 3.35e-14 | 5.49e-13 | 0.6600 | 0.375000 | 2.63e-01 | 0.436000 | -1.91e-01 | 1.66e-05 | 2.57e-03 | 5.76e-07 | 2.87e-02 |
Translesion synthesis by POLK | 15 | 8.51e-05 | 3.34e-04 | 0.6550 | 0.333000 | 2.69e-01 | 0.456000 | -1.93e-01 | 2.54e-02 | 7.17e-02 | 2.25e-03 | 1.95e-01 |
ATF6 (ATF6-alpha) activates chaperone genes | 10 | 9.19e-05 | 3.58e-04 | 0.6540 | 0.364000 | -1.99e-01 | 0.502000 | -6.00e-02 | 4.63e-02 | 2.77e-01 | 5.96e-03 | 7.43e-01 |
Heme biosynthesis | 13 | 3.93e-05 | 1.65e-04 | 0.6520 | -0.209000 | -2.27e-01 | 0.472000 | -3.28e-01 | 1.92e-01 | 1.56e-01 | 3.24e-03 | 4.09e-02 |
Common Pathway of Fibrin Clot Formation | 10 | 1.58e-03 | 5.10e-03 | 0.6520 | 0.305000 | 2.34e-01 | -0.274000 | 4.49e-01 | 9.47e-02 | 2.00e-01 | 1.33e-01 | 1.40e-02 |
Autodegradation of the E3 ubiquitin ligase COP1 | 46 | 1.97e-09 | 1.59e-08 | 0.6510 | 0.186000 | 2.39e-01 | 0.543000 | 1.92e-01 | 2.94e-02 | 5.06e-03 | 1.84e-10 | 2.40e-02 |
rRNA processing in the mitochondrion | 17 | 3.25e-03 | 9.71e-03 | 0.6510 | 0.116000 | 6.34e-02 | -0.407000 | -4.90e-01 | 4.09e-01 | 6.51e-01 | 3.68e-03 | 4.64e-04 |
Defective CFTR causes cystic fibrosis | 52 | 2.26e-09 | 1.78e-08 | 0.6500 | 0.197000 | 2.47e-01 | 0.506000 | 2.58e-01 | 1.38e-02 | 2.04e-03 | 2.80e-10 | 1.28e-03 |
Signaling by FGFR4 in disease | 10 | 2.86e-02 | 5.88e-02 | 0.6480 | 0.147000 | -1.65e-01 | -0.351000 | -4.98e-01 | 4.23e-01 | 3.66e-01 | 5.44e-02 | 6.36e-03 |
Attenuation phase | 21 | 7.92e-04 | 2.70e-03 | 0.6460 | -0.427000 | -3.81e-01 | 0.008280 | -2.99e-01 | 7.09e-04 | 2.52e-03 | 9.48e-01 | 1.76e-02 |
Influenza Viral RNA Transcription and Replication | 96 | 1.91e-17 | 4.17e-16 | 0.6450 | 0.319000 | 2.44e-01 | 0.456000 | 2.16e-01 | 7.05e-08 | 3.71e-05 | 1.13e-14 | 2.57e-04 |
Vpu mediated degradation of CD4 | 46 | 4.91e-09 | 3.74e-08 | 0.6430 | 0.216000 | 2.52e-01 | 0.520000 | 1.79e-01 | 1.12e-02 | 3.18e-03 | 1.02e-09 | 3.55e-02 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 49 | 2.13e-09 | 1.70e-08 | 0.6400 | 0.211000 | 2.47e-01 | 0.517000 | 1.92e-01 | 1.08e-02 | 2.75e-03 | 3.75e-10 | 2.04e-02 |
cGMP effects | 12 | 1.88e-04 | 7.17e-04 | 0.6390 | -0.145000 | 9.65e-02 | -0.610000 | 7.49e-02 | 3.83e-01 | 5.63e-01 | 2.51e-04 | 6.53e-01 |
Diseases of carbohydrate metabolism | 27 | 5.72e-05 | 2.30e-04 | 0.6390 | -0.269000 | -2.18e-01 | 0.385000 | 3.74e-01 | 1.54e-02 | 5.05e-02 | 5.43e-04 | 7.72e-04 |
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | 13 | 9.49e-03 | 2.40e-02 | 0.6380 | -0.256000 | -1.82e-01 | 0.505000 | 2.30e-01 | 1.10e-01 | 2.55e-01 | 1.60e-03 | 1.50e-01 |
Signaling by FGFR3 fusions in cancer | 10 | 1.15e-02 | 2.80e-02 | 0.6380 | 0.334000 | -7.98e-02 | -0.293000 | -4.51e-01 | 6.72e-02 | 6.62e-01 | 1.09e-01 | 1.36e-02 |
P2Y receptors | 10 | 4.32e-02 | 8.18e-02 | 0.6370 | 0.416000 | 3.84e-01 | -0.109000 | 2.71e-01 | 2.29e-02 | 3.54e-02 | 5.50e-01 | 1.37e-01 |
PD-1 signaling | 10 | 2.15e-02 | 4.68e-02 | 0.6370 | 0.232000 | 4.61e-01 | -0.351000 | -1.26e-01 | 2.04e-01 | 1.16e-02 | 5.44e-02 | 4.90e-01 |
Cyclin E associated events during G1/S transition | 75 | 2.27e-16 | 4.26e-15 | 0.6360 | 0.269000 | 3.02e-01 | 0.486000 | 6.39e-02 | 5.62e-05 | 6.10e-06 | 3.32e-13 | 3.39e-01 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 54 | 1.62e-11 | 1.90e-10 | 0.6360 | 0.196000 | 2.41e-01 | 0.538000 | 1.34e-01 | 1.28e-02 | 2.19e-03 | 7.85e-12 | 8.83e-02 |
Hh mutants that don't undergo autocatalytic processing are degraded by ERAD | 48 | 7.66e-09 | 5.65e-08 | 0.6340 | 0.164000 | 2.20e-01 | 0.524000 | 2.28e-01 | 4.96e-02 | 8.55e-03 | 3.35e-10 | 6.20e-03 |
G2/M Checkpoints | 124 | 4.64e-31 | 3.81e-29 | 0.6320 | 0.314000 | 3.03e-01 | 0.455000 | -4.95e-02 | 1.58e-09 | 6.09e-09 | 2.35e-18 | 3.42e-01 |
Complement cascade | 34 | 3.42e-05 | 1.44e-04 | 0.6320 | 0.228000 | 3.54e-01 | 0.239000 | 4.05e-01 | 2.13e-02 | 3.53e-04 | 1.60e-02 | 4.33e-05 |
Cyclin A:Cdk2-associated events at S phase entry | 77 | 2.70e-17 | 5.63e-16 | 0.6320 | 0.263000 | 3.01e-01 | 0.487000 | 4.20e-02 | 6.57e-05 | 5.18e-06 | 1.47e-13 | 5.25e-01 |
Switching of origins to a post-replicative state | 83 | 2.08e-19 | 5.57e-18 | 0.6310 | 0.294000 | 2.48e-01 | 0.499000 | 3.38e-02 | 3.76e-06 | 9.49e-05 | 4.16e-15 | 5.95e-01 |
G beta:gamma signalling through BTK | 13 | 7.16e-03 | 1.91e-02 | 0.6210 | 0.021800 | 1.57e-01 | 0.159000 | 5.79e-01 | 8.92e-01 | 3.29e-01 | 3.22e-01 | 3.02e-04 |
HDR through Homologous Recombination (HRR) | 61 | 3.54e-19 | 9.10e-18 | 0.6180 | 0.288000 | 2.30e-01 | 0.454000 | -2.02e-01 | 1.03e-04 | 1.94e-03 | 8.93e-10 | 6.30e-03 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 48 | 1.43e-09 | 1.18e-08 | 0.6170 | 0.154000 | 1.96e-01 | 0.542000 | 1.59e-01 | 6.60e-02 | 1.89e-02 | 8.40e-11 | 5.64e-02 |
Hh mutants abrogate ligand secretion | 50 | 8.15e-09 | 5.91e-08 | 0.6160 | 0.156000 | 2.11e-01 | 0.514000 | 2.17e-01 | 5.62e-02 | 1.01e-02 | 3.29e-10 | 7.98e-03 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 20 | 4.00e-04 | 1.41e-03 | 0.6150 | 0.026800 | -3.42e-01 | -0.312000 | -4.04e-01 | 8.36e-01 | 8.15e-03 | 1.58e-02 | 1.75e-03 |
Effects of PIP2 hydrolysis | 22 | 1.42e-04 | 5.49e-04 | 0.6130 | -0.347000 | -5.45e-02 | -0.388000 | -3.19e-01 | 4.83e-03 | 6.58e-01 | 1.65e-03 | 9.63e-03 |
Regulation of Apoptosis | 47 | 2.98e-08 | 1.87e-07 | 0.6120 | 0.184000 | 2.03e-01 | 0.509000 | 2.01e-01 | 2.94e-02 | 1.63e-02 | 1.58e-09 | 1.71e-02 |
Prostacyclin signalling through prostacyclin receptor | 14 | 8.53e-03 | 2.19e-02 | 0.6100 | 0.031400 | 1.79e-01 | 0.188000 | 5.51e-01 | 8.39e-01 | 2.47e-01 | 2.24e-01 | 3.55e-04 |
Chromosome Maintenance | 82 | 2.48e-24 | 1.09e-22 | 0.6090 | 0.252000 | 2.55e-01 | 0.464000 | -1.66e-01 | 7.95e-05 | 6.53e-05 | 3.95e-13 | 9.54e-03 |
ER-Phagosome pathway | 69 | 7.24e-10 | 6.42e-09 | 0.6080 | 0.200000 | 2.65e-01 | 0.423000 | 2.84e-01 | 4.19e-03 | 1.43e-04 | 1.22e-09 | 4.68e-05 |
Constitutive Signaling by NOTCH1 HD Domain Mutants | 12 | 2.32e-04 | 8.69e-04 | 0.6060 | -0.452000 | 1.24e-01 | -0.323000 | -2.07e-01 | 6.74e-03 | 4.57e-01 | 5.24e-02 | 2.15e-01 |
Signaling by NOTCH1 HD Domain Mutants in Cancer | 12 | 2.32e-04 | 8.69e-04 | 0.6060 | -0.452000 | 1.24e-01 | -0.323000 | -2.07e-01 | 6.74e-03 | 4.57e-01 | 5.24e-02 | 2.15e-01 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 70 | 1.96e-14 | 3.34e-13 | 0.6040 | 0.249000 | 2.02e-01 | 0.505000 | 8.61e-02 | 3.27e-04 | 3.54e-03 | 2.69e-13 | 2.13e-01 |
Translesion Synthesis by POLH | 16 | 1.36e-05 | 6.05e-05 | 0.6040 | 0.144000 | 6.89e-02 | 0.547000 | -2.02e-01 | 3.20e-01 | 6.33e-01 | 1.52e-04 | 1.63e-01 |
Antigen processing-Cross presentation | 83 | 4.46e-11 | 4.69e-10 | 0.6040 | 0.223000 | 2.83e-01 | 0.374000 | 3.07e-01 | 4.39e-04 | 8.53e-06 | 3.94e-09 | 1.34e-06 |
Signaling by Leptin | 10 | 1.46e-01 | 2.19e-01 | 0.6010 | -0.296000 | -4.11e-01 | -0.279000 | -1.64e-01 | 1.05e-01 | 2.43e-02 | 1.27e-01 | 3.69e-01 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 24 | 1.43e-08 | 9.91e-08 | 0.6010 | 0.185000 | 1.21e-01 | 0.486000 | -2.76e-01 | 1.17e-01 | 3.07e-01 | 3.79e-05 | 1.92e-02 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 67 | 3.01e-13 | 4.39e-12 | 0.6000 | 0.237000 | 1.97e-01 | 0.504000 | 1.05e-01 | 8.08e-04 | 5.42e-03 | 9.35e-13 | 1.39e-01 |
Collagen chain trimerization | 32 | 3.87e-10 | 3.65e-09 | 0.6000 | -0.455000 | -7.76e-02 | -0.348000 | 1.63e-01 | 8.50e-06 | 4.48e-01 | 6.71e-04 | 1.12e-01 |
Diseases associated with N-glycosylation of proteins | 16 | 6.80e-03 | 1.83e-02 | 0.6000 | -0.228000 | -3.38e-01 | 0.358000 | 2.55e-01 | 1.15e-01 | 1.93e-02 | 1.32e-02 | 7.70e-02 |
FRS-mediated FGFR2 signaling | 14 | 4.67e-03 | 1.33e-02 | 0.5980 | -0.072000 | -4.80e-01 | -0.267000 | -2.26e-01 | 6.41e-01 | 1.88e-03 | 8.32e-02 | 1.43e-01 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 69 | 9.73e-14 | 1.56e-12 | 0.5980 | 0.242000 | 1.97e-01 | 0.501000 | 9.39e-02 | 5.08e-04 | 4.70e-03 | 6.35e-13 | 1.78e-01 |
Formation of Fibrin Clot (Clotting Cascade) | 17 | 3.31e-04 | 1.20e-03 | 0.5970 | 0.312000 | 2.07e-01 | -0.090200 | 4.56e-01 | 2.60e-02 | 1.39e-01 | 5.20e-01 | 1.13e-03 |
FRS-mediated FGFR4 signaling | 11 | 1.36e-02 | 3.22e-02 | 0.5960 | -0.026400 | -4.66e-01 | -0.202000 | -3.11e-01 | 8.80e-01 | 7.46e-03 | 2.46e-01 | 7.42e-02 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 66 | 1.01e-12 | 1.34e-11 | 0.5950 | 0.228000 | 1.88e-01 | 0.504000 | 1.14e-01 | 1.40e-03 | 8.46e-03 | 1.44e-12 | 1.11e-01 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 54 | 8.84e-08 | 5.09e-07 | 0.5940 | -0.108000 | -3.09e-01 | -0.320000 | -3.78e-01 | 1.69e-01 | 8.53e-05 | 4.70e-05 | 1.61e-06 |
Resolution of Sister Chromatid Cohesion | 95 | 1.18e-32 | 1.03e-30 | 0.5920 | 0.308000 | 1.18e-01 | 0.375000 | -3.18e-01 | 2.28e-07 | 4.76e-02 | 2.77e-10 | 8.77e-08 |
PI-3K cascade:FGFR3 | 10 | 4.22e-03 | 1.22e-02 | 0.5920 | 0.151000 | -4.19e-01 | -0.207000 | -3.30e-01 | 4.08e-01 | 2.19e-02 | 2.57e-01 | 7.04e-02 |
TP53 Regulates Transcription of Death Receptors and Ligands | 11 | 4.30e-02 | 8.15e-02 | 0.5900 | -0.207000 | -6.35e-02 | -0.499000 | -2.28e-01 | 2.35e-01 | 7.15e-01 | 4.15e-03 | 1.90e-01 |
Interferon gamma signaling | 63 | 8.53e-10 | 7.41e-09 | 0.5890 | 0.247000 | 3.41e-01 | 0.098400 | 4.01e-01 | 7.10e-04 | 2.95e-06 | 1.77e-01 | 3.87e-08 |
Competing endogenous RNAs (ceRNAs) regulate PTEN translation | 10 | 1.58e-01 | 2.32e-01 | 0.5880 | -0.233000 | -3.01e-01 | -0.385000 | -2.31e-01 | 2.01e-01 | 9.96e-02 | 3.53e-02 | 2.06e-01 |
Retrograde neurotrophin signalling | 13 | 2.10e-02 | 4.58e-02 | 0.5880 | -0.278000 | -1.66e-01 | 0.450000 | 1.94e-01 | 8.26e-02 | 2.99e-01 | 4.94e-03 | 2.25e-01 |
Signaling by FGFR3 in disease | 14 | 5.54e-03 | 1.54e-02 | 0.5870 | 0.166000 | -2.19e-01 | -0.304000 | -4.21e-01 | 2.83e-01 | 1.56e-01 | 4.89e-02 | 6.43e-03 |
Signaling by FGFR3 point mutants in cancer | 14 | 5.54e-03 | 1.54e-02 | 0.5870 | 0.166000 | -2.19e-01 | -0.304000 | -4.21e-01 | 2.83e-01 | 1.56e-01 | 4.89e-02 | 6.43e-03 |
Purine catabolism | 16 | 7.58e-03 | 2.01e-02 | 0.5860 | 0.114000 | 2.32e-01 | 0.499000 | 1.65e-01 | 4.30e-01 | 1.09e-01 | 5.48e-04 | 2.54e-01 |
Homologous DNA Pairing and Strand Exchange | 40 | 4.61e-12 | 5.65e-11 | 0.5850 | 0.250000 | 1.75e-01 | 0.450000 | -2.16e-01 | 6.22e-03 | 5.60e-02 | 8.62e-07 | 1.79e-02 |
Regulation of pyruvate dehydrogenase (PDH) complex | 15 | 1.11e-02 | 2.72e-02 | 0.5850 | -0.021600 | -3.48e-01 | -0.302000 | -3.60e-01 | 8.85e-01 | 1.96e-02 | 4.30e-02 | 1.59e-02 |
Presynaptic phase of homologous DNA pairing and strand exchange | 37 | 2.43e-10 | 2.40e-09 | 0.5840 | 0.273000 | 2.04e-01 | 0.432000 | -1.94e-01 | 4.02e-03 | 3.21e-02 | 5.40e-06 | 4.15e-02 |
Regulation of APC/C activators between G1/S and early anaphase | 74 | 3.26e-15 | 5.93e-14 | 0.5840 | 0.243000 | 1.92e-01 | 0.492000 | 4.80e-02 | 3.06e-04 | 4.27e-03 | 2.50e-13 | 4.76e-01 |
Stabilization of p53 | 50 | 2.50e-08 | 1.61e-07 | 0.5830 | 0.204000 | 2.35e-01 | 0.473000 | 1.40e-01 | 1.25e-02 | 4.03e-03 | 7.51e-09 | 8.69e-02 |
APC/C-mediated degradation of cell cycle proteins | 81 | 9.79e-18 | 2.22e-16 | 0.5830 | 0.245000 | 1.94e-01 | 0.492000 | 1.08e-02 | 1.40e-04 | 2.59e-03 | 2.00e-14 | 8.66e-01 |
Regulation of mitotic cell cycle | 81 | 9.79e-18 | 2.22e-16 | 0.5830 | 0.245000 | 1.94e-01 | 0.492000 | 1.08e-02 | 1.40e-04 | 2.59e-03 | 2.00e-14 | 8.66e-01 |
Telomere Maintenance | 62 | 1.05e-16 | 2.12e-15 | 0.5830 | 0.222000 | 2.63e-01 | 0.443000 | -1.58e-01 | 2.49e-03 | 3.42e-04 | 1.70e-09 | 3.16e-02 |
Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 10 | 3.34e-03 | 9.94e-03 | 0.5810 | -0.201000 | -1.88e-01 | 0.356000 | -3.66e-01 | 2.72e-01 | 3.03e-01 | 5.10e-02 | 4.48e-02 |
Influenza Infection | 112 | 3.44e-18 | 8.53e-17 | 0.5800 | 0.310000 | 2.04e-01 | 0.421000 | 1.49e-01 | 1.52e-08 | 2.03e-04 | 1.56e-14 | 6.55e-03 |
Translation | 230 | 3.88e-33 | 3.63e-31 | 0.5780 | 0.139000 | 1.07e-01 | 0.453000 | 3.13e-01 | 3.08e-04 | 5.48e-03 | 2.95e-32 | 3.29e-16 |
Autodegradation of Cdh1 by Cdh1:APC/C | 58 | 4.99e-10 | 4.58e-09 | 0.5740 | 0.164000 | 1.61e-01 | 0.505000 | 1.50e-01 | 3.14e-02 | 3.42e-02 | 3.00e-11 | 4.83e-02 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 89 | 1.26e-22 | 4.15e-21 | 0.5740 | 0.307000 | 2.29e-01 | 0.388000 | -1.78e-01 | 5.64e-07 | 1.87e-04 | 2.49e-10 | 3.68e-03 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 68 | 8.86e-13 | 1.19e-11 | 0.5710 | 0.201000 | 1.60e-01 | 0.501000 | 9.54e-02 | 4.26e-03 | 2.24e-02 | 8.97e-13 | 1.74e-01 |
Resolution of D-Loop Structures | 30 | 6.70e-09 | 4.97e-08 | 0.5690 | 0.225000 | 1.60e-01 | 0.436000 | -2.40e-01 | 3.32e-02 | 1.29e-01 | 3.58e-05 | 2.31e-02 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 83 | 3.78e-28 | 2.48e-26 | 0.5680 | 0.243000 | 7.13e-02 | 0.397000 | -3.18e-01 | 1.36e-04 | 2.62e-01 | 4.01e-10 | 5.82e-07 |
Amplification of signal from the kinetochores | 83 | 3.78e-28 | 2.48e-26 | 0.5680 | 0.243000 | 7.13e-02 | 0.397000 | -3.18e-01 | 1.36e-04 | 2.62e-01 | 4.01e-10 | 5.82e-07 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 20 | 9.04e-03 | 2.30e-02 | 0.5670 | -0.012100 | -1.35e-01 | -0.323000 | -4.46e-01 | 9.25e-01 | 2.95e-01 | 1.25e-02 | 5.48e-04 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 17 | 1.85e-05 | 8.02e-05 | 0.5660 | 0.082300 | 1.72e-01 | 0.472000 | -2.47e-01 | 5.57e-01 | 2.20e-01 | 7.47e-04 | 7.77e-02 |
ABC transporter disorders | 60 | 1.35e-08 | 9.40e-08 | 0.5660 | 0.148000 | 1.89e-01 | 0.464000 | 2.17e-01 | 4.73e-02 | 1.15e-02 | 5.09e-10 | 3.70e-03 |
CDK-mediated phosphorylation and removal of Cdc6 | 66 | 9.42e-12 | 1.13e-10 | 0.5650 | 0.208000 | 1.79e-01 | 0.484000 | 9.59e-02 | 3.49e-03 | 1.18e-02 | 1.03e-11 | 1.78e-01 |
Mitochondrial translation elongation | 85 | 1.42e-13 | 2.17e-12 | 0.5650 | -0.042900 | -4.00e-02 | 0.499000 | 2.57e-01 | 4.94e-01 | 5.25e-01 | 1.74e-15 | 4.31e-05 |
Degradation of DVL | 50 | 3.68e-08 | 2.26e-07 | 0.5640 | 0.170000 | 2.03e-01 | 0.480000 | 1.34e-01 | 3.82e-02 | 1.31e-02 | 4.47e-09 | 1.02e-01 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 29 | 2.49e-08 | 1.61e-07 | 0.5610 | 0.233000 | 1.42e-01 | 0.435000 | -2.25e-01 | 2.97e-02 | 1.85e-01 | 4.95e-05 | 3.57e-02 |
Transport of Ribonucleoproteins into the Host Nucleus | 27 | 4.12e-09 | 3.18e-08 | 0.5610 | 0.007080 | -1.72e-01 | 0.313000 | -4.33e-01 | 9.49e-01 | 1.23e-01 | 4.85e-03 | 9.99e-05 |
Mitochondrial translation termination | 85 | 2.03e-13 | 3.00e-12 | 0.5610 | -0.030300 | -4.98e-02 | 0.494000 | 2.59e-01 | 6.29e-01 | 4.28e-01 | 3.50e-15 | 3.66e-05 |
Resolution of Abasic Sites (AP sites) | 37 | 1.96e-07 | 1.06e-06 | 0.5610 | 0.183000 | 2.85e-01 | 0.447000 | -1.46e-02 | 5.40e-02 | 2.76e-03 | 2.58e-06 | 8.78e-01 |
Nuclear import of Rev protein | 28 | 8.15e-10 | 7.13e-09 | 0.5610 | 0.028300 | -1.28e-01 | 0.378000 | -3.92e-01 | 7.96e-01 | 2.42e-01 | 5.32e-04 | 3.27e-04 |
APC/C:Cdc20 mediated degradation of Securin | 62 | 4.60e-10 | 4.31e-09 | 0.5600 | 0.196000 | 1.51e-01 | 0.480000 | 1.49e-01 | 7.81e-03 | 3.94e-02 | 6.33e-11 | 4.29e-02 |
ATF6 (ATF6-alpha) activates chaperones | 12 | 3.26e-04 | 1.19e-03 | 0.5600 | 0.333000 | -1.75e-01 | 0.414000 | -2.03e-02 | 4.56e-02 | 2.93e-01 | 1.31e-02 | 9.03e-01 |
ADP signalling through P2Y purinoceptor 12 | 16 | 1.04e-02 | 2.57e-02 | 0.5590 | 0.147000 | 1.62e-01 | 0.129000 | 4.98e-01 | 3.09e-01 | 2.63e-01 | 3.70e-01 | 5.68e-04 |
Signaling by WNT in cancer | 28 | 2.60e-03 | 7.96e-03 | 0.5580 | -0.262000 | -3.70e-01 | -0.150000 | -2.90e-01 | 1.66e-02 | 7.10e-04 | 1.70e-01 | 7.90e-03 |
Hedgehog ligand biogenesis | 53 | 1.58e-07 | 8.67e-07 | 0.5570 | 0.115000 | 1.51e-01 | 0.474000 | 2.25e-01 | 1.49e-01 | 5.72e-02 | 2.48e-09 | 4.68e-03 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 25 | 2.34e-08 | 1.53e-07 | 0.5560 | -0.009120 | -1.50e-01 | 0.342000 | -4.12e-01 | 9.37e-01 | 1.95e-01 | 3.10e-03 | 3.59e-04 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 25 | 2.34e-08 | 1.53e-07 | 0.5560 | -0.009120 | -1.50e-01 | 0.342000 | -4.12e-01 | 9.37e-01 | 1.95e-01 | 3.10e-03 | 3.59e-04 |
Synthesis, secretion, and deacylation of Ghrelin | 10 | 1.37e-01 | 2.07e-01 | 0.5560 | 0.178000 | 1.44e-01 | 0.217000 | 4.58e-01 | 3.30e-01 | 4.31e-01 | 2.36e-01 | 1.21e-02 |
Mitochondrial translation initiation | 85 | 1.32e-12 | 1.71e-11 | 0.5550 | -0.045300 | -4.45e-02 | 0.476000 | 2.76e-01 | 4.71e-01 | 4.79e-01 | 3.17e-14 | 1.08e-05 |
MASTL Facilitates Mitotic Progression | 10 | 1.56e-02 | 3.62e-02 | 0.5550 | 0.369000 | 1.20e-01 | 0.373000 | -1.35e-01 | 4.35e-02 | 5.12e-01 | 4.12e-02 | 4.61e-01 |
Degradation of cysteine and homocysteine | 11 | 5.72e-03 | 1.58e-02 | 0.5540 | -0.061700 | -2.10e-01 | 0.501000 | -9.07e-02 | 7.23e-01 | 2.29e-01 | 4.01e-03 | 6.02e-01 |
Degradation of GLI1 by the proteasome | 53 | 4.78e-08 | 2.89e-07 | 0.5530 | 0.175000 | 1.67e-01 | 0.471000 | 1.58e-01 | 2.80e-02 | 3.61e-02 | 2.95e-09 | 4.69e-02 |
Interactions of Rev with host cellular proteins | 31 | 1.14e-10 | 1.14e-09 | 0.5510 | 0.071200 | -6.90e-02 | 0.389000 | -3.78e-01 | 4.93e-01 | 5.06e-01 | 1.81e-04 | 2.72e-04 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 62 | 1.36e-08 | 9.41e-08 | 0.5510 | 0.165000 | 2.29e-01 | 0.439000 | 1.77e-01 | 2.52e-02 | 1.85e-03 | 2.26e-09 | 1.58e-02 |
Homology Directed Repair | 95 | 1.33e-23 | 4.73e-22 | 0.5500 | 0.270000 | 1.98e-01 | 0.395000 | -1.84e-01 | 5.40e-06 | 8.61e-04 | 3.03e-11 | 2.01e-03 |
Activated NTRK2 signals through FRS2 and FRS3 | 10 | 1.08e-01 | 1.70e-01 | 0.5490 | -0.143000 | -4.44e-01 | -0.212000 | -1.96e-01 | 4.32e-01 | 1.51e-02 | 2.46e-01 | 2.83e-01 |
CD28 dependent Vav1 pathway | 12 | 9.51e-02 | 1.53e-01 | 0.5480 | 0.363000 | 3.63e-01 | -0.086600 | 1.72e-01 | 2.96e-02 | 2.96e-02 | 6.03e-01 | 3.02e-01 |
Miscellaneous transport and binding events | 18 | 7.14e-03 | 1.91e-02 | 0.5480 | -0.201000 | -4.31e-01 | 0.000852 | -2.72e-01 | 1.41e-01 | 1.53e-03 | 9.95e-01 | 4.60e-02 |
NCAM1 interactions | 26 | 1.92e-04 | 7.28e-04 | 0.5470 | -0.432000 | -2.32e-01 | -0.229000 | 8.33e-02 | 1.36e-04 | 4.11e-02 | 4.36e-02 | 4.63e-01 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 30 | 1.89e-03 | 5.97e-03 | 0.5470 | 0.425000 | 3.36e-01 | 0.054500 | 4.58e-02 | 5.67e-05 | 1.43e-03 | 6.05e-01 | 6.64e-01 |
PI-3K cascade:FGFR1 | 11 | 7.65e-03 | 2.02e-02 | 0.5460 | 0.068400 | -4.44e-01 | -0.151000 | -2.72e-01 | 6.95e-01 | 1.08e-02 | 3.86e-01 | 1.19e-01 |
Diseases associated with glycosylation precursor biosynthesis | 18 | 6.19e-03 | 1.68e-02 | 0.5460 | -0.214000 | -7.67e-02 | 0.197000 | 4.55e-01 | 1.16e-01 | 5.73e-01 | 1.49e-01 | 8.27e-04 |
Signal regulatory protein family interactions | 13 | 4.94e-02 | 9.09e-02 | 0.5450 | 0.019900 | 5.58e-03 | 0.246000 | 4.87e-01 | 9.01e-01 | 9.72e-01 | 1.25e-01 | 2.39e-03 |
Rev-mediated nuclear export of HIV RNA | 30 | 4.67e-10 | 4.34e-09 | 0.5450 | 0.053200 | -6.93e-02 | 0.391000 | -3.69e-01 | 6.14e-01 | 5.11e-01 | 2.09e-04 | 4.66e-04 |
NEP/NS2 Interacts with the Cellular Export Machinery | 27 | 6.41e-09 | 4.78e-08 | 0.5450 | 0.044600 | -1.35e-01 | 0.345000 | -3.97e-01 | 6.89e-01 | 2.25e-01 | 1.93e-03 | 3.57e-04 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 24 | 1.14e-02 | 2.77e-02 | 0.5450 | -0.293000 | -2.48e-01 | -0.303000 | -2.39e-01 | 1.29e-02 | 3.54e-02 | 1.02e-02 | 4.30e-02 |
Trafficking of AMPA receptors | 24 | 1.14e-02 | 2.77e-02 | 0.5450 | -0.293000 | -2.48e-01 | -0.303000 | -2.39e-01 | 1.29e-02 | 3.54e-02 | 1.02e-02 | 4.30e-02 |
Degradation of GLI2 by the proteasome | 52 | 8.20e-08 | 4.76e-07 | 0.5440 | 0.154000 | 1.65e-01 | 0.472000 | 1.51e-01 | 5.57e-02 | 4.03e-02 | 3.87e-09 | 6.05e-02 |
GLI3 is processed to GLI3R by the proteasome | 52 | 1.67e-07 | 9.04e-07 | 0.5420 | 0.168000 | 1.67e-01 | 0.461000 | 1.60e-01 | 3.66e-02 | 3.70e-02 | 8.99e-09 | 4.63e-02 |
Pentose phosphate pathway | 13 | 4.64e-02 | 8.68e-02 | 0.5420 | 0.125000 | 1.63e-01 | 0.477000 | 1.56e-01 | 4.37e-01 | 3.10e-01 | 2.91e-03 | 3.31e-01 |
Antimicrobial peptides | 13 | 1.50e-02 | 3.49e-02 | 0.5400 | 0.138000 | 4.29e-01 | -0.063200 | 2.90e-01 | 3.90e-01 | 7.35e-03 | 6.93e-01 | 7.00e-02 |
Export of Viral Ribonucleoproteins from Nucleus | 28 | 1.02e-08 | 7.31e-08 | 0.5390 | 0.009770 | -1.64e-01 | 0.298000 | -4.18e-01 | 9.29e-01 | 1.32e-01 | 6.37e-03 | 1.29e-04 |
SUMOylation of DNA replication proteins | 40 | 3.55e-12 | 4.43e-11 | 0.5360 | 0.186000 | 6.43e-02 | 0.383000 | -3.20e-01 | 4.24e-02 | 4.82e-01 | 2.73e-05 | 4.70e-04 |
Regulation of necroptotic cell death | 12 | 8.27e-03 | 2.17e-02 | 0.5360 | 0.088400 | 3.11e-01 | -0.426000 | 4.07e-02 | 5.96e-01 | 6.20e-02 | 1.06e-02 | 8.07e-01 |
Cell Cycle Checkpoints | 235 | 2.75e-55 | 1.20e-52 | 0.5360 | 0.275000 | 1.79e-01 | 0.394000 | -1.56e-01 | 4.74e-13 | 2.37e-06 | 2.88e-25 | 3.92e-05 |
VLDLR internalisation and degradation | 11 | 4.08e-02 | 7.80e-02 | 0.5360 | 0.008790 | 1.70e-01 | 0.499000 | 9.71e-02 | 9.60e-01 | 3.30e-01 | 4.20e-03 | 5.77e-01 |
NIK-->noncanonical NF-kB signaling | 52 | 2.01e-07 | 1.08e-06 | 0.5320 | 0.164000 | 1.72e-01 | 0.455000 | 1.41e-01 | 4.05e-02 | 3.18e-02 | 1.40e-08 | 7.89e-02 |
Activation of Matrix Metalloproteinases | 17 | 8.46e-03 | 2.19e-02 | 0.5310 | -0.344000 | -2.27e-01 | 0.023300 | 3.34e-01 | 1.42e-02 | 1.05e-01 | 8.68e-01 | 1.72e-02 |
Postmitotic nuclear pore complex (NPC) reformation | 25 | 7.87e-08 | 4.59e-07 | 0.5290 | 0.061700 | -1.21e-01 | 0.407000 | -3.10e-01 | 5.94e-01 | 2.96e-01 | 4.30e-04 | 7.25e-03 |
Apoptotic factor-mediated response | 13 | 2.69e-02 | 5.63e-02 | 0.5290 | -0.125000 | 1.19e-01 | 0.464000 | 1.86e-01 | 4.37e-01 | 4.57e-01 | 3.77e-03 | 2.45e-01 |
Regulation of RUNX3 expression and activity | 48 | 1.76e-06 | 8.59e-06 | 0.5240 | 0.163000 | 2.13e-01 | 0.430000 | 1.30e-01 | 5.06e-02 | 1.06e-02 | 2.49e-07 | 1.20e-01 |
Mitochondrial translation | 91 | 1.12e-12 | 1.47e-11 | 0.5230 | -0.053800 | -7.07e-02 | 0.460000 | 2.34e-01 | 3.76e-01 | 2.44e-01 | 3.61e-14 | 1.19e-04 |
Pyruvate metabolism | 26 | 1.51e-04 | 5.82e-04 | 0.5230 | 0.005260 | -3.20e-01 | -0.122000 | -3.96e-01 | 9.63e-01 | 4.76e-03 | 2.83e-01 | 4.82e-04 |
Regulation of FZD by ubiquitination | 13 | 1.84e-01 | 2.59e-01 | 0.5230 | -0.305000 | -3.15e-01 | -0.227000 | -1.71e-01 | 5.66e-02 | 4.93e-02 | 1.56e-01 | 2.85e-01 |
Vpr-mediated nuclear import of PICs | 29 | 1.58e-08 | 1.09e-07 | 0.5220 | -0.012600 | -1.68e-01 | 0.346000 | -3.54e-01 | 9.07e-01 | 1.18e-01 | 1.28e-03 | 9.72e-04 |
Interleukin-12 signaling | 35 | 5.99e-04 | 2.07e-03 | 0.5220 | 0.428000 | 2.81e-01 | 0.052300 | 9.11e-02 | 1.21e-05 | 3.99e-03 | 5.92e-01 | 3.51e-01 |
Transport of the SLBP Dependant Mature mRNA | 31 | 5.32e-09 | 4.01e-08 | 0.5220 | -0.037500 | -1.35e-01 | 0.310000 | -3.96e-01 | 7.18e-01 | 1.93e-01 | 2.78e-03 | 1.36e-04 |
Synthesis of PE | 11 | 1.68e-02 | 3.85e-02 | 0.5210 | -0.433000 | -9.82e-03 | -0.250000 | -1.45e-01 | 1.28e-02 | 9.55e-01 | 1.52e-01 | 4.06e-01 |
Dectin-1 mediated noncanonical NF-kB signaling | 53 | 1.65e-07 | 9.00e-07 | 0.5200 | 0.148000 | 1.61e-01 | 0.455000 | 1.27e-01 | 6.29e-02 | 4.25e-02 | 1.04e-08 | 1.10e-01 |
Sulfur amino acid metabolism | 20 | 2.15e-05 | 9.29e-05 | 0.5200 | 0.022900 | -2.74e-01 | 0.424000 | -1.23e-01 | 8.59e-01 | 3.42e-02 | 1.02e-03 | 3.40e-01 |
G1/S DNA Damage Checkpoints | 60 | 5.10e-09 | 3.87e-08 | 0.5200 | 0.189000 | 2.38e-01 | 0.418000 | 5.23e-02 | 1.14e-02 | 1.45e-03 | 2.10e-08 | 4.84e-01 |
EML4 and NUDC in mitotic spindle formation | 87 | 7.85e-25 | 3.81e-23 | 0.5180 | 0.223000 | 4.75e-02 | 0.366000 | -2.88e-01 | 3.36e-04 | 4.45e-01 | 3.80e-09 | 3.43e-06 |
Formation of the beta-catenin:TCF transactivating complex | 29 | 1.70e-03 | 5.44e-03 | 0.5170 | -0.261000 | -1.70e-01 | -0.173000 | -3.75e-01 | 1.51e-02 | 1.14e-01 | 1.06e-01 | 4.70e-04 |
Misspliced GSK3beta mutants stabilize beta-catenin | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
S33 mutants of beta-catenin aren't phosphorylated | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
S37 mutants of beta-catenin aren't phosphorylated | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
S45 mutants of beta-catenin aren't phosphorylated | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
T41 mutants of beta-catenin aren't phosphorylated | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex | 14 | 1.90e-02 | 4.21e-02 | 0.5170 | -0.046500 | -3.08e-01 | -0.059100 | -4.08e-01 | 7.63e-01 | 4.58e-02 | 7.02e-01 | 8.16e-03 |
Transport of the SLBP independent Mature mRNA | 30 | 2.92e-08 | 1.84e-07 | 0.5170 | -0.059700 | -1.62e-01 | 0.297000 | -3.87e-01 | 5.72e-01 | 1.24e-01 | 4.93e-03 | 2.48e-04 |
Degradation of AXIN | 49 | 1.53e-06 | 7.51e-06 | 0.5160 | 0.206000 | 1.78e-01 | 0.422000 | 1.18e-01 | 1.27e-02 | 3.09e-02 | 3.22e-07 | 1.52e-01 |
Prolactin receptor signaling | 11 | 1.51e-01 | 2.23e-01 | 0.5160 | -0.126000 | -3.72e-01 | -0.249000 | -2.22e-01 | 4.70e-01 | 3.25e-02 | 1.53e-01 | 2.02e-01 |
Separation of Sister Chromatids | 154 | 4.19e-35 | 4.23e-33 | 0.5150 | 0.253000 | 1.20e-01 | 0.412000 | -1.32e-01 | 6.53e-08 | 1.01e-02 | 1.16e-18 | 4.81e-03 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 57 | 6.93e-07 | 3.54e-06 | 0.5150 | 0.198000 | 1.89e-01 | 0.407000 | 1.58e-01 | 9.84e-03 | 1.36e-02 | 1.10e-07 | 3.96e-02 |
Regulation of PTEN mRNA translation | 11 | 2.09e-01 | 2.87e-01 | 0.5150 | -0.145000 | -2.03e-01 | -0.387000 | -2.30e-01 | 4.05e-01 | 2.44e-01 | 2.62e-02 | 1.87e-01 |
G beta:gamma signalling through PLC beta | 15 | 1.65e-02 | 3.79e-02 | 0.5140 | -0.083700 | 4.49e-02 | 0.122000 | 4.90e-01 | 5.75e-01 | 7.63e-01 | 4.12e-01 | 1.01e-03 |
Assembly of collagen fibrils and other multimeric structures | 45 | 1.13e-10 | 1.14e-09 | 0.5140 | -0.392000 | -2.40e-02 | -0.326000 | 5.67e-02 | 5.41e-06 | 7.80e-01 | 1.52e-04 | 5.11e-01 |
G beta:gamma signalling through CDC42 | 15 | 1.35e-02 | 3.21e-02 | 0.5140 | 0.006070 | 1.09e-01 | 0.077900 | 4.96e-01 | 9.68e-01 | 4.65e-01 | 6.02e-01 | 8.82e-04 |
FRS-mediated FGFR3 signaling | 12 | 2.85e-02 | 5.87e-02 | 0.5130 | 0.054500 | -3.49e-01 | -0.215000 | -3.04e-01 | 7.44e-01 | 3.62e-02 | 1.96e-01 | 6.86e-02 |
p53-Dependent G1 DNA Damage Response | 58 | 3.23e-08 | 2.01e-07 | 0.5130 | 0.191000 | 2.27e-01 | 0.413000 | 6.70e-02 | 1.21e-02 | 2.82e-03 | 5.22e-08 | 3.78e-01 |
p53-Dependent G1/S DNA damage checkpoint | 58 | 3.23e-08 | 2.01e-07 | 0.5130 | 0.191000 | 2.27e-01 | 0.413000 | 6.70e-02 | 1.21e-02 | 2.82e-03 | 5.22e-08 | 3.78e-01 |
NS1 Mediated Effects on Host Pathways | 33 | 1.20e-09 | 1.01e-08 | 0.5130 | 0.065700 | -8.44e-02 | 0.297000 | -4.04e-01 | 5.14e-01 | 4.02e-01 | 3.16e-03 | 5.88e-05 |
Base Excision Repair | 45 | 4.41e-08 | 2.69e-07 | 0.5120 | 0.172000 | 2.99e-01 | 0.373000 | -6.58e-02 | 4.64e-02 | 5.23e-04 | 1.50e-05 | 4.45e-01 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 19 | 7.68e-03 | 2.02e-02 | 0.5100 | 0.008000 | -1.16e-02 | -0.159000 | -4.85e-01 | 9.52e-01 | 9.30e-01 | 2.29e-01 | 2.55e-04 |
STING mediated induction of host immune responses | 12 | 9.63e-02 | 1.55e-01 | 0.5100 | 0.239000 | 4.36e-01 | -0.101000 | -5.19e-02 | 1.53e-01 | 8.87e-03 | 5.44e-01 | 7.56e-01 |
Purine salvage | 12 | 1.60e-01 | 2.33e-01 | 0.5080 | 0.325000 | 2.36e-01 | 0.291000 | 1.09e-01 | 5.11e-02 | 1.56e-01 | 8.07e-02 | 5.14e-01 |
Initiation of Nuclear Envelope (NE) Reformation | 19 | 2.13e-04 | 8.02e-04 | 0.5070 | 0.185000 | 2.34e-02 | 0.460000 | -1.04e-01 | 1.62e-01 | 8.60e-01 | 5.19e-04 | 4.32e-01 |
Mitotic Spindle Checkpoint | 100 | 1.92e-27 | 1.15e-25 | 0.5070 | 0.225000 | 3.37e-02 | 0.367000 | -2.66e-01 | 1.05e-04 | 5.61e-01 | 2.35e-10 | 4.32e-06 |
Ion homeostasis | 41 | 2.88e-04 | 1.05e-03 | 0.5060 | -0.214000 | -3.07e-01 | -0.310000 | -1.44e-01 | 1.80e-02 | 6.71e-04 | 6.08e-04 | 1.12e-01 |
Processing of DNA double-strand break ends | 58 | 3.53e-11 | 3.77e-10 | 0.5050 | 0.280000 | 2.07e-01 | 0.322000 | -1.73e-01 | 2.23e-04 | 6.56e-03 | 2.26e-05 | 2.25e-02 |
Cytosolic sulfonation of small molecules | 15 | 8.22e-02 | 1.37e-01 | 0.5050 | 0.138000 | 3.18e-01 | 0.166000 | 3.27e-01 | 3.53e-01 | 3.28e-02 | 2.66e-01 | 2.84e-02 |
Thromboxane signalling through TP receptor | 19 | 9.88e-03 | 2.47e-02 | 0.5040 | -0.125000 | 5.45e-02 | 0.190000 | 4.47e-01 | 3.45e-01 | 6.81e-01 | 1.53e-01 | 7.47e-04 |
Downstream signaling of activated FGFR4 | 16 | 2.26e-02 | 4.88e-02 | 0.5040 | 0.021400 | -2.80e-01 | -0.213000 | -3.60e-01 | 8.82e-01 | 5.23e-02 | 1.40e-01 | 1.26e-02 |
Downstream signaling of activated FGFR2 | 19 | 1.25e-02 | 3.01e-02 | 0.5040 | -0.019700 | -3.20e-01 | -0.259000 | -2.90e-01 | 8.82e-01 | 1.58e-02 | 5.04e-02 | 2.88e-02 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 13 | 8.01e-03 | 2.10e-02 | 0.5030 | 0.171000 | 3.06e-01 | 0.217000 | -2.88e-01 | 2.86e-01 | 5.60e-02 | 1.75e-01 | 7.20e-02 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 38 | 3.80e-10 | 3.61e-09 | 0.5030 | -0.006950 | -1.26e-01 | 0.257000 | -4.13e-01 | 9.41e-01 | 1.81e-01 | 6.14e-03 | 1.04e-05 |
Meiotic recombination | 22 | 4.40e-05 | 1.83e-04 | 0.5010 | 0.149000 | 1.29e-01 | 0.424000 | -1.81e-01 | 2.26e-01 | 2.97e-01 | 5.81e-04 | 1.41e-01 |
ADP signalling through P2Y purinoceptor 1 | 20 | 5.14e-03 | 1.44e-02 | 0.5000 | -0.030800 | -5.09e-03 | 0.134000 | 4.81e-01 | 8.11e-01 | 9.69e-01 | 2.99e-01 | 1.98e-04 |
Elevation of cytosolic Ca2+ levels | 12 | 3.34e-02 | 6.66e-02 | 0.5000 | -0.387000 | -7.88e-02 | -0.302000 | -5.06e-02 | 2.04e-02 | 6.36e-01 | 7.02e-02 | 7.61e-01 |
RORA activates gene expression | 17 | 6.02e-02 | 1.07e-01 | 0.4980 | -0.037200 | -1.96e-01 | -0.258000 | -3.77e-01 | 7.91e-01 | 1.63e-01 | 6.60e-02 | 7.12e-03 |
Transport of Mature mRNA Derived from an Intronless Transcript | 37 | 2.06e-09 | 1.66e-08 | 0.4970 | -0.024100 | -1.47e-01 | 0.244000 | -4.06e-01 | 8.00e-01 | 1.21e-01 | 1.01e-02 | 1.91e-05 |
Detoxification of Reactive Oxygen Species | 29 | 6.88e-03 | 1.85e-02 | 0.4960 | 0.103000 | 1.82e-01 | 0.369000 | 2.58e-01 | 3.35e-01 | 8.97e-02 | 5.90e-04 | 1.62e-02 |
Telomere C-strand synthesis initiation | 12 | 2.02e-02 | 4.44e-02 | 0.4960 | 0.151000 | 3.59e-01 | 0.246000 | -1.84e-01 | 3.65e-01 | 3.13e-02 | 1.40e-01 | 2.70e-01 |
HDR through Single Strand Annealing (SSA) | 36 | 8.47e-08 | 4.89e-07 | 0.4950 | 0.215000 | 1.54e-01 | 0.366000 | -2.05e-01 | 2.59e-02 | 1.10e-01 | 1.48e-04 | 3.34e-02 |
Interactions of Vpr with host cellular proteins | 31 | 3.38e-08 | 2.09e-07 | 0.4950 | -0.009950 | -1.52e-01 | 0.324000 | -3.42e-01 | 9.24e-01 | 1.43e-01 | 1.80e-03 | 9.86e-04 |
FOXO-mediated transcription of cell cycle genes | 15 | 1.13e-01 | 1.76e-01 | 0.4950 | -0.073700 | -1.09e-01 | -0.273000 | -3.91e-01 | 6.21e-01 | 4.64e-01 | 6.70e-02 | 8.75e-03 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 50 | 6.50e-10 | 5.88e-09 | 0.4930 | 0.115000 | -2.41e-01 | -0.058600 | -4.10e-01 | 1.61e-01 | 3.24e-03 | 4.74e-01 | 5.38e-07 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 17 | 2.04e-03 | 6.41e-03 | 0.4910 | 0.257000 | -1.13e-01 | 0.232000 | 3.30e-01 | 6.71e-02 | 4.19e-01 | 9.77e-02 | 1.86e-02 |
Citric acid cycle (TCA cycle) | 22 | 7.74e-05 | 3.07e-04 | 0.4900 | 0.207000 | -1.32e-01 | 0.017000 | -4.24e-01 | 9.34e-02 | 2.85e-01 | 8.90e-01 | 5.75e-04 |
CLEC7A (Dectin-1) induces NFAT activation | 10 | 2.23e-01 | 3.02e-01 | 0.4880 | 0.130000 | -8.80e-03 | -0.393000 | -2.57e-01 | 4.77e-01 | 9.62e-01 | 3.13e-02 | 1.59e-01 |
Glycogen synthesis | 12 | 1.87e-01 | 2.62e-01 | 0.4870 | -0.378000 | -2.88e-01 | -0.056000 | 8.60e-02 | 2.32e-02 | 8.36e-02 | 7.37e-01 | 6.06e-01 |
MET activates PTK2 signaling | 17 | 1.30e-02 | 3.11e-02 | 0.4850 | -0.207000 | -4.55e-02 | -0.426000 | -9.34e-02 | 1.40e-01 | 7.45e-01 | 2.35e-03 | 5.05e-01 |
FRS-mediated FGFR1 signaling | 13 | 3.88e-02 | 7.48e-02 | 0.4850 | -0.008090 | -3.76e-01 | -0.167000 | -2.56e-01 | 9.60e-01 | 1.89e-02 | 2.97e-01 | 1.10e-01 |
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | 13 | 1.64e-01 | 2.37e-01 | 0.4840 | -0.317000 | -3.38e-01 | 0.090800 | -1.07e-01 | 4.80e-02 | 3.49e-02 | 5.71e-01 | 5.04e-01 |
TRAF6-mediated induction of TAK1 complex within TLR4 complex | 13 | 1.64e-01 | 2.37e-01 | 0.4840 | -0.317000 | -3.38e-01 | 0.090800 | -1.07e-01 | 4.80e-02 | 3.49e-02 | 5.71e-01 | 5.04e-01 |
Nitric oxide stimulates guanylate cyclase | 18 | 9.74e-04 | 3.25e-03 | 0.4810 | -0.248000 | -6.50e-04 | -0.406000 | 6.40e-02 | 6.81e-02 | 9.96e-01 | 2.83e-03 | 6.38e-01 |
ATF4 activates genes in response to endoplasmic reticulum stress | 24 | 4.77e-03 | 1.35e-02 | 0.4800 | 0.321000 | 2.82e-01 | 0.170000 | -1.39e-01 | 6.46e-03 | 1.70e-02 | 1.49e-01 | 2.38e-01 |
PECAM1 interactions | 11 | 4.71e-02 | 8.78e-02 | 0.4800 | 0.129000 | 3.26e-01 | -0.313000 | 9.88e-02 | 4.58e-01 | 6.15e-02 | 7.26e-02 | 5.70e-01 |
Metabolism of porphyrins | 21 | 2.78e-04 | 1.02e-03 | 0.4790 | -0.080400 | -7.19e-02 | 0.456000 | -9.80e-02 | 5.24e-01 | 5.69e-01 | 2.99e-04 | 4.37e-01 |
G2/M DNA damage checkpoint | 58 | 1.75e-09 | 1.43e-08 | 0.4790 | 0.265000 | 2.21e-01 | 0.293000 | -1.55e-01 | 4.81e-04 | 3.65e-03 | 1.15e-04 | 4.15e-02 |
Mitochondrial iron-sulfur cluster biogenesis | 12 | 1.43e-02 | 3.35e-02 | 0.4780 | -0.210000 | -1.86e-02 | 0.418000 | -9.45e-02 | 2.08e-01 | 9.11e-01 | 1.22e-02 | 5.71e-01 |
InlB-mediated entry of Listeria monocytogenes into host cell | 13 | 1.76e-01 | 2.50e-01 | 0.4770 | -0.127000 | -3.21e-01 | -0.186000 | -2.71e-01 | 4.26e-01 | 4.51e-02 | 2.45e-01 | 9.11e-02 |
Regulation of beta-cell development | 20 | 7.56e-02 | 1.27e-01 | 0.4760 | -0.120000 | -1.68e-01 | -0.325000 | -2.80e-01 | 3.51e-01 | 1.93e-01 | 1.20e-02 | 3.00e-02 |
Activation of SMO | 14 | 1.24e-01 | 1.90e-01 | 0.4760 | -0.159000 | -3.21e-02 | 0.305000 | 3.28e-01 | 3.04e-01 | 8.35e-01 | 4.79e-02 | 3.38e-02 |
Interleukin-12 family signaling | 41 | 3.91e-04 | 1.39e-03 | 0.4760 | 0.399000 | 2.33e-01 | 0.039000 | 1.09e-01 | 1.01e-05 | 1.00e-02 | 6.66e-01 | 2.26e-01 |
AMER1 mutants destabilize the destruction complex | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
APC truncation mutants have impaired AXIN binding | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
AXIN missense mutants destabilize the destruction complex | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
AXIN mutants destabilize the destruction complex, activating WNT signaling | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
Truncations of AMER1 destabilize the destruction complex | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
truncated APC mutants destabilize the destruction complex | 13 | 3.76e-02 | 7.29e-02 | 0.4740 | 0.009570 | -2.79e-01 | -0.056500 | -3.80e-01 | 9.52e-01 | 8.19e-02 | 7.24e-01 | 1.78e-02 |
Nucleotide salvage | 20 | 4.92e-02 | 9.09e-02 | 0.4740 | 0.211000 | 2.60e-01 | 0.316000 | 1.14e-01 | 1.03e-01 | 4.38e-02 | 1.46e-02 | 3.77e-01 |
Deadenylation of mRNA | 24 | 3.51e-03 | 1.03e-02 | 0.4740 | 0.185000 | 8.72e-02 | -0.122000 | -4.10e-01 | 1.17e-01 | 4.60e-01 | 2.99e-01 | 5.14e-04 |
Collagen biosynthesis and modifying enzymes | 50 | 1.04e-10 | 1.07e-09 | 0.4740 | -0.359000 | -2.69e-02 | -0.155000 | 2.67e-01 | 1.15e-05 | 7.42e-01 | 5.88e-02 | 1.11e-03 |
Listeria monocytogenes entry into host cells | 17 | 8.30e-02 | 1.38e-01 | 0.4740 | -0.144000 | -3.41e-01 | -0.165000 | -2.46e-01 | 3.05e-01 | 1.50e-02 | 2.40e-01 | 7.91e-02 |
RIPK1-mediated regulated necrosis | 14 | 1.42e-02 | 3.34e-02 | 0.4730 | 0.109000 | 3.23e-01 | -0.309000 | 1.10e-01 | 4.82e-01 | 3.66e-02 | 4.56e-02 | 4.75e-01 |
Regulated Necrosis | 14 | 1.42e-02 | 3.34e-02 | 0.4730 | 0.109000 | 3.23e-01 | -0.309000 | 1.10e-01 | 4.82e-01 | 3.66e-02 | 4.56e-02 | 4.75e-01 |
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | 12 | 1.16e-01 | 1.81e-01 | 0.4720 | 0.142000 | -4.12e-02 | 0.265000 | 3.61e-01 | 3.95e-01 | 8.05e-01 | 1.12e-01 | 3.04e-02 |
Downstream signaling of activated FGFR3 | 17 | 2.86e-02 | 5.88e-02 | 0.4720 | 0.075800 | -2.09e-01 | -0.222000 | -3.52e-01 | 5.89e-01 | 1.36e-01 | 1.14e-01 | 1.20e-02 |
Signaling by ROBO receptors | 162 | 7.97e-13 | 1.08e-11 | 0.4710 | 0.230000 | 2.38e-01 | 0.258000 | 2.15e-01 | 4.79e-07 | 1.88e-07 | 1.67e-08 | 2.37e-06 |
IRAK4 deficiency (TLR2/4) | 11 | 1.17e-01 | 1.83e-01 | 0.4710 | -0.052800 | 1.06e-01 | 0.115000 | 4.41e-01 | 7.62e-01 | 5.43e-01 | 5.10e-01 | 1.13e-02 |
Mitotic Metaphase and Anaphase | 206 | 3.47e-41 | 5.06e-39 | 0.4710 | 0.202000 | 7.95e-02 | 0.400000 | -1.20e-01 | 6.58e-07 | 4.99e-02 | 4.90e-23 | 3.00e-03 |
Processing of Intronless Pre-mRNAs | 17 | 7.41e-03 | 1.97e-02 | 0.4700 | 0.158000 | -4.53e-02 | -0.037700 | -4.38e-01 | 2.61e-01 | 7.46e-01 | 7.88e-01 | 1.75e-03 |
Glycogen metabolism | 23 | 2.28e-02 | 4.92e-02 | 0.4690 | -0.289000 | -2.49e-01 | -0.270000 | -4.19e-02 | 1.65e-02 | 3.89e-02 | 2.52e-02 | 7.28e-01 |
Cell Cycle, Mitotic | 457 | 2.46e-89 | 1.61e-86 | 0.4690 | 0.216000 | 1.40e-01 | 0.352000 | -1.72e-01 | 3.46e-15 | 3.64e-07 | 9.41e-38 | 4.08e-10 |
Glucagon-type ligand receptors | 16 | 1.71e-02 | 3.90e-02 | 0.4680 | -0.169000 | 7.40e-02 | 0.100000 | 4.18e-01 | 2.43e-01 | 6.09e-01 | 4.88e-01 | 3.77e-03 |
CASP8 activity is inhibited | 10 | 6.06e-02 | 1.07e-01 | 0.4670 | 0.063300 | 3.00e-01 | -0.349000 | 4.56e-02 | 7.29e-01 | 1.00e-01 | 5.58e-02 | 8.03e-01 |
Dimerization of procaspase-8 | 10 | 6.06e-02 | 1.07e-01 | 0.4670 | 0.063300 | 3.00e-01 | -0.349000 | 4.56e-02 | 7.29e-01 | 1.00e-01 | 5.58e-02 | 8.03e-01 |
Regulation by c-FLIP | 10 | 6.06e-02 | 1.07e-01 | 0.4670 | 0.063300 | 3.00e-01 | -0.349000 | 4.56e-02 | 7.29e-01 | 1.00e-01 | 5.58e-02 | 8.03e-01 |
Mitotic Anaphase | 205 | 2.24e-40 | 2.94e-38 | 0.4670 | 0.199000 | 7.51e-02 | 0.398000 | -1.18e-01 | 1.00e-06 | 6.46e-02 | 1.03e-22 | 3.60e-03 |
MyD88 deficiency (TLR2/4) | 10 | 1.72e-01 | 2.46e-01 | 0.4650 | -0.034400 | 1.11e-01 | 0.116000 | 4.35e-01 | 8.51e-01 | 5.42e-01 | 5.24e-01 | 1.73e-02 |
SUMOylation of SUMOylation proteins | 29 | 8.56e-07 | 4.32e-06 | 0.4650 | 0.019900 | -1.34e-01 | 0.276000 | -3.49e-01 | 8.53e-01 | 2.12e-01 | 1.02e-02 | 1.16e-03 |
IRF3-mediated induction of type I IFN | 10 | 2.10e-01 | 2.87e-01 | 0.4650 | 0.197000 | 4.14e-01 | -0.032400 | -6.46e-02 | 2.80e-01 | 2.33e-02 | 8.59e-01 | 7.24e-01 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 33 | 8.72e-03 | 2.23e-02 | 0.4640 | -0.168000 | -1.32e-01 | -0.302000 | -2.80e-01 | 9.43e-02 | 1.89e-01 | 2.66e-03 | 5.45e-03 |
Nuclear Pore Complex (NPC) Disassembly | 31 | 1.65e-07 | 9.00e-07 | 0.4630 | 0.071100 | -9.67e-02 | 0.327000 | -3.05e-01 | 4.93e-01 | 3.52e-01 | 1.65e-03 | 3.25e-03 |
FOXO-mediated transcription of cell death genes | 14 | 4.66e-03 | 1.33e-02 | 0.4630 | 0.074200 | -9.18e-02 | 0.161000 | -4.18e-01 | 6.31e-01 | 5.52e-01 | 2.96e-01 | 6.83e-03 |
MECP2 regulates neuronal receptors and channels | 12 | 1.63e-01 | 2.36e-01 | 0.4630 | 0.209000 | 2.82e-01 | -0.283000 | -1.05e-01 | 2.10e-01 | 9.05e-02 | 9.00e-02 | 5.28e-01 |
Transferrin endocytosis and recycling | 24 | 2.06e-02 | 4.52e-02 | 0.4630 | -0.218000 | -2.00e-01 | 0.273000 | 2.28e-01 | 6.42e-02 | 8.99e-02 | 2.05e-02 | 5.34e-02 |
Regulation of MECP2 expression and activity | 28 | 1.04e-02 | 2.57e-02 | 0.4630 | -0.062100 | -2.45e-01 | -0.216000 | -3.23e-01 | 5.70e-01 | 2.50e-02 | 4.85e-02 | 3.14e-03 |
Regulation of RAS by GAPs | 60 | 3.25e-06 | 1.54e-05 | 0.4620 | 0.187000 | 2.31e-01 | 0.345000 | 7.96e-02 | 1.22e-02 | 2.01e-03 | 3.92e-06 | 2.87e-01 |
Metabolism of Angiotensinogen to Angiotensins | 11 | 1.81e-01 | 2.56e-01 | 0.4620 | -0.255000 | -2.28e-01 | 0.071700 | 3.02e-01 | 1.43e-01 | 1.91e-01 | 6.81e-01 | 8.32e-02 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | 14 | 1.27e-01 | 1.94e-01 | 0.4600 | 0.210000 | 2.65e-01 | 0.024800 | 3.12e-01 | 1.75e-01 | 8.65e-02 | 8.72e-01 | 4.34e-02 |
Acetylcholine regulates insulin secretion | 10 | 2.58e-01 | 3.39e-01 | 0.4600 | -0.388000 | -2.19e-01 | -0.075300 | 8.48e-02 | 3.36e-02 | 2.30e-01 | 6.80e-01 | 6.42e-01 |
Constitutive Signaling by EGFRvIII | 15 | 1.64e-01 | 2.37e-01 | 0.4600 | -0.128000 | -1.81e-01 | -0.188000 | -3.57e-01 | 3.92e-01 | 2.26e-01 | 2.08e-01 | 1.68e-02 |
Signaling by EGFRvIII in Cancer | 15 | 1.64e-01 | 2.37e-01 | 0.4600 | -0.128000 | -1.81e-01 | -0.188000 | -3.57e-01 | 3.92e-01 | 2.26e-01 | 2.08e-01 | 1.68e-02 |
Presynaptic function of Kainate receptors | 16 | 2.74e-02 | 5.69e-02 | 0.4590 | -0.033800 | 5.63e-02 | 0.074900 | 4.48e-01 | 8.15e-01 | 6.97e-01 | 6.04e-01 | 1.90e-03 |
SHC-mediated cascade:FGFR2 | 12 | 8.63e-02 | 1.42e-01 | 0.4590 | 0.022900 | -3.20e-01 | -0.231000 | -2.33e-01 | 8.91e-01 | 5.50e-02 | 1.67e-01 | 1.62e-01 |
Transcriptional Regulation by E2F6 | 33 | 1.04e-04 | 4.03e-04 | 0.4590 | 0.328000 | 1.69e-01 | 0.243000 | -1.23e-01 | 1.11e-03 | 9.28e-02 | 1.58e-02 | 2.21e-01 |
Asymmetric localization of PCP proteins | 58 | 4.53e-06 | 2.11e-05 | 0.4580 | -0.000948 | 7.43e-02 | 0.413000 | 1.83e-01 | 9.90e-01 | 3.28e-01 | 5.47e-08 | 1.57e-02 |
Protein methylation | 11 | 2.28e-01 | 3.09e-01 | 0.4560 | 0.267000 | 1.40e-01 | 0.120000 | 3.20e-01 | 1.25e-01 | 4.20e-01 | 4.91e-01 | 6.60e-02 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 26 | 1.42e-02 | 3.34e-02 | 0.4560 | -0.257000 | -2.94e-01 | 0.025000 | -2.34e-01 | 2.33e-02 | 9.55e-03 | 8.25e-01 | 3.87e-02 |
Viral Messenger RNA Synthesis | 38 | 3.84e-08 | 2.35e-07 | 0.4560 | -0.041400 | -1.20e-01 | 0.380000 | -2.17e-01 | 6.59e-01 | 1.99e-01 | 5.07e-05 | 2.09e-02 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 17 | 5.89e-03 | 1.62e-02 | 0.4550 | 0.193000 | 2.28e-01 | 0.217000 | -2.65e-01 | 1.68e-01 | 1.03e-01 | 1.21e-01 | 5.86e-02 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 17 | 5.89e-03 | 1.62e-02 | 0.4550 | 0.193000 | 2.28e-01 | 0.217000 | -2.65e-01 | 1.68e-01 | 1.03e-01 | 1.21e-01 | 5.86e-02 |
Metabolism of folate and pterines | 15 | 3.98e-02 | 7.65e-02 | 0.4540 | -0.234000 | -1.61e-01 | 0.355000 | -3.55e-03 | 1.17e-01 | 2.79e-01 | 1.74e-02 | 9.81e-01 |
EGFR downregulation | 26 | 2.56e-02 | 5.41e-02 | 0.4540 | -0.201000 | -3.64e-01 | -0.133000 | -1.26e-01 | 7.65e-02 | 1.34e-03 | 2.39e-01 | 2.68e-01 |
VEGFR2 mediated cell proliferation | 19 | 5.67e-02 | 1.02e-01 | 0.4530 | -0.033600 | 4.93e-02 | -0.353000 | -2.78e-01 | 8.00e-01 | 7.10e-01 | 7.79e-03 | 3.59e-02 |
Long-term potentiation | 16 | 1.26e-02 | 3.04e-02 | 0.4530 | -0.147000 | -8.33e-02 | -0.417000 | 4.66e-02 | 3.09e-01 | 5.64e-01 | 3.84e-03 | 7.47e-01 |
EPHB-mediated forward signaling | 32 | 2.12e-03 | 6.60e-03 | 0.4510 | 0.260000 | 2.15e-01 | 0.002650 | 3.01e-01 | 1.11e-02 | 3.57e-02 | 9.79e-01 | 3.26e-03 |
Gluconeogenesis | 25 | 3.11e-02 | 6.30e-02 | 0.4510 | -0.216000 | -2.24e-01 | -0.106000 | -3.09e-01 | 6.20e-02 | 5.29e-02 | 3.58e-01 | 7.45e-03 |
DAG and IP3 signaling | 38 | 7.00e-03 | 1.88e-02 | 0.4500 | -0.175000 | -2.44e-01 | -0.271000 | -1.96e-01 | 6.19e-02 | 9.21e-03 | 3.88e-03 | 3.65e-02 |
Ras activation upon Ca2+ influx through NMDA receptor | 15 | 6.93e-02 | 1.20e-01 | 0.4480 | -0.138000 | -3.92e-02 | -0.407000 | -1.22e-01 | 3.53e-01 | 7.93e-01 | 6.40e-03 | 4.14e-01 |
PKA activation in glucagon signalling | 15 | 1.21e-01 | 1.86e-01 | 0.4480 | -0.222000 | -3.75e-01 | 0.102000 | 1.95e-02 | 1.37e-01 | 1.19e-02 | 4.92e-01 | 8.96e-01 |
Nucleotide-like (purinergic) receptors | 13 | 8.78e-02 | 1.44e-01 | 0.4480 | 0.256000 | 2.49e-01 | -0.171000 | 2.09e-01 | 1.10e-01 | 1.20e-01 | 2.85e-01 | 1.93e-01 |
Signaling by FGFR2 IIIa TM | 18 | 2.75e-02 | 5.71e-02 | 0.4470 | -0.125000 | -2.64e-01 | 0.326000 | 8.83e-02 | 3.59e-01 | 5.27e-02 | 1.66e-02 | 5.17e-01 |
Mitotic Prometaphase | 175 | 2.71e-36 | 2.97e-34 | 0.4460 | 0.183000 | 7.35e-02 | 0.305000 | -2.59e-01 | 3.27e-05 | 9.42e-02 | 3.62e-12 | 3.59e-09 |
TP53 Regulates Transcription of Cell Cycle Genes | 46 | 1.02e-08 | 7.31e-08 | 0.4460 | 0.126000 | 1.57e-01 | 0.169000 | -3.61e-01 | 1.41e-01 | 6.58e-02 | 4.73e-02 | 2.35e-05 |
G-protein activation | 17 | 1.59e-02 | 3.67e-02 | 0.4460 | 0.013400 | 5.44e-02 | 0.017700 | 4.42e-01 | 9.24e-01 | 6.98e-01 | 8.99e-01 | 1.60e-03 |
Cell Cycle | 570 | 1.80e-98 | 2.36e-95 | 0.4460 | 0.204000 | 1.43e-01 | 0.332000 | -1.61e-01 | 1.34e-16 | 7.05e-09 | 2.24e-41 | 7.69e-11 |
Major pathway of rRNA processing in the nucleolus and cytosol | 140 | 1.00e-09 | 8.64e-09 | 0.4460 | 0.265000 | 2.59e-01 | 0.189000 | 1.59e-01 | 6.22e-08 | 1.29e-07 | 1.19e-04 | 1.18e-03 |
activated TAK1 mediates p38 MAPK activation | 18 | 4.35e-02 | 8.22e-02 | 0.4450 | -0.130000 | -3.71e-01 | -0.032500 | -2.06e-01 | 3.40e-01 | 6.38e-03 | 8.11e-01 | 1.31e-01 |
Cyclin D associated events in G1 | 41 | 2.21e-05 | 9.43e-05 | 0.4450 | 0.305000 | 1.88e-01 | 0.222000 | -1.42e-01 | 7.19e-04 | 3.72e-02 | 1.40e-02 | 1.17e-01 |
G1 Phase | 41 | 2.21e-05 | 9.43e-05 | 0.4450 | 0.305000 | 1.88e-01 | 0.222000 | -1.42e-01 | 7.19e-04 | 3.72e-02 | 1.40e-02 | 1.17e-01 |
DNA Double-Strand Break Repair | 122 | 4.73e-21 | 1.44e-19 | 0.4450 | 0.209000 | 1.46e-01 | 0.318000 | -1.78e-01 | 6.72e-05 | 5.41e-03 | 1.46e-09 | 6.93e-04 |
Cytosolic iron-sulfur cluster assembly | 11 | 2.09e-02 | 4.58e-02 | 0.4440 | -0.239000 | 4.94e-03 | 0.171000 | -3.33e-01 | 1.70e-01 | 9.77e-01 | 3.25e-01 | 5.60e-02 |
DNA Damage/Telomere Stress Induced Senescence | 26 | 2.16e-05 | 9.29e-05 | 0.4430 | 0.062600 | 1.16e-01 | 0.216000 | -3.64e-01 | 5.81e-01 | 3.08e-01 | 5.65e-02 | 1.32e-03 |
Plasma lipoprotein clearance | 24 | 2.77e-02 | 5.73e-02 | 0.4430 | -0.048200 | 1.22e-01 | 0.331000 | 2.64e-01 | 6.83e-01 | 3.03e-01 | 5.02e-03 | 2.51e-02 |
Receptor-type tyrosine-protein phosphatases | 12 | 3.10e-02 | 6.28e-02 | 0.4430 | -0.142000 | -2.02e-01 | -0.176000 | 3.23e-01 | 3.96e-01 | 2.25e-01 | 2.91e-01 | 5.26e-02 |
Unblocking of NMDA receptors, glutamate binding and activation | 14 | 2.40e-02 | 5.13e-02 | 0.4420 | -0.138000 | -1.26e-01 | -0.389000 | 9.73e-02 | 3.70e-01 | 4.13e-01 | 1.18e-02 | 5.29e-01 |
Norepinephrine Neurotransmitter Release Cycle | 10 | 2.59e-01 | 3.39e-01 | 0.4420 | -0.047600 | -1.94e-02 | -0.414000 | -1.48e-01 | 7.95e-01 | 9.16e-01 | 2.35e-02 | 4.16e-01 |
Signaling by BMP | 20 | 2.49e-03 | 7.68e-03 | 0.4420 | 0.016100 | -3.19e-01 | -0.305000 | -2.88e-02 | 9.01e-01 | 1.37e-02 | 1.82e-02 | 8.24e-01 |
Collagen degradation | 24 | 2.86e-03 | 8.66e-03 | 0.4400 | -0.273000 | -1.68e-01 | -0.075000 | 2.92e-01 | 2.05e-02 | 1.54e-01 | 5.25e-01 | 1.32e-02 |
Nephrin family interactions | 18 | 1.50e-02 | 3.49e-02 | 0.4400 | 0.067600 | 3.34e-01 | -0.233000 | -1.53e-01 | 6.20e-01 | 1.42e-02 | 8.76e-02 | 2.62e-01 |
Dual Incision in GG-NER | 39 | 7.51e-06 | 3.43e-05 | 0.4400 | 0.179000 | 1.51e-01 | 0.359000 | -9.69e-02 | 5.32e-02 | 1.03e-01 | 1.03e-04 | 2.95e-01 |
Serotonin Neurotransmitter Release Cycle | 10 | 2.76e-01 | 3.58e-01 | 0.4400 | -0.050200 | -7.29e-02 | -0.408000 | -1.39e-01 | 7.83e-01 | 6.90e-01 | 2.56e-02 | 4.47e-01 |
Cardiac conduction | 87 | 1.21e-07 | 6.81e-07 | 0.4390 | -0.126000 | -2.30e-01 | -0.326000 | -1.34e-01 | 4.19e-02 | 2.14e-04 | 1.52e-07 | 3.06e-02 |
Synthesis of PC | 24 | 9.31e-03 | 2.36e-02 | 0.4390 | -0.343000 | -1.46e-01 | -0.018100 | -2.33e-01 | 3.67e-03 | 2.17e-01 | 8.78e-01 | 4.86e-02 |
CS/DS degradation | 10 | 2.51e-01 | 3.31e-01 | 0.4390 | -0.241000 | -2.00e-02 | 0.209000 | 3.01e-01 | 1.86e-01 | 9.13e-01 | 2.53e-01 | 9.93e-02 |
Insulin processing | 20 | 8.62e-02 | 1.42e-01 | 0.4390 | -0.118000 | -1.69e-01 | -0.344000 | -1.78e-01 | 3.62e-01 | 1.91e-01 | 7.74e-03 | 1.69e-01 |
Uptake and actions of bacterial toxins | 24 | 8.93e-02 | 1.47e-01 | 0.4370 | -0.218000 | -2.44e-01 | -0.230000 | -1.76e-01 | 6.44e-02 | 3.86e-02 | 5.15e-02 | 1.35e-01 |
SUMOylation of ubiquitinylation proteins | 33 | 9.24e-07 | 4.64e-06 | 0.4360 | 0.007930 | -9.77e-02 | 0.248000 | -3.45e-01 | 9.37e-01 | 3.32e-01 | 1.38e-02 | 6.02e-04 |
rRNA processing in the nucleus and cytosol | 149 | 6.44e-10 | 5.87e-09 | 0.4360 | 0.260000 | 2.71e-01 | 0.174000 | 1.38e-01 | 4.85e-08 | 1.15e-08 | 2.58e-04 | 3.77e-03 |
Blood group systems biosynthesis | 12 | 8.30e-02 | 1.38e-01 | 0.4360 | -0.112000 | -3.33e-01 | 0.256000 | -3.30e-02 | 5.01e-01 | 4.60e-02 | 1.24e-01 | 8.43e-01 |
Transcriptional regulation by small RNAs | 42 | 1.69e-08 | 1.15e-07 | 0.4360 | -0.022800 | -1.41e-01 | 0.311000 | -2.70e-01 | 7.99e-01 | 1.14e-01 | 4.95e-04 | 2.50e-03 |
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | 11 | 8.36e-03 | 2.17e-02 | 0.4350 | -0.165000 | 3.21e-01 | -0.177000 | 1.67e-01 | 3.45e-01 | 6.54e-02 | 3.10e-01 | 3.38e-01 |
Phase 0 - rapid depolarisation | 28 | 4.09e-03 | 1.18e-02 | 0.4350 | -0.143000 | -1.87e-01 | -0.364000 | -3.68e-02 | 1.92e-01 | 8.76e-02 | 8.59e-04 | 7.36e-01 |
SHC-mediated cascade:FGFR3 | 10 | 1.47e-01 | 2.19e-01 | 0.4340 | 0.194000 | -1.31e-01 | -0.161000 | -3.28e-01 | 2.89e-01 | 4.73e-01 | 3.78e-01 | 7.26e-02 |
Biosynthesis of specialized proresolving mediators (SPMs) | 13 | 1.16e-01 | 1.81e-01 | 0.4320 | 0.133000 | 3.09e-01 | -0.045200 | 2.67e-01 | 4.07e-01 | 5.34e-02 | 7.78e-01 | 9.54e-02 |
Early Phase of HIV Life Cycle | 13 | 1.77e-01 | 2.51e-01 | 0.4300 | 0.335000 | 2.18e-01 | 0.080700 | -1.38e-01 | 3.66e-02 | 1.74e-01 | 6.15e-01 | 3.89e-01 |
Zinc transporters | 13 | 2.99e-01 | 3.82e-01 | 0.4300 | 0.303000 | 2.83e-01 | -0.104000 | -4.79e-02 | 5.85e-02 | 7.70e-02 | 5.18e-01 | 7.65e-01 |
Telomere Extension By Telomerase | 21 | 2.49e-03 | 7.68e-03 | 0.4300 | 0.140000 | 2.63e-01 | 0.178000 | -2.54e-01 | 2.66e-01 | 3.72e-02 | 1.58e-01 | 4.39e-02 |
TNFR2 non-canonical NF-kB pathway | 74 | 5.27e-06 | 2.44e-05 | 0.4290 | 0.088900 | 1.86e-01 | 0.335000 | 1.72e-01 | 1.86e-01 | 5.66e-03 | 6.45e-07 | 1.08e-02 |
Cytochrome c-mediated apoptotic response | 10 | 2.38e-01 | 3.19e-01 | 0.4280 | -0.172000 | 6.95e-04 | 0.368000 | 1.34e-01 | 3.48e-01 | 9.97e-01 | 4.38e-02 | 4.64e-01 |
Post-chaperonin tubulin folding pathway | 17 | 4.61e-02 | 8.63e-02 | 0.4270 | -0.179000 | -9.24e-02 | 0.371000 | 6.54e-02 | 2.01e-01 | 5.10e-01 | 8.06e-03 | 6.41e-01 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 22 | 3.65e-03 | 1.07e-02 | 0.4270 | -0.160000 | -1.35e-01 | 0.366000 | -6.59e-02 | 1.93e-01 | 2.72e-01 | 2.93e-03 | 5.93e-01 |
Cargo concentration in the ER | 22 | 1.99e-02 | 4.40e-02 | 0.4270 | -0.009110 | -1.74e-01 | 0.251000 | 2.98e-01 | 9.41e-01 | 1.59e-01 | 4.15e-02 | 1.55e-02 |
Nucleobase catabolism | 30 | 3.65e-02 | 7.14e-02 | 0.4260 | 0.121000 | 1.45e-01 | 0.297000 | 2.40e-01 | 2.50e-01 | 1.69e-01 | 4.88e-03 | 2.29e-02 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 17 | 1.60e-01 | 2.33e-01 | 0.4260 | -0.155000 | -1.86e-01 | -0.132000 | -3.25e-01 | 2.70e-01 | 1.84e-01 | 3.48e-01 | 2.04e-02 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 17 | 1.60e-01 | 2.33e-01 | 0.4260 | -0.155000 | -1.86e-01 | -0.132000 | -3.25e-01 | 2.70e-01 | 1.84e-01 | 3.48e-01 | 2.04e-02 |
Voltage gated Potassium channels | 20 | 6.02e-02 | 1.07e-01 | 0.4250 | -0.296000 | -1.61e-01 | -0.253000 | -6.04e-02 | 2.22e-02 | 2.12e-01 | 5.05e-02 | 6.40e-01 |
Glutamate and glutamine metabolism | 11 | 2.80e-01 | 3.62e-01 | 0.4240 | -0.072200 | 6.17e-02 | 0.368000 | 1.88e-01 | 6.79e-01 | 7.23e-01 | 3.45e-02 | 2.81e-01 |
Synthesis of IP2, IP, and Ins in the cytosol | 13 | 1.19e-01 | 1.85e-01 | 0.4240 | -0.165000 | -3.50e-01 | -0.145000 | 9.47e-02 | 3.02e-01 | 2.89e-02 | 3.66e-01 | 5.54e-01 |
Budding and maturation of HIV virion | 23 | 3.15e-02 | 6.36e-02 | 0.4240 | -0.008770 | -1.19e-01 | 0.271000 | 3.03e-01 | 9.42e-01 | 3.23e-01 | 2.43e-02 | 1.20e-02 |
Regulation of PTEN stability and activity | 62 | 3.88e-06 | 1.83e-05 | 0.4230 | 0.135000 | 1.21e-01 | 0.374000 | 8.17e-02 | 6.64e-02 | 9.92e-02 | 3.70e-07 | 2.66e-01 |
Metal ion SLC transporters | 21 | 1.07e-01 | 1.68e-01 | 0.4230 | 0.338000 | 2.20e-01 | 0.078900 | 1.01e-01 | 7.42e-03 | 8.10e-02 | 5.31e-01 | 4.21e-01 |
Glycogen breakdown (glycogenolysis) | 14 | 2.21e-01 | 3.01e-01 | 0.4220 | -0.134000 | -1.23e-01 | -0.350000 | -1.50e-01 | 3.87e-01 | 4.25e-01 | 2.34e-02 | 3.32e-01 |
Late endosomal microautophagy | 25 | 2.58e-02 | 5.44e-02 | 0.4220 | -0.071600 | -1.36e-01 | 0.329000 | 2.14e-01 | 5.36e-01 | 2.38e-01 | 4.42e-03 | 6.41e-02 |
PERK regulates gene expression | 28 | 9.50e-03 | 2.40e-02 | 0.4220 | 0.303000 | 2.21e-01 | 0.169000 | -9.35e-02 | 5.59e-03 | 4.29e-02 | 1.23e-01 | 3.92e-01 |
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | 11 | 1.95e-01 | 2.71e-01 | 0.4210 | -0.025000 | -2.41e-01 | -0.065400 | -3.38e-01 | 8.86e-01 | 1.67e-01 | 7.07e-01 | 5.22e-02 |
Energy dependent regulation of mTOR by LKB1-AMPK | 28 | 1.63e-02 | 3.74e-02 | 0.4200 | -0.169000 | -3.38e-01 | -0.003120 | -1.83e-01 | 1.23e-01 | 1.99e-03 | 9.77e-01 | 9.33e-02 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 17 | 3.81e-02 | 7.37e-02 | 0.4190 | -0.056600 | -3.78e-01 | -0.115000 | -1.27e-01 | 6.87e-01 | 6.96e-03 | 4.11e-01 | 3.65e-01 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 36 | 8.75e-04 | 2.96e-03 | 0.4190 | -0.105000 | -2.64e-01 | -0.002590 | -3.07e-01 | 2.76e-01 | 6.12e-03 | 9.79e-01 | 1.44e-03 |
Defects in vitamin and cofactor metabolism | 19 | 1.75e-01 | 2.50e-01 | 0.4180 | -0.177000 | -2.96e-01 | -0.138000 | -1.93e-01 | 1.82e-01 | 2.57e-02 | 2.98e-01 | 1.45e-01 |
MicroRNA (miRNA) biogenesis | 23 | 1.61e-02 | 3.72e-02 | 0.4180 | -0.207000 | -1.78e-01 | 0.316000 | 1.42e-02 | 8.54e-02 | 1.40e-01 | 8.70e-03 | 9.06e-01 |
Collagen formation | 70 | 3.99e-12 | 4.94e-11 | 0.4180 | -0.322000 | -1.54e-02 | -0.191000 | 1.84e-01 | 3.14e-06 | 8.24e-01 | 5.74e-03 | 7.79e-03 |
Defects in cobalamin (B12) metabolism | 11 | 2.93e-01 | 3.76e-01 | 0.4170 | -0.149000 | -3.69e-01 | -0.046300 | -1.18e-01 | 3.93e-01 | 3.42e-02 | 7.90e-01 | 4.99e-01 |
RET signaling | 32 | 4.76e-02 | 8.87e-02 | 0.4160 | -0.235000 | -2.26e-01 | -0.185000 | -1.82e-01 | 2.14e-02 | 2.71e-02 | 7.09e-02 | 7.52e-02 |
Metabolism of amino acids and derivatives | 242 | 1.57e-17 | 3.48e-16 | 0.4160 | 0.206000 | 1.64e-01 | 0.286000 | 1.47e-01 | 3.53e-08 | 1.16e-05 | 1.96e-14 | 8.36e-05 |
TRAF6 mediated IRF7 activation | 15 | 1.53e-01 | 2.26e-01 | 0.4130 | 0.188000 | 3.16e-01 | -0.090000 | -1.65e-01 | 2.08e-01 | 3.39e-02 | 5.46e-01 | 2.68e-01 |
Regulation of RUNX2 expression and activity | 63 | 4.61e-05 | 1.90e-04 | 0.4130 | 0.175000 | 1.15e-01 | 0.329000 | 1.37e-01 | 1.64e-02 | 1.16e-01 | 6.39e-06 | 5.98e-02 |
PKMTs methylate histone lysines | 37 | 1.39e-03 | 4.52e-03 | 0.4130 | 0.018700 | -6.10e-02 | -0.119000 | -3.90e-01 | 8.44e-01 | 5.21e-01 | 2.12e-01 | 3.99e-05 |
Plasma lipoprotein assembly | 10 | 4.13e-01 | 4.96e-01 | 0.4130 | 0.004120 | -5.62e-02 | 0.272000 | 3.06e-01 | 9.82e-01 | 7.58e-01 | 1.37e-01 | 9.41e-02 |
Interferon Signaling | 145 | 1.68e-08 | 1.15e-07 | 0.4120 | 0.216000 | 2.35e-01 | 0.188000 | 1.80e-01 | 7.13e-06 | 1.09e-06 | 9.74e-05 | 1.82e-04 |
Host Interactions of HIV factors | 112 | 7.54e-14 | 1.22e-12 | 0.4120 | 0.131000 | 1.36e-01 | 0.365000 | -3.17e-02 | 1.65e-02 | 1.33e-02 | 2.64e-11 | 5.63e-01 |
CaMK IV-mediated phosphorylation of CREB | 10 | 3.53e-01 | 4.38e-01 | 0.4110 | 0.032800 | -5.80e-02 | -0.374000 | -1.56e-01 | 8.58e-01 | 7.51e-01 | 4.04e-02 | 3.92e-01 |
UCH proteinases | 78 | 6.40e-08 | 3.78e-07 | 0.4110 | 0.145000 | 1.77e-01 | 0.341000 | 1.75e-02 | 2.67e-02 | 6.87e-03 | 1.99e-07 | 7.90e-01 |
Activation of RAC1 | 12 | 1.57e-01 | 2.30e-01 | 0.4110 | 0.226000 | -1.55e-02 | -0.313000 | -1.41e-01 | 1.76e-01 | 9.26e-01 | 6.06e-02 | 3.99e-01 |
Signaling by NTRK3 (TRKC) | 17 | 1.76e-01 | 2.50e-01 | 0.4110 | -0.049800 | -7.71e-02 | -0.348000 | -1.97e-01 | 7.22e-01 | 5.82e-01 | 1.29e-02 | 1.59e-01 |
Thrombin signalling through proteinase activated receptors (PARs) | 25 | 2.11e-02 | 4.61e-02 | 0.4100 | -0.112000 | 2.69e-02 | 0.155000 | 3.62e-01 | 3.33e-01 | 8.16e-01 | 1.80e-01 | 1.72e-03 |
Negative regulation of FGFR2 signaling | 21 | 1.51e-02 | 3.52e-02 | 0.4090 | -0.084800 | -3.94e-01 | -0.033300 | -6.46e-02 | 5.01e-01 | 1.78e-03 | 7.92e-01 | 6.09e-01 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 23 | 6.41e-02 | 1.12e-01 | 0.4090 | -0.063000 | -8.52e-02 | -0.356000 | -1.73e-01 | 6.01e-01 | 4.80e-01 | 3.16e-03 | 1.52e-01 |
Glucose metabolism | 74 | 8.83e-09 | 6.37e-08 | 0.4090 | -0.137000 | -2.29e-01 | 0.099400 | -2.94e-01 | 4.24e-02 | 6.77e-04 | 1.40e-01 | 1.23e-05 |
HSF1 activation | 23 | 1.73e-02 | 3.95e-02 | 0.4090 | -0.211000 | -2.10e-01 | 0.089600 | -2.66e-01 | 8.06e-02 | 8.12e-02 | 4.57e-01 | 2.71e-02 |
Non-integrin membrane-ECM interactions | 39 | 4.81e-05 | 1.97e-04 | 0.4090 | -0.195000 | -2.56e-02 | -0.358000 | 3.90e-04 | 3.48e-02 | 7.83e-01 | 1.10e-04 | 9.97e-01 |
CaM pathway | 32 | 2.97e-02 | 6.08e-02 | 0.4080 | -0.149000 | -2.70e-01 | -0.226000 | -1.42e-01 | 1.45e-01 | 8.15e-03 | 2.73e-02 | 1.64e-01 |
Calmodulin induced events | 32 | 2.97e-02 | 6.08e-02 | 0.4080 | -0.149000 | -2.70e-01 | -0.226000 | -1.42e-01 | 1.45e-01 | 8.15e-03 | 2.73e-02 | 1.64e-01 |
Meiotic synapsis | 27 | 3.40e-03 | 1.01e-02 | 0.4080 | 0.193000 | 2.48e-01 | 0.116000 | -2.32e-01 | 8.29e-02 | 2.55e-02 | 2.99e-01 | 3.71e-02 |
Signaling by NOTCH4 | 74 | 3.98e-05 | 1.66e-04 | 0.4060 | 0.137000 | 1.90e-01 | 0.299000 | 1.42e-01 | 4.23e-02 | 4.67e-03 | 8.56e-06 | 3.43e-02 |
Platelet calcium homeostasis | 22 | 3.08e-02 | 6.26e-02 | 0.4050 | -0.265000 | -1.13e-01 | -0.282000 | -3.67e-02 | 3.14e-02 | 3.59e-01 | 2.21e-02 | 7.66e-01 |
Cellular response to heat stress | 86 | 1.83e-08 | 1.23e-07 | 0.4040 | -0.164000 | -2.34e-01 | 0.050300 | -2.82e-01 | 8.72e-03 | 1.81e-04 | 4.21e-01 | 6.37e-06 |
DAP12 signaling | 25 | 5.89e-02 | 1.05e-01 | 0.4040 | 0.220000 | 3.33e-01 | -0.055800 | -2.31e-02 | 5.68e-02 | 3.96e-03 | 6.29e-01 | 8.42e-01 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 26 | 2.61e-02 | 5.49e-02 | 0.4030 | 0.011500 | -1.04e-01 | 0.251000 | 2.97e-01 | 9.19e-01 | 3.59e-01 | 2.69e-02 | 8.77e-03 |
Regulation of TP53 Activity through Methylation | 14 | 1.72e-01 | 2.46e-01 | 0.4030 | -0.167000 | -8.06e-02 | -0.093400 | -3.45e-01 | 2.81e-01 | 6.02e-01 | 5.45e-01 | 2.54e-02 |
M Phase | 322 | 5.85e-50 | 1.92e-47 | 0.4010 | 0.158000 | 7.02e-02 | 0.330000 | -1.49e-01 | 1.30e-06 | 3.13e-02 | 3.29e-24 | 4.92e-06 |
Cellular response to hypoxia | 64 | 5.07e-05 | 2.07e-04 | 0.4010 | 0.123000 | 1.30e-01 | 0.340000 | 1.15e-01 | 9.01e-02 | 7.31e-02 | 2.61e-06 | 1.12e-01 |
Synthesis of PIPs at the early endosome membrane | 16 | 1.88e-01 | 2.63e-01 | 0.4000 | 0.021100 | 3.88e-02 | -0.345000 | -1.97e-01 | 8.84e-01 | 7.88e-01 | 1.67e-02 | 1.73e-01 |
RHO GTPases Activate Formins | 109 | 5.89e-18 | 1.41e-16 | 0.4000 | 0.155000 | 6.86e-02 | 0.273000 | -2.38e-01 | 5.13e-03 | 2.17e-01 | 9.09e-07 | 1.85e-05 |
ERBB2 Regulates Cell Motility | 12 | 3.04e-01 | 3.86e-01 | 0.3990 | -0.329000 | -1.88e-01 | -0.020000 | 1.23e-01 | 4.85e-02 | 2.59e-01 | 9.04e-01 | 4.62e-01 |
Assembly and cell surface presentation of NMDA receptors | 15 | 3.87e-02 | 7.48e-02 | 0.3990 | -0.092200 | -2.13e-01 | -0.303000 | 1.17e-01 | 5.37e-01 | 1.54e-01 | 4.24e-02 | 4.32e-01 |
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 14 | 9.23e-02 | 1.51e-01 | 0.3980 | -0.223000 | 8.02e-04 | 0.060900 | 3.24e-01 | 1.48e-01 | 9.96e-01 | 6.93e-01 | 3.59e-02 |
Metabolism of non-coding RNA | 48 | 2.86e-08 | 1.81e-07 | 0.3980 | 0.071100 | -7.70e-02 | 0.338000 | -1.81e-01 | 3.94e-01 | 3.57e-01 | 5.09e-05 | 3.00e-02 |
snRNP Assembly | 48 | 2.86e-08 | 1.81e-07 | 0.3980 | 0.071100 | -7.70e-02 | 0.338000 | -1.81e-01 | 3.94e-01 | 3.57e-01 | 5.09e-05 | 3.00e-02 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 12 | 3.77e-01 | 4.63e-01 | 0.3970 | -0.149000 | -3.23e-01 | -0.112000 | -1.36e-01 | 3.71e-01 | 5.26e-02 | 5.00e-01 | 4.15e-01 |
Signal amplification | 27 | 1.28e-02 | 3.07e-02 | 0.3960 | 0.042200 | 3.20e-02 | 0.092400 | 3.82e-01 | 7.05e-01 | 7.73e-01 | 4.06e-01 | 5.97e-04 |
Nuclear Envelope (NE) Reassembly | 64 | 3.43e-10 | 3.31e-09 | 0.3960 | 0.033500 | -8.59e-02 | 0.364000 | -1.27e-01 | 6.43e-01 | 2.35e-01 | 4.89e-07 | 7.93e-02 |
Beta-catenin phosphorylation cascade | 16 | 9.42e-02 | 1.53e-01 | 0.3960 | -0.079700 | -2.36e-01 | 0.002350 | -3.07e-01 | 5.81e-01 | 1.02e-01 | 9.87e-01 | 3.35e-02 |
ABC-family proteins mediated transport | 84 | 2.65e-06 | 1.28e-05 | 0.3960 | 0.092100 | 8.16e-02 | 0.345000 | 1.48e-01 | 1.45e-01 | 1.97e-01 | 4.53e-08 | 1.90e-02 |
Interleukin-10 signaling | 24 | 4.95e-02 | 9.09e-02 | 0.3960 | 0.165000 | 8.94e-02 | 0.122000 | 3.26e-01 | 1.61e-01 | 4.48e-01 | 2.99e-01 | 5.73e-03 |
Signaling by ERBB2 ECD mutants | 15 | 2.58e-01 | 3.38e-01 | 0.3950 | -0.157000 | -1.25e-01 | -0.130000 | -3.14e-01 | 2.91e-01 | 4.02e-01 | 3.83e-01 | 3.54e-02 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 16 | 6.57e-02 | 1.15e-01 | 0.3940 | -0.206000 | -1.72e-01 | -0.269000 | 1.06e-01 | 1.54e-01 | 2.34e-01 | 6.27e-02 | 4.65e-01 |
p130Cas linkage to MAPK signaling for integrins | 12 | 4.93e-02 | 9.09e-02 | 0.3920 | 0.082800 | 8.31e-02 | -0.293000 | 2.32e-01 | 6.20e-01 | 6.18e-01 | 7.88e-02 | 1.63e-01 |
Synaptic adhesion-like molecules | 15 | 7.13e-02 | 1.22e-01 | 0.3910 | -0.116000 | -2.02e-01 | -0.013500 | 3.14e-01 | 4.36e-01 | 1.76e-01 | 9.28e-01 | 3.51e-02 |
Circadian Clock | 63 | 1.76e-05 | 7.64e-05 | 0.3910 | 0.090500 | -1.45e-01 | -0.211000 | -2.82e-01 | 2.14e-01 | 4.65e-02 | 3.81e-03 | 1.11e-04 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 61 | 5.59e-07 | 2.89e-06 | 0.3910 | 0.156000 | 1.40e-01 | 0.323000 | -6.91e-02 | 3.49e-02 | 5.90e-02 | 1.30e-05 | 3.51e-01 |
Meiosis | 47 | 3.98e-06 | 1.86e-05 | 0.3900 | 0.152000 | 1.86e-01 | 0.235000 | -1.97e-01 | 7.16e-02 | 2.72e-02 | 5.32e-03 | 1.93e-02 |
Nuclear Envelope Breakdown | 48 | 4.47e-08 | 2.71e-07 | 0.3900 | 0.023500 | -3.97e-02 | 0.309000 | -2.34e-01 | 7.79e-01 | 6.35e-01 | 2.18e-04 | 5.15e-03 |
GRB2:SOS provides linkage to MAPK signaling for Integrins | 12 | 4.38e-02 | 8.26e-02 | 0.3900 | 0.067200 | 8.36e-03 | -0.324000 | 2.05e-01 | 6.87e-01 | 9.60e-01 | 5.17e-02 | 2.19e-01 |
FCERI mediated Ca+2 mobilization | 27 | 2.87e-02 | 5.89e-02 | 0.3890 | 0.138000 | 1.45e-01 | -0.312000 | -1.17e-01 | 2.14e-01 | 1.94e-01 | 4.97e-03 | 2.92e-01 |
Negative regulation of FGFR4 signaling | 18 | 3.05e-02 | 6.21e-02 | 0.3890 | -0.059000 | -3.71e-01 | 0.045600 | -8.96e-02 | 6.65e-01 | 6.45e-03 | 7.38e-01 | 5.11e-01 |
Cleavage of the damaged purine | 11 | 9.38e-02 | 1.52e-01 | 0.3890 | 0.043500 | 3.32e-01 | 0.099300 | -1.70e-01 | 8.03e-01 | 5.65e-02 | 5.69e-01 | 3.28e-01 |
Depurination | 11 | 9.38e-02 | 1.52e-01 | 0.3890 | 0.043500 | 3.32e-01 | 0.099300 | -1.70e-01 | 8.03e-01 | 5.65e-02 | 5.69e-01 | 3.28e-01 |
Recognition and association of DNA glycosylase with site containing an affected purine | 11 | 9.38e-02 | 1.52e-01 | 0.3890 | 0.043500 | 3.32e-01 | 0.099300 | -1.70e-01 | 8.03e-01 | 5.65e-02 | 5.69e-01 | 3.28e-01 |
Transcriptional activation of mitochondrial biogenesis | 50 | 3.25e-03 | 9.71e-03 | 0.3880 | -0.009440 | -1.33e-01 | -0.232000 | -2.80e-01 | 9.08e-01 | 1.03e-01 | 4.53e-03 | 6.09e-04 |
Pre-NOTCH Processing in Golgi | 16 | 1.52e-01 | 2.24e-01 | 0.3880 | -0.333000 | -1.44e-01 | 0.135000 | 2.16e-02 | 2.12e-02 | 3.20e-01 | 3.49e-01 | 8.81e-01 |
PKA activation | 16 | 1.19e-01 | 1.85e-01 | 0.3880 | -0.136000 | -3.53e-01 | 0.058200 | 5.98e-02 | 3.47e-01 | 1.45e-02 | 6.87e-01 | 6.79e-01 |
Hyaluronan metabolism | 14 | 3.69e-01 | 4.55e-01 | 0.3870 | 0.061700 | 8.87e-02 | 0.306000 | 2.10e-01 | 6.90e-01 | 5.66e-01 | 4.74e-02 | 1.74e-01 |
Free fatty acids regulate insulin secretion | 10 | 5.76e-01 | 6.36e-01 | 0.3850 | -0.290000 | -2.51e-01 | -0.029400 | 2.21e-02 | 1.12e-01 | 1.69e-01 | 8.72e-01 | 9.04e-01 |
Uptake and function of anthrax toxins | 11 | 3.92e-01 | 4.77e-01 | 0.3840 | -0.168000 | -3.45e-01 | -0.014100 | -1.24e-02 | 3.35e-01 | 4.74e-02 | 9.36e-01 | 9.43e-01 |
Phosphorylation of the APC/C | 20 | 5.94e-03 | 1.62e-02 | 0.3840 | 0.241000 | -2.30e-02 | 0.290000 | -7.16e-02 | 6.24e-02 | 8.58e-01 | 2.50e-02 | 5.79e-01 |
Glycolysis | 58 | 4.77e-07 | 2.49e-06 | 0.3840 | -0.086300 | -1.97e-01 | 0.128000 | -2.91e-01 | 2.56e-01 | 9.50e-03 | 9.25e-02 | 1.26e-04 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 11 | 2.91e-01 | 3.74e-01 | 0.3830 | 0.049500 | -1.17e-01 | 0.309000 | 1.88e-01 | 7.76e-01 | 5.02e-01 | 7.62e-02 | 2.79e-01 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 21 | 4.54e-03 | 1.30e-02 | 0.3820 | 0.187000 | -4.03e-02 | 0.323000 | -7.13e-02 | 1.38e-01 | 7.49e-01 | 1.04e-02 | 5.72e-01 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 21 | 4.54e-03 | 1.30e-02 | 0.3820 | 0.187000 | -4.03e-02 | 0.323000 | -7.13e-02 | 1.38e-01 | 7.49e-01 | 1.04e-02 | 5.72e-01 |
Activation of G protein gated Potassium channels | 18 | 2.34e-02 | 5.03e-02 | 0.3820 | 0.059400 | 1.07e-01 | -0.094000 | 3.50e-01 | 6.63e-01 | 4.32e-01 | 4.90e-01 | 1.03e-02 |
G protein gated Potassium channels | 18 | 2.34e-02 | 5.03e-02 | 0.3820 | 0.059400 | 1.07e-01 | -0.094000 | 3.50e-01 | 6.63e-01 | 4.32e-01 | 4.90e-01 | 1.03e-02 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 18 | 2.34e-02 | 5.03e-02 | 0.3820 | 0.059400 | 1.07e-01 | -0.094000 | 3.50e-01 | 6.63e-01 | 4.32e-01 | 4.90e-01 | 1.03e-02 |
Activation of NF-kappaB in B cells | 61 | 2.80e-05 | 1.19e-04 | 0.3820 | 0.130000 | 1.47e-01 | 0.326000 | 2.89e-02 | 8.05e-02 | 4.74e-02 | 1.05e-05 | 6.97e-01 |
APC-Cdc20 mediated degradation of Nek2A | 24 | 2.01e-03 | 6.33e-03 | 0.3810 | 0.170000 | -2.14e-02 | 0.329000 | -8.98e-02 | 1.51e-01 | 8.56e-01 | 5.29e-03 | 4.47e-01 |
Nucleobase biosynthesis | 15 | 7.22e-02 | 1.23e-01 | 0.3810 | 0.006170 | 4.36e-02 | 0.378000 | -1.73e-02 | 9.67e-01 | 7.70e-01 | 1.12e-02 | 9.08e-01 |
Carnitine metabolism | 12 | 2.55e-01 | 3.36e-01 | 0.3810 | -0.237000 | -1.87e-02 | -0.223000 | -1.97e-01 | 1.55e-01 | 9.11e-01 | 1.82e-01 | 2.37e-01 |
Disorders of developmental biology | 11 | 1.50e-01 | 2.23e-01 | 0.3800 | 0.128000 | -1.95e-01 | -0.079600 | -2.90e-01 | 4.63e-01 | 2.62e-01 | 6.48e-01 | 9.63e-02 |
Loss of function of MECP2 in Rett syndrome | 11 | 1.50e-01 | 2.23e-01 | 0.3800 | 0.128000 | -1.95e-01 | -0.079600 | -2.90e-01 | 4.63e-01 | 2.62e-01 | 6.48e-01 | 9.63e-02 |
Pervasive developmental disorders | 11 | 1.50e-01 | 2.23e-01 | 0.3800 | 0.128000 | -1.95e-01 | -0.079600 | -2.90e-01 | 4.63e-01 | 2.62e-01 | 6.48e-01 | 9.63e-02 |
LDL clearance | 15 | 2.73e-01 | 3.55e-01 | 0.3790 | -0.061200 | 2.79e-02 | 0.322000 | 1.89e-01 | 6.82e-01 | 8.52e-01 | 3.08e-02 | 2.06e-01 |
Role of phospholipids in phagocytosis | 27 | 2.50e-02 | 5.31e-02 | 0.3790 | 0.007680 | 2.54e-01 | 0.216000 | 1.80e-01 | 9.45e-01 | 2.22e-02 | 5.23e-02 | 1.06e-01 |
Activation of the AP-1 family of transcription factors | 10 | 2.39e-01 | 3.19e-01 | 0.3790 | 0.034600 | -2.90e-01 | -0.108000 | -2.16e-01 | 8.50e-01 | 1.12e-01 | 5.55e-01 | 2.37e-01 |
FGFR2 mutant receptor activation | 21 | 6.87e-02 | 1.19e-01 | 0.3780 | -0.146000 | -3.00e-01 | 0.176000 | 2.54e-02 | 2.47e-01 | 1.73e-02 | 1.62e-01 | 8.40e-01 |
Hedgehog 'on' state | 75 | 8.77e-05 | 3.43e-04 | 0.3780 | 0.092600 | 9.50e-02 | 0.317000 | 1.59e-01 | 1.66e-01 | 1.55e-01 | 2.15e-06 | 1.74e-02 |
TNFs bind their physiological receptors | 11 | 4.02e-01 | 4.85e-01 | 0.3780 | -0.039700 | 1.31e-01 | 0.172000 | 3.07e-01 | 8.20e-01 | 4.51e-01 | 3.24e-01 | 7.76e-02 |
Mitotic G2-G2/M phases | 175 | 1.47e-21 | 4.71e-20 | 0.3780 | 0.129000 | 9.22e-02 | 0.330000 | -9.13e-02 | 3.31e-03 | 3.60e-02 | 5.27e-14 | 3.78e-02 |
G2/M Transition | 173 | 4.56e-21 | 1.42e-19 | 0.3770 | 0.131000 | 9.37e-02 | 0.328000 | -8.99e-02 | 3.02e-03 | 3.41e-02 | 1.02e-13 | 4.20e-02 |
Translation of structural proteins | 26 | 5.83e-02 | 1.05e-01 | 0.3760 | -0.171000 | -1.82e-01 | 0.259000 | 1.10e-01 | 1.30e-01 | 1.09e-01 | 2.25e-02 | 3.33e-01 |
rRNA processing | 166 | 2.39e-08 | 1.55e-07 | 0.3760 | 0.245000 | 2.51e-01 | 0.114000 | 7.31e-02 | 5.35e-08 | 2.75e-08 | 1.14e-02 | 1.05e-01 |
Prolonged ERK activation events | 13 | 1.91e-01 | 2.67e-01 | 0.3750 | 0.006430 | -2.81e-01 | -0.137000 | -2.08e-01 | 9.68e-01 | 7.95e-02 | 3.94e-01 | 1.95e-01 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 75 | 3.01e-07 | 1.59e-06 | 0.3750 | 0.140000 | 8.79e-02 | 0.336000 | 2.22e-05 | 3.62e-02 | 1.89e-01 | 4.89e-07 | 1.00e+00 |
Post NMDA receptor activation events | 51 | 1.10e-02 | 2.71e-02 | 0.3750 | -0.151000 | -2.11e-01 | -0.218000 | -1.59e-01 | 6.20e-02 | 9.05e-03 | 7.17e-03 | 4.97e-02 |
Signaling by cytosolic FGFR1 fusion mutants | 18 | 2.42e-01 | 3.21e-01 | 0.3740 | -0.034000 | -1.80e-01 | -0.248000 | -2.13e-01 | 8.03e-01 | 1.87e-01 | 6.86e-02 | 1.18e-01 |
Surfactant metabolism | 14 | 2.33e-01 | 3.13e-01 | 0.3740 | -0.064100 | -7.60e-02 | 0.123000 | 3.39e-01 | 6.78e-01 | 6.23e-01 | 4.24e-01 | 2.81e-02 |
FCGR3A-mediated phagocytosis | 61 | 4.60e-04 | 1.61e-03 | 0.3740 | 0.159000 | 2.57e-01 | 0.016400 | 2.20e-01 | 3.23e-02 | 5.17e-04 | 8.25e-01 | 3.00e-03 |
Leishmania phagocytosis | 61 | 4.60e-04 | 1.61e-03 | 0.3740 | 0.159000 | 2.57e-01 | 0.016400 | 2.20e-01 | 3.23e-02 | 5.17e-04 | 8.25e-01 | 3.00e-03 |
Parasite infection | 61 | 4.60e-04 | 1.61e-03 | 0.3740 | 0.159000 | 2.57e-01 | 0.016400 | 2.20e-01 | 3.23e-02 | 5.17e-04 | 8.25e-01 | 3.00e-03 |
Phase II - Conjugation of compounds | 66 | 4.92e-04 | 1.72e-03 | 0.3740 | 0.276000 | 1.47e-01 | 0.142000 | 1.48e-01 | 1.06e-04 | 3.88e-02 | 4.68e-02 | 3.82e-02 |
PI3K events in ERBB2 signaling | 13 | 3.78e-01 | 4.63e-01 | 0.3740 | -0.248000 | -2.41e-01 | -0.131000 | 5.33e-02 | 1.21e-01 | 1.33e-01 | 4.14e-01 | 7.39e-01 |
Inwardly rectifying K+ channels | 20 | 2.61e-02 | 5.49e-02 | 0.3730 | 0.088600 | 1.03e-01 | -0.061700 | 3.42e-01 | 4.93e-01 | 4.25e-01 | 6.33e-01 | 8.10e-03 |
TRAF3-dependent IRF activation pathway | 13 | 2.06e-01 | 2.82e-01 | 0.3730 | 0.117000 | 3.20e-01 | -0.055700 | -1.42e-01 | 4.63e-01 | 4.61e-02 | 7.28e-01 | 3.76e-01 |
Signaling by ERBB2 TMD/JMD mutants | 18 | 2.30e-01 | 3.10e-01 | 0.3730 | -0.300000 | -1.62e-01 | -0.128000 | -8.13e-02 | 2.78e-02 | 2.34e-01 | 3.49e-01 | 5.51e-01 |
Signaling by NODAL | 13 | 1.18e-01 | 1.84e-01 | 0.3730 | -0.039800 | -3.16e-01 | 0.179000 | 7.16e-02 | 8.04e-01 | 4.83e-02 | 2.63e-01 | 6.55e-01 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 1.03e-01 | 1.63e-01 | 0.3730 | 0.177000 | -1.17e-02 | 0.327000 | 2.36e-02 | 2.51e-01 | 9.40e-01 | 3.43e-02 | 8.78e-01 |
Constitutive Signaling by AKT1 E17K in Cancer | 25 | 2.40e-02 | 5.13e-02 | 0.3720 | -0.039600 | -2.00e-01 | -0.021500 | -3.11e-01 | 7.32e-01 | 8.42e-02 | 8.53e-01 | 7.10e-03 |
Processing of SMDT1 | 15 | 2.12e-01 | 2.91e-01 | 0.3720 | 0.103000 | -2.37e-02 | 0.318000 | 1.62e-01 | 4.89e-01 | 8.74e-01 | 3.32e-02 | 2.78e-01 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 39 | 3.02e-03 | 9.06e-03 | 0.3720 | 0.090200 | -8.48e-02 | -0.126000 | -3.27e-01 | 3.30e-01 | 3.60e-01 | 1.73e-01 | 4.11e-04 |
Nicotinamide salvaging | 13 | 4.20e-01 | 5.02e-01 | 0.3710 | 0.174000 | 2.79e-01 | 0.021200 | 1.69e-01 | 2.76e-01 | 8.12e-02 | 8.95e-01 | 2.92e-01 |
Triglyceride catabolism | 15 | 1.93e-01 | 2.69e-01 | 0.3700 | 0.029300 | 2.33e-02 | -0.104000 | -3.54e-01 | 8.44e-01 | 8.76e-01 | 4.85e-01 | 1.78e-02 |
YAP1- and WWTR1 (TAZ)-stimulated gene expression | 13 | 5.22e-01 | 5.92e-01 | 0.3700 | -0.221000 | -2.72e-01 | -0.092100 | -7.60e-02 | 1.68e-01 | 8.96e-02 | 5.65e-01 | 6.35e-01 |
Integrin cell surface interactions | 51 | 1.35e-07 | 7.53e-07 | 0.3700 | -0.074000 | 1.40e-01 | -0.312000 | 1.22e-01 | 3.61e-01 | 8.47e-02 | 1.19e-04 | 1.33e-01 |
Notch-HLH transcription pathway | 25 | 1.59e-01 | 2.33e-01 | 0.3700 | -0.087700 | -1.19e-01 | -0.270000 | -2.05e-01 | 4.48e-01 | 3.02e-01 | 1.95e-02 | 7.63e-02 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 24 | 2.76e-02 | 5.71e-02 | 0.3700 | 0.131000 | -1.23e-01 | -0.276000 | -1.68e-01 | 2.68e-01 | 2.97e-01 | 1.92e-02 | 1.55e-01 |
CRMPs in Sema3A signaling | 15 | 2.55e-02 | 5.41e-02 | 0.3690 | -0.118000 | 8.43e-02 | -0.312000 | 1.33e-01 | 4.28e-01 | 5.72e-01 | 3.63e-02 | 3.73e-01 |
Ca-dependent events | 34 | 3.16e-02 | 6.36e-02 | 0.3690 | -0.113000 | -2.65e-01 | -0.203000 | -1.11e-01 | 2.57e-01 | 7.57e-03 | 4.10e-02 | 2.63e-01 |
Regulation of HSF1-mediated heat shock response | 69 | 1.02e-07 | 5.79e-07 | 0.3680 | -0.098400 | -1.91e-01 | 0.141000 | -2.64e-01 | 1.58e-01 | 6.25e-03 | 4.24e-02 | 1.51e-04 |
Regulation of TLR by endogenous ligand | 10 | 9.90e-02 | 1.58e-01 | 0.3680 | -0.156000 | 1.09e-01 | -0.168000 | 2.67e-01 | 3.92e-01 | 5.51e-01 | 3.58e-01 | 1.44e-01 |
GRB2 events in ERBB2 signaling | 13 | 4.28e-01 | 5.09e-01 | 0.3680 | -0.247000 | -2.07e-01 | -0.177000 | -1.69e-02 | 1.23e-01 | 1.96e-01 | 2.70e-01 | 9.16e-01 |
HCMV Late Events | 47 | 1.20e-05 | 5.37e-05 | 0.3680 | 0.002430 | -1.18e-01 | 0.345000 | -4.70e-02 | 9.77e-01 | 1.60e-01 | 4.28e-05 | 5.77e-01 |
Scavenging by Class A Receptors | 13 | 1.71e-01 | 2.45e-01 | 0.3680 | -0.139000 | 2.08e-02 | 0.038000 | 3.38e-01 | 3.84e-01 | 8.97e-01 | 8.13e-01 | 3.50e-02 |
IRE1alpha activates chaperones | 49 | 1.27e-03 | 4.21e-03 | 0.3680 | -0.137000 | -2.17e-01 | 0.248000 | 9.03e-02 | 9.80e-02 | 8.79e-03 | 2.66e-03 | 2.74e-01 |
Gene Silencing by RNA | 59 | 1.04e-07 | 5.93e-07 | 0.3680 | -0.086500 | -1.39e-01 | 0.252000 | -2.12e-01 | 2.51e-01 | 6.56e-02 | 8.18e-04 | 4.93e-03 |
tRNA Aminoacylation | 24 | 6.72e-02 | 1.17e-01 | 0.3680 | -0.148000 | -1.66e-01 | 0.280000 | 8.35e-02 | 2.08e-01 | 1.59e-01 | 1.75e-02 | 4.79e-01 |
Glyoxylate metabolism and glycine degradation | 24 | 8.44e-02 | 1.39e-01 | 0.3670 | -0.051000 | -1.77e-01 | -0.102000 | -3.01e-01 | 6.66e-01 | 1.33e-01 | 3.87e-01 | 1.07e-02 |
Metabolism of nucleotides | 85 | 2.76e-05 | 1.18e-04 | 0.3670 | 0.101000 | 1.06e-01 | 0.309000 | 1.33e-01 | 1.08e-01 | 9.29e-02 | 8.33e-07 | 3.40e-02 |
Interleukin-35 Signalling | 10 | 2.00e-01 | 2.76e-01 | 0.3660 | 0.315000 | 3.97e-02 | -0.157000 | 9.25e-02 | 8.45e-02 | 8.28e-01 | 3.91e-01 | 6.13e-01 |
ROS and RNS production in phagocytes | 28 | 6.69e-02 | 1.16e-01 | 0.3660 | -0.000192 | 1.62e-01 | 0.191000 | 2.67e-01 | 9.99e-01 | 1.38e-01 | 7.98e-02 | 1.47e-02 |
Regulation of TP53 Degradation | 32 | 5.73e-04 | 1.98e-03 | 0.3660 | 0.143000 | -5.86e-02 | 0.051500 | -3.28e-01 | 1.63e-01 | 5.67e-01 | 6.14e-01 | 1.34e-03 |
Assembly Of The HIV Virion | 13 | 3.44e-01 | 4.29e-01 | 0.3660 | -0.157000 | -1.95e-01 | 0.250000 | 9.16e-02 | 3.27e-01 | 2.23e-01 | 1.18e-01 | 5.67e-01 |
Lewis blood group biosynthesis | 10 | 1.46e-01 | 2.18e-01 | 0.3660 | 0.025500 | -3.22e-01 | 0.158000 | 6.53e-02 | 8.89e-01 | 7.77e-02 | 3.86e-01 | 7.21e-01 |
Muscle contraction | 143 | 3.48e-10 | 3.34e-09 | 0.3660 | -0.133000 | -6.20e-02 | -0.316000 | -1.11e-01 | 6.28e-03 | 2.02e-01 | 7.30e-11 | 2.22e-02 |
Metabolism of steroid hormones | 18 | 5.46e-02 | 9.89e-02 | 0.3650 | 0.081200 | 3.69e-02 | -0.010400 | 3.54e-01 | 5.51e-01 | 7.86e-01 | 9.39e-01 | 9.28e-03 |
Syndecan interactions | 19 | 9.70e-03 | 2.45e-02 | 0.3650 | -0.079800 | -8.09e-03 | -0.305000 | 1.84e-01 | 5.47e-01 | 9.51e-01 | 2.14e-02 | 1.66e-01 |
CREB1 phosphorylation through the activation of Adenylate Cyclase | 10 | 2.84e-01 | 3.66e-01 | 0.3640 | -0.070000 | -3.31e-01 | 0.121000 | 6.13e-02 | 7.02e-01 | 7.01e-02 | 5.07e-01 | 7.37e-01 |
G beta:gamma signalling through PI3Kgamma | 20 | 9.35e-02 | 1.52e-01 | 0.3630 | 0.071300 | 1.49e-01 | 0.031500 | 3.22e-01 | 5.81e-01 | 2.50e-01 | 8.07e-01 | 1.26e-02 |
Mitotic Prophase | 77 | 4.24e-11 | 4.49e-10 | 0.3630 | 0.078100 | -2.45e-02 | 0.302000 | -1.85e-01 | 2.37e-01 | 7.11e-01 | 4.83e-06 | 5.13e-03 |
Transcriptional regulation of pluripotent stem cells | 14 | 3.07e-02 | 6.24e-02 | 0.3620 | 0.038100 | -3.22e-01 | -0.121000 | 1.05e-01 | 8.05e-01 | 3.69e-02 | 4.31e-01 | 4.98e-01 |
Degradation of beta-catenin by the destruction complex | 75 | 3.30e-06 | 1.56e-05 | 0.3610 | 0.111000 | 1.03e-01 | 0.327000 | 2.52e-02 | 9.60e-02 | 1.25e-01 | 9.84e-07 | 7.07e-01 |
TAK1 activates NFkB by phosphorylation and activation of IKKs complex | 24 | 2.22e-01 | 3.02e-01 | 0.3610 | -0.234000 | -2.27e-01 | -0.057000 | -1.44e-01 | 4.76e-02 | 5.42e-02 | 6.29e-01 | 2.22e-01 |
Pausing and recovery of Tat-mediated HIV elongation | 26 | 3.00e-03 | 8.99e-03 | 0.3610 | -0.073900 | -7.75e-03 | 0.339000 | -9.75e-02 | 5.14e-01 | 9.45e-01 | 2.76e-03 | 3.90e-01 |
Tat-mediated HIV elongation arrest and recovery | 26 | 3.00e-03 | 8.99e-03 | 0.3610 | -0.073900 | -7.75e-03 | 0.339000 | -9.75e-02 | 5.14e-01 | 9.45e-01 | 2.76e-03 | 3.90e-01 |
GPVI-mediated activation cascade | 30 | 7.64e-03 | 2.02e-02 | 0.3600 | 0.092600 | 3.19e-01 | -0.125000 | 6.11e-02 | 3.80e-01 | 2.49e-03 | 2.37e-01 | 5.63e-01 |
PCP/CE pathway | 85 | 3.20e-06 | 1.53e-05 | 0.3600 | -0.043200 | 6.25e-02 | 0.331000 | 1.19e-01 | 4.92e-01 | 3.20e-01 | 1.35e-07 | 5.92e-02 |
Regulation of TNFR1 signaling | 27 | 3.33e-02 | 6.65e-02 | 0.3600 | 0.075500 | 2.27e-01 | -0.224000 | -1.48e-01 | 4.97e-01 | 4.10e-02 | 4.45e-02 | 1.82e-01 |
Interleukin-2 signaling | 11 | 4.58e-01 | 5.33e-01 | 0.3600 | 0.025100 | 6.18e-02 | -0.315000 | -1.60e-01 | 8.86e-01 | 7.23e-01 | 7.06e-02 | 3.57e-01 |
Methylation | 11 | 1.22e-01 | 1.88e-01 | 0.3600 | 0.263000 | -1.73e-02 | 0.223000 | -9.97e-02 | 1.31e-01 | 9.21e-01 | 2.00e-01 | 5.67e-01 |
SHC-mediated cascade:FGFR1 | 11 | 2.43e-01 | 3.22e-01 | 0.3590 | 0.107000 | -1.83e-01 | -0.109000 | -2.69e-01 | 5.39e-01 | 2.94e-01 | 5.32e-01 | 1.22e-01 |
EPHA-mediated growth cone collapse | 14 | 7.22e-02 | 1.23e-01 | 0.3590 | 0.011800 | 3.00e-01 | -0.139000 | 1.39e-01 | 9.39e-01 | 5.20e-02 | 3.66e-01 | 3.68e-01 |
Diseases of programmed cell death | 20 | 7.58e-03 | 2.01e-02 | 0.3590 | -0.019300 | 1.13e-01 | 0.301000 | -1.59e-01 | 8.81e-01 | 3.81e-01 | 2.00e-02 | 2.17e-01 |
TICAM1, RIP1-mediated IKK complex recruitment | 16 | 3.41e-01 | 4.25e-01 | 0.3580 | 0.023700 | -5.57e-02 | -0.289000 | -2.03e-01 | 8.70e-01 | 7.00e-01 | 4.55e-02 | 1.59e-01 |
Interleukin-7 signaling | 20 | 1.63e-01 | 2.36e-01 | 0.3580 | -0.104000 | 1.73e-02 | -0.258000 | -2.25e-01 | 4.19e-01 | 8.94e-01 | 4.58e-02 | 8.15e-02 |
PLC beta mediated events | 47 | 8.53e-03 | 2.19e-02 | 0.3580 | -0.117000 | -2.34e-01 | -0.225000 | -9.47e-02 | 1.64e-01 | 5.49e-03 | 7.58e-03 | 2.62e-01 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 11 | 3.09e-01 | 3.91e-01 | 0.3570 | 0.098400 | 3.34e-01 | -0.073500 | -3.51e-02 | 5.72e-01 | 5.54e-02 | 6.73e-01 | 8.40e-01 |
Calnexin/calreticulin cycle | 23 | 2.65e-02 | 5.55e-02 | 0.3570 | -0.049000 | -2.85e-01 | 0.186000 | 9.66e-02 | 6.84e-01 | 1.82e-02 | 1.22e-01 | 4.23e-01 |
Activation of kainate receptors upon glutamate binding | 23 | 4.02e-02 | 7.71e-02 | 0.3570 | 0.001540 | 4.22e-02 | 0.035100 | 3.53e-01 | 9.90e-01 | 7.26e-01 | 7.71e-01 | 3.42e-03 |
Dual incision in TC-NER | 62 | 8.67e-06 | 3.94e-05 | 0.3570 | 0.140000 | 1.19e-01 | 0.302000 | -4.91e-02 | 5.75e-02 | 1.07e-01 | 3.90e-05 | 5.04e-01 |
HCMV Early Events | 53 | 1.44e-07 | 7.99e-07 | 0.3570 | 0.056100 | -8.64e-02 | 0.221000 | -2.61e-01 | 4.81e-01 | 2.77e-01 | 5.43e-03 | 1.04e-03 |
Rap1 signalling | 15 | 3.03e-01 | 3.86e-01 | 0.3570 | -0.097600 | -1.49e-03 | -0.297000 | -1.72e-01 | 5.13e-01 | 9.92e-01 | 4.68e-02 | 2.48e-01 |
Membrane binding and targetting of GAG proteins | 11 | 5.12e-01 | 5.82e-01 | 0.3560 | -0.187000 | -2.27e-01 | 0.183000 | 8.10e-02 | 2.82e-01 | 1.92e-01 | 2.94e-01 | 6.42e-01 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 11 | 5.12e-01 | 5.82e-01 | 0.3560 | -0.187000 | -2.27e-01 | 0.183000 | 8.10e-02 | 2.82e-01 | 1.92e-01 | 2.94e-01 | 6.42e-01 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 13 | 4.89e-01 | 5.62e-01 | 0.3550 | -0.034000 | -8.20e-02 | -0.285000 | -1.92e-01 | 8.32e-01 | 6.09e-01 | 7.49e-02 | 2.31e-01 |
Mitochondrial tRNA aminoacylation | 18 | 2.13e-01 | 2.91e-01 | 0.3550 | -0.141000 | -2.15e-01 | 0.221000 | 1.05e-01 | 3.01e-01 | 1.15e-01 | 1.05e-01 | 4.39e-01 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 31 | 1.08e-02 | 2.67e-02 | 0.3540 | -0.044900 | -2.36e-01 | 0.220000 | 1.39e-01 | 6.66e-01 | 2.33e-02 | 3.40e-02 | 1.79e-01 |
Triglyceride metabolism | 23 | 6.29e-02 | 1.11e-01 | 0.3540 | -0.053300 | 6.87e-02 | -0.143000 | -3.12e-01 | 6.58e-01 | 5.69e-01 | 2.34e-01 | 9.70e-03 |
Response of EIF2AK1 (HRI) to heme deficiency | 14 | 8.72e-02 | 1.43e-01 | 0.3540 | 0.107000 | 1.66e-01 | 0.212000 | -2.03e-01 | 4.89e-01 | 2.82e-01 | 1.70e-01 | 1.89e-01 |
Cell recruitment (pro-inflammatory response) | 19 | 9.90e-02 | 1.58e-01 | 0.3540 | -0.055200 | 1.81e-01 | 0.113000 | 2.76e-01 | 6.77e-01 | 1.71e-01 | 3.94e-01 | 3.72e-02 |
Purinergic signaling in leishmaniasis infection | 19 | 9.90e-02 | 1.58e-01 | 0.3540 | -0.055200 | 1.81e-01 | 0.113000 | 2.76e-01 | 6.77e-01 | 1.71e-01 | 3.94e-01 | 3.72e-02 |
Signaling by EGFR | 45 | 4.37e-02 | 8.25e-02 | 0.3530 | -0.151000 | -1.74e-01 | -0.178000 | -2.00e-01 | 7.94e-02 | 4.39e-02 | 3.86e-02 | 2.04e-02 |
DAP12 interactions | 28 | 9.88e-02 | 1.58e-01 | 0.3530 | 0.184000 | 2.90e-01 | -0.034200 | 7.25e-02 | 9.21e-02 | 7.86e-03 | 7.54e-01 | 5.07e-01 |
APC/C:Cdc20 mediated degradation of Cyclin B | 22 | 9.84e-03 | 2.46e-02 | 0.3530 | 0.187000 | -2.93e-02 | 0.291000 | -6.25e-02 | 1.29e-01 | 8.12e-01 | 1.81e-02 | 6.12e-01 |
Mitochondrial protein import | 59 | 5.12e-05 | 2.08e-04 | 0.3530 | 0.026400 | 6.02e-02 | 0.345000 | 3.14e-02 | 7.26e-01 | 4.24e-01 | 4.56e-06 | 6.77e-01 |
IRS-mediated signalling | 33 | 3.40e-02 | 6.73e-02 | 0.3520 | -0.011400 | -1.93e-01 | -0.149000 | -2.53e-01 | 9.10e-01 | 5.48e-02 | 1.38e-01 | 1.19e-02 |
Transport of bile salts and organic acids, metal ions and amine compounds | 49 | 1.04e-02 | 2.57e-02 | 0.3520 | 0.295000 | 1.86e-01 | -0.014700 | 4.49e-02 | 3.57e-04 | 2.45e-02 | 8.59e-01 | 5.87e-01 |
Synthesis of very long-chain fatty acyl-CoAs | 13 | 3.80e-01 | 4.65e-01 | 0.3520 | -0.081500 | -1.29e-01 | -0.075800 | -3.08e-01 | 6.11e-01 | 4.19e-01 | 6.36e-01 | 5.49e-02 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 68 | 2.34e-04 | 8.72e-04 | 0.3510 | -0.108000 | -1.96e-01 | 0.176000 | 2.05e-01 | 1.22e-01 | 5.31e-03 | 1.20e-02 | 3.42e-03 |
Chondroitin sulfate biosynthesis | 15 | 8.29e-02 | 1.38e-01 | 0.3510 | -0.146000 | 1.61e-01 | 0.061000 | 2.69e-01 | 3.29e-01 | 2.80e-01 | 6.83e-01 | 7.16e-02 |
Arachidonic acid metabolism | 36 | 1.77e-02 | 3.99e-02 | 0.3500 | 0.142000 | 2.47e-01 | -0.031600 | 2.01e-01 | 1.41e-01 | 1.02e-02 | 7.43e-01 | 3.70e-02 |
TNFR1-induced NFkappaB signaling pathway | 24 | 5.34e-02 | 9.73e-02 | 0.3500 | 0.014200 | 1.78e-01 | -0.193000 | -2.31e-01 | 9.04e-01 | 1.31e-01 | 1.01e-01 | 5.05e-02 |
RHO GTPases Activate NADPH Oxidases | 19 | 2.49e-01 | 3.29e-01 | 0.3500 | 0.186000 | 2.85e-01 | -0.071700 | 4.36e-02 | 1.61e-01 | 3.18e-02 | 5.88e-01 | 7.42e-01 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 32 | 6.38e-02 | 1.12e-01 | 0.3500 | 0.240000 | 2.07e-01 | -0.148000 | -2.15e-02 | 1.91e-02 | 4.32e-02 | 1.48e-01 | 8.33e-01 |
Regulation of TP53 Activity through Phosphorylation | 86 | 2.45e-11 | 2.79e-10 | 0.3500 | 0.108000 | 2.93e-02 | 0.216000 | -2.52e-01 | 8.50e-02 | 6.39e-01 | 5.44e-04 | 5.64e-05 |
Stimuli-sensing channels | 51 | 1.59e-02 | 3.67e-02 | 0.3490 | -0.248000 | -1.82e-01 | -0.147000 | -7.12e-02 | 2.20e-03 | 2.46e-02 | 6.89e-02 | 3.79e-01 |
Synthesis of PA | 24 | 2.57e-01 | 3.38e-01 | 0.3480 | -0.184000 | -1.83e-01 | -0.117000 | -2.01e-01 | 1.19e-01 | 1.22e-01 | 3.21e-01 | 8.84e-02 |
Signaling by PDGF | 47 | 3.94e-03 | 1.14e-02 | 0.3480 | -0.191000 | -1.05e-01 | -0.266000 | -5.60e-02 | 2.36e-02 | 2.12e-01 | 1.64e-03 | 5.07e-01 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 80 | 9.95e-06 | 4.49e-05 | 0.3480 | 0.105000 | 1.30e-01 | 0.303000 | 3.43e-02 | 1.04e-01 | 4.53e-02 | 2.82e-06 | 5.96e-01 |
Sialic acid metabolism | 25 | 8.39e-02 | 1.39e-01 | 0.3480 | -0.117000 | -2.07e-01 | 0.232000 | 1.03e-01 | 3.12e-01 | 7.38e-02 | 4.46e-02 | 3.75e-01 |
Incretin synthesis, secretion, and inactivation | 10 | 2.14e-01 | 2.92e-01 | 0.3470 | -0.000790 | 1.55e-01 | -0.130000 | 2.82e-01 | 9.97e-01 | 3.97e-01 | 4.76e-01 | 1.23e-01 |
RHO GTPases activate KTN1 | 10 | 2.33e-01 | 3.13e-01 | 0.3460 | -0.126000 | 5.88e-03 | -0.082400 | 3.12e-01 | 4.92e-01 | 9.74e-01 | 6.52e-01 | 8.75e-02 |
Regulation of FOXO transcriptional activity by acetylation | 10 | 2.29e-01 | 3.09e-01 | 0.3460 | 0.043200 | -1.12e-03 | 0.089700 | -3.31e-01 | 8.13e-01 | 9.95e-01 | 6.23e-01 | 6.97e-02 |
Formation of the cornified envelope | 15 | 3.90e-01 | 4.76e-01 | 0.3460 | -0.117000 | -2.37e-01 | -0.207000 | -8.40e-02 | 4.33e-01 | 1.12e-01 | 1.66e-01 | 5.73e-01 |
AURKA Activation by TPX2 | 71 | 2.34e-09 | 1.84e-08 | 0.3460 | 0.044900 | 1.83e-02 | 0.270000 | -2.10e-01 | 5.14e-01 | 7.90e-01 | 8.61e-05 | 2.19e-03 |
Plasma lipoprotein assembly, remodeling, and clearance | 47 | 1.36e-02 | 3.22e-02 | 0.3450 | -0.074400 | 3.12e-02 | 0.246000 | 2.29e-01 | 3.78e-01 | 7.12e-01 | 3.55e-03 | 6.76e-03 |
NF-kB is activated and signals survival | 11 | 5.01e-01 | 5.75e-01 | 0.3450 | -0.292000 | -1.58e-01 | 0.052800 | -7.64e-02 | 9.33e-02 | 3.64e-01 | 7.62e-01 | 6.61e-01 |
Transcriptional regulation of granulopoiesis | 26 | 3.52e-02 | 6.93e-02 | 0.3450 | 0.086400 | 2.49e-01 | 0.222000 | -1.32e-02 | 4.46e-01 | 2.81e-02 | 4.97e-02 | 9.08e-01 |
Signaling by Erythropoietin | 24 | 1.82e-01 | 2.57e-01 | 0.3450 | -0.005220 | -1.86e-02 | -0.194000 | -2.85e-01 | 9.65e-01 | 8.75e-01 | 1.01e-01 | 1.58e-02 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | 19 | 1.30e-02 | 3.11e-02 | 0.3440 | -0.019400 | 9.59e-02 | 0.269000 | -1.92e-01 | 8.84e-01 | 4.70e-01 | 4.26e-02 | 1.48e-01 |
Neurodegenerative Diseases | 19 | 1.30e-02 | 3.11e-02 | 0.3440 | -0.019400 | 9.59e-02 | 0.269000 | -1.92e-01 | 8.84e-01 | 4.70e-01 | 4.26e-02 | 1.48e-01 |
XBP1(S) activates chaperone genes | 47 | 4.30e-03 | 1.24e-02 | 0.3440 | -0.129000 | -1.87e-01 | 0.247000 | 7.75e-02 | 1.26e-01 | 2.66e-02 | 3.46e-03 | 3.58e-01 |
Smooth Muscle Contraction | 34 | 8.37e-05 | 3.30e-04 | 0.3430 | -0.122000 | 2.45e-01 | -0.057800 | 1.99e-01 | 2.19e-01 | 1.34e-02 | 5.60e-01 | 4.48e-02 |
Class B/2 (Secretin family receptors) | 42 | 8.65e-03 | 2.22e-02 | 0.3430 | -0.160000 | -6.66e-02 | 0.105000 | 2.76e-01 | 7.23e-02 | 4.56e-01 | 2.40e-01 | 1.98e-03 |
NOTCH4 Activation and Transmission of Signal to the Nucleus | 11 | 2.42e-01 | 3.21e-01 | 0.3420 | 0.000467 | 3.07e-01 | 0.017500 | 1.50e-01 | 9.98e-01 | 7.76e-02 | 9.20e-01 | 3.89e-01 |
COPII-mediated vesicle transport | 58 | 2.51e-03 | 7.70e-03 | 0.3420 | -0.156000 | -2.23e-01 | 0.177000 | 1.07e-01 | 3.98e-02 | 3.41e-03 | 1.97e-02 | 1.58e-01 |
Depolymerisation of the Nuclear Lamina | 15 | 4.79e-02 | 8.91e-02 | 0.3410 | 0.019600 | 1.56e-01 | 0.205000 | -2.23e-01 | 8.96e-01 | 2.97e-01 | 1.69e-01 | 1.34e-01 |
SUMOylation of transcription cofactors | 39 | 2.73e-02 | 5.69e-02 | 0.3410 | 0.021100 | -8.50e-02 | -0.153000 | -2.92e-01 | 8.20e-01 | 3.58e-01 | 9.75e-02 | 1.63e-03 |
Negative regulation of MET activity | 19 | 3.12e-01 | 3.93e-01 | 0.3410 | -0.106000 | -2.53e-01 | -0.138000 | -1.48e-01 | 4.22e-01 | 5.68e-02 | 2.99e-01 | 2.64e-01 |
ECM proteoglycans | 40 | 1.36e-03 | 4.46e-03 | 0.3400 | -0.092300 | -1.36e-02 | -0.327000 | 3.81e-03 | 3.13e-01 | 8.82e-01 | 3.49e-04 | 9.67e-01 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 65 | 5.15e-03 | 1.44e-02 | 0.3400 | -0.099300 | -1.78e-01 | -0.227000 | -1.49e-01 | 1.67e-01 | 1.32e-02 | 1.53e-03 | 3.76e-02 |
tRNA processing in the nucleus | 51 | 1.03e-05 | 4.61e-05 | 0.3390 | -0.055100 | -5.01e-02 | 0.309000 | -1.19e-01 | 4.96e-01 | 5.36e-01 | 1.38e-04 | 1.40e-01 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 25 | 1.72e-03 | 5.50e-03 | 0.3390 | 0.114000 | -1.47e-01 | 0.196000 | -2.06e-01 | 3.26e-01 | 2.03e-01 | 9.07e-02 | 7.51e-02 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 20 | 1.33e-02 | 3.16e-02 | 0.3390 | 0.081500 | -1.48e-01 | 0.279000 | -9.30e-02 | 5.28e-01 | 2.51e-01 | 3.09e-02 | 4.72e-01 |
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | 11 | 6.39e-01 | 6.90e-01 | 0.3390 | -0.054000 | -5.20e-02 | -0.249000 | -2.17e-01 | 7.57e-01 | 7.65e-01 | 1.53e-01 | 2.12e-01 |
Regulation of innate immune responses to cytosolic DNA | 11 | 5.19e-01 | 5.89e-01 | 0.3390 | 0.113000 | 2.97e-01 | 0.072100 | 9.34e-02 | 5.15e-01 | 8.84e-02 | 6.79e-01 | 5.92e-01 |
Synthesis of IP3 and IP4 in the cytosol | 21 | 5.43e-02 | 9.86e-02 | 0.3390 | -0.331000 | -5.68e-02 | -0.032700 | 3.38e-02 | 8.74e-03 | 6.52e-01 | 7.96e-01 | 7.89e-01 |
Cristae formation | 11 | 2.99e-01 | 3.82e-01 | 0.3380 | 0.187000 | 3.29e-02 | 0.279000 | -1.12e-02 | 2.82e-01 | 8.50e-01 | 1.09e-01 | 9.49e-01 |
SUMOylation of RNA binding proteins | 41 | 8.28e-05 | 3.27e-04 | 0.3380 | 0.002790 | -1.44e-01 | 0.169000 | -2.55e-01 | 9.75e-01 | 1.10e-01 | 6.18e-02 | 4.82e-03 |
Integration of energy metabolism | 85 | 2.03e-03 | 6.38e-03 | 0.3380 | -0.178000 | -2.24e-01 | -0.109000 | -1.43e-01 | 4.68e-03 | 3.61e-04 | 8.20e-02 | 2.31e-02 |
PI3K Cascade | 29 | 7.08e-02 | 1.22e-01 | 0.3380 | -0.039500 | -2.27e-01 | -0.120000 | -2.15e-01 | 7.13e-01 | 3.43e-02 | 2.63e-01 | 4.47e-02 |
Signaling by FGFR1 in disease | 31 | 4.88e-02 | 9.04e-02 | 0.3370 | 0.036700 | -1.64e-01 | -0.203000 | -2.10e-01 | 7.24e-01 | 1.13e-01 | 5.09e-02 | 4.27e-02 |
FOXO-mediated transcription | 52 | 5.24e-03 | 1.46e-02 | 0.3370 | 0.027800 | -4.20e-02 | -0.138000 | -3.03e-01 | 7.29e-01 | 6.01e-01 | 8.47e-02 | 1.58e-04 |
Negative regulation of FGFR1 signaling | 20 | 5.64e-02 | 1.02e-01 | 0.3370 | -0.043900 | -3.22e-01 | 0.043600 | -7.60e-02 | 7.34e-01 | 1.27e-02 | 7.36e-01 | 5.56e-01 |
Aquaporin-mediated transport | 34 | 4.51e-02 | 8.47e-02 | 0.3370 | -0.148000 | -2.16e-01 | 0.108000 | 1.81e-01 | 1.34e-01 | 2.92e-02 | 2.75e-01 | 6.78e-02 |
PIWI-interacting RNA (piRNA) biogenesis | 16 | 2.82e-01 | 3.64e-01 | 0.3360 | -0.003440 | 6.46e-03 | 0.320000 | 1.04e-01 | 9.81e-01 | 9.64e-01 | 2.67e-02 | 4.73e-01 |
Regulation of TP53 Activity through Association with Co-factors | 12 | 5.14e-01 | 5.84e-01 | 0.3360 | -0.113000 | -2.73e-01 | -0.138000 | -8.23e-02 | 4.99e-01 | 1.02e-01 | 4.07e-01 | 6.22e-01 |
Netrin-1 signaling | 41 | 2.18e-02 | 4.74e-02 | 0.3360 | -0.013900 | -1.19e-01 | -0.284000 | -1.33e-01 | 8.78e-01 | 1.87e-01 | 1.65e-03 | 1.41e-01 |
Regulation of IFNG signaling | 13 | 2.30e-01 | 3.09e-01 | 0.3360 | 0.190000 | 9.50e-02 | -0.077100 | 2.48e-01 | 2.36e-01 | 5.53e-01 | 6.31e-01 | 1.21e-01 |
Asparagine N-linked glycosylation | 247 | 7.65e-15 | 1.36e-13 | 0.3350 | -0.113000 | -2.14e-01 | 0.166000 | 1.62e-01 | 2.27e-03 | 7.63e-09 | 7.68e-06 | 1.27e-05 |
Fanconi Anemia Pathway | 31 | 2.05e-03 | 6.42e-03 | 0.3350 | 0.034900 | 5.92e-02 | 0.307000 | -1.16e-01 | 7.37e-01 | 5.68e-01 | 3.10e-03 | 2.66e-01 |
DNA Repair | 266 | 1.70e-24 | 7.98e-23 | 0.3350 | 0.140000 | 1.25e-01 | 0.259000 | -1.01e-01 | 9.35e-05 | 4.89e-04 | 4.55e-13 | 4.81e-03 |
Inflammasomes | 19 | 4.70e-03 | 1.33e-02 | 0.3350 | -0.150000 | 2.82e-01 | -0.056300 | 8.26e-02 | 2.59e-01 | 3.33e-02 | 6.71e-01 | 5.33e-01 |
Assembly of active LPL and LIPC lipase complexes | 11 | 6.07e-01 | 6.62e-01 | 0.3350 | -0.272000 | -1.82e-01 | 0.018200 | 6.92e-02 | 1.19e-01 | 2.97e-01 | 9.17e-01 | 6.91e-01 |
Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 11 | 5.75e-01 | 6.36e-01 | 0.3340 | 0.217000 | 1.25e-01 | -0.135000 | -1.76e-01 | 2.14e-01 | 4.71e-01 | 4.39e-01 | 3.13e-01 |
Gap junction trafficking | 13 | 5.27e-01 | 5.95e-01 | 0.3340 | -0.061400 | -5.04e-02 | 0.241000 | 2.17e-01 | 7.02e-01 | 7.53e-01 | 1.32e-01 | 1.76e-01 |
HS-GAG degradation | 19 | 7.95e-02 | 1.33e-01 | 0.3340 | -0.200000 | 5.97e-03 | 0.019500 | 2.67e-01 | 1.32e-01 | 9.64e-01 | 8.83e-01 | 4.43e-02 |
Cleavage of the damaged pyrimidine | 16 | 9.52e-02 | 1.53e-01 | 0.3340 | 0.016400 | 3.18e-01 | 0.100000 | 6.63e-03 | 9.09e-01 | 2.78e-02 | 4.87e-01 | 9.63e-01 |
Depyrimidination | 16 | 9.52e-02 | 1.53e-01 | 0.3340 | 0.016400 | 3.18e-01 | 0.100000 | 6.63e-03 | 9.09e-01 | 2.78e-02 | 4.87e-01 | 9.63e-01 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 16 | 9.52e-02 | 1.53e-01 | 0.3340 | 0.016400 | 3.18e-01 | 0.100000 | 6.63e-03 | 9.09e-01 | 2.78e-02 | 4.87e-01 | 9.63e-01 |
RUNX3 regulates NOTCH signaling | 14 | 4.82e-01 | 5.56e-01 | 0.3330 | -0.089800 | -7.81e-02 | -0.278000 | -1.41e-01 | 5.61e-01 | 6.13e-01 | 7.20e-02 | 3.61e-01 |
Ca2+ pathway | 51 | 3.54e-03 | 1.04e-02 | 0.3330 | -0.197000 | -1.26e-01 | -0.237000 | -1.66e-02 | 1.52e-02 | 1.19e-01 | 3.43e-03 | 8.38e-01 |
Formation of tubulin folding intermediates by CCT/TriC | 19 | 2.44e-02 | 5.20e-02 | 0.3320 | 0.024900 | -1.29e-01 | 0.180000 | -2.46e-01 | 8.51e-01 | 3.30e-01 | 1.75e-01 | 6.33e-02 |
Purine ribonucleoside monophosphate biosynthesis | 12 | 2.89e-01 | 3.71e-01 | 0.3320 | 0.030000 | 1.31e-01 | 0.303000 | -9.69e-03 | 8.57e-01 | 4.33e-01 | 6.88e-02 | 9.54e-01 |
Signaling by EGFR in Cancer | 20 | 3.92e-01 | 4.77e-01 | 0.3310 | -0.177000 | -1.95e-01 | -0.080300 | -1.84e-01 | 1.70e-01 | 1.31e-01 | 5.34e-01 | 1.55e-01 |
Selective autophagy | 52 | 1.53e-02 | 3.55e-02 | 0.3310 | -0.195000 | -2.47e-01 | 0.042300 | -9.41e-02 | 1.53e-02 | 2.06e-03 | 5.98e-01 | 2.41e-01 |
Formation of the Early Elongation Complex | 32 | 2.24e-02 | 4.86e-02 | 0.3310 | -0.147000 | -1.11e-01 | 0.275000 | 1.12e-02 | 1.51e-01 | 2.78e-01 | 7.08e-03 | 9.13e-01 |
Formation of the HIV-1 Early Elongation Complex | 32 | 2.24e-02 | 4.86e-02 | 0.3310 | -0.147000 | -1.11e-01 | 0.275000 | 1.12e-02 | 1.51e-01 | 2.78e-01 | 7.08e-03 | 9.13e-01 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 14 | 4.33e-01 | 5.13e-01 | 0.3310 | -0.002700 | -1.48e-01 | -0.253000 | -1.53e-01 | 9.86e-01 | 3.38e-01 | 1.01e-01 | 3.21e-01 |
TRP channels | 12 | 1.97e-01 | 2.73e-01 | 0.3310 | 0.034000 | 2.30e-01 | -0.159000 | 1.73e-01 | 8.38e-01 | 1.67e-01 | 3.40e-01 | 2.99e-01 |
Glycosphingolipid metabolism | 33 | 2.63e-02 | 5.51e-02 | 0.3300 | -0.141000 | 5.52e-02 | 0.142000 | 2.57e-01 | 1.62e-01 | 5.84e-01 | 1.59e-01 | 1.07e-02 |
Diseases of DNA repair | 10 | 4.24e-01 | 5.05e-01 | 0.3300 | -0.105000 | 7.60e-02 | 0.293000 | 7.82e-02 | 5.64e-01 | 6.77e-01 | 1.09e-01 | 6.69e-01 |
KSRP (KHSRP) binds and destabilizes mRNA | 16 | 4.47e-01 | 5.24e-01 | 0.3290 | 0.259000 | 1.94e-01 | 0.034200 | -5.02e-02 | 7.33e-02 | 1.79e-01 | 8.13e-01 | 7.28e-01 |
Global Genome Nucleotide Excision Repair (GG-NER) | 80 | 8.17e-06 | 3.72e-05 | 0.3290 | 0.159000 | 8.90e-02 | 0.274000 | -8.15e-03 | 1.39e-02 | 1.69e-01 | 2.35e-05 | 9.00e-01 |
Hedgehog 'off' state | 90 | 4.05e-05 | 1.69e-04 | 0.3290 | 0.042400 | 3.91e-03 | 0.301000 | 1.25e-01 | 4.88e-01 | 9.49e-01 | 8.10e-07 | 4.00e-02 |
Dopamine Neurotransmitter Release Cycle | 13 | 2.00e-01 | 2.76e-01 | 0.3290 | 0.064600 | -5.50e-02 | -0.317000 | 2.06e-02 | 6.87e-01 | 7.31e-01 | 4.78e-02 | 8.98e-01 |
Deactivation of the beta-catenin transactivating complex | 34 | 1.33e-01 | 2.02e-01 | 0.3290 | -0.149000 | -1.36e-01 | -0.132000 | -2.23e-01 | 1.33e-01 | 1.70e-01 | 1.82e-01 | 2.45e-02 |
Plasma lipoprotein remodeling | 15 | 3.18e-01 | 3.99e-01 | 0.3280 | -0.143000 | 5.41e-02 | 0.190000 | 2.20e-01 | 3.38e-01 | 7.17e-01 | 2.03e-01 | 1.40e-01 |
NRAGE signals death through JNK | 54 | 5.85e-03 | 1.61e-02 | 0.3280 | -0.248000 | -1.41e-01 | -0.162000 | -1.57e-02 | 1.66e-03 | 7.29e-02 | 3.91e-02 | 8.42e-01 |
Neutrophil degranulation | 353 | 2.25e-15 | 4.16e-14 | 0.3280 | 0.073500 | 1.34e-01 | 0.149000 | 2.49e-01 | 1.84e-02 | 1.79e-05 | 1.70e-06 | 1.22e-15 |
SUMO E3 ligases SUMOylate target proteins | 143 | 3.36e-13 | 4.85e-12 | 0.3280 | 0.143000 | 3.77e-02 | 0.053200 | -2.88e-01 | 3.25e-03 | 4.37e-01 | 2.73e-01 | 3.02e-09 |
HIV elongation arrest and recovery | 28 | 3.47e-03 | 1.02e-02 | 0.3280 | -0.036200 | 1.48e-02 | 0.293000 | -1.41e-01 | 7.40e-01 | 8.92e-01 | 7.27e-03 | 1.98e-01 |
Pausing and recovery of HIV elongation | 28 | 3.47e-03 | 1.02e-02 | 0.3280 | -0.036200 | 1.48e-02 | 0.293000 | -1.41e-01 | 7.40e-01 | 8.92e-01 | 7.27e-03 | 1.98e-01 |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | 13 | 4.37e-01 | 5.15e-01 | 0.3270 | -0.292000 | -1.31e-01 | -0.011000 | 6.79e-02 | 6.84e-02 | 4.12e-01 | 9.45e-01 | 6.72e-01 |
Defective EXT2 causes exostoses 2 | 13 | 4.37e-01 | 5.15e-01 | 0.3270 | -0.292000 | -1.31e-01 | -0.011000 | 6.79e-02 | 6.84e-02 | 4.12e-01 | 9.45e-01 | 6.72e-01 |
NOTCH1 Intracellular Domain Regulates Transcription | 43 | 6.60e-02 | 1.15e-01 | 0.3270 | -0.075700 | -1.57e-01 | -0.208000 | -1.83e-01 | 3.91e-01 | 7.54e-02 | 1.81e-02 | 3.85e-02 |
Recruitment of NuMA to mitotic centrosomes | 79 | 2.17e-09 | 1.73e-08 | 0.3260 | 0.011900 | -1.94e-02 | 0.250000 | -2.09e-01 | 8.55e-01 | 7.66e-01 | 1.27e-04 | 1.35e-03 |
Loss of Nlp from mitotic centrosomes | 68 | 5.14e-08 | 3.08e-07 | 0.3260 | 0.011100 | -1.46e-02 | 0.253000 | -2.04e-01 | 8.74e-01 | 8.35e-01 | 3.17e-04 | 3.58e-03 |
Loss of proteins required for interphase microtubule organization from the centrosome | 68 | 5.14e-08 | 3.08e-07 | 0.3260 | 0.011100 | -1.46e-02 | 0.253000 | -2.04e-01 | 8.74e-01 | 8.35e-01 | 3.17e-04 | 3.58e-03 |
Vasopressin regulates renal water homeostasis via Aquaporins | 32 | 5.29e-02 | 9.65e-02 | 0.3260 | -0.100000 | -1.84e-01 | 0.123000 | 2.17e-01 | 3.26e-01 | 7.17e-02 | 2.28e-01 | 3.41e-02 |
Regulation of TP53 Expression and Degradation | 33 | 2.83e-03 | 8.57e-03 | 0.3260 | 0.116000 | -7.20e-02 | 0.042300 | -2.93e-01 | 2.51e-01 | 4.74e-01 | 6.74e-01 | 3.63e-03 |
Regulation of KIT signaling | 16 | 2.27e-01 | 3.07e-01 | 0.3250 | 0.120000 | 1.68e-01 | -0.251000 | 1.39e-02 | 4.05e-01 | 2.46e-01 | 8.21e-02 | 9.23e-01 |
G-protein mediated events | 48 | 2.00e-02 | 4.43e-02 | 0.3250 | -0.109000 | -2.13e-01 | -0.206000 | -7.74e-02 | 1.91e-01 | 1.09e-02 | 1.35e-02 | 3.54e-01 |
Erythropoietin activates RAS | 13 | 4.20e-01 | 5.02e-01 | 0.3250 | 0.065400 | -3.15e-02 | -0.105000 | -2.99e-01 | 6.83e-01 | 8.44e-01 | 5.14e-01 | 6.20e-02 |
Activation of BAD and translocation to mitochondria | 14 | 6.18e-01 | 6.72e-01 | 0.3250 | 0.224000 | 2.26e-01 | 0.035800 | 5.54e-02 | 1.47e-01 | 1.43e-01 | 8.16e-01 | 7.20e-01 |
FCERI mediated NF-kB activation | 72 | 1.78e-04 | 6.82e-04 | 0.3240 | 0.143000 | 1.12e-01 | 0.268000 | 2.02e-02 | 3.56e-02 | 1.02e-01 | 8.59e-05 | 7.68e-01 |
mRNA decay by 3' to 5' exoribonuclease | 15 | 5.65e-01 | 6.28e-01 | 0.3240 | 0.127000 | 1.52e-01 | 0.215000 | 1.40e-01 | 3.95e-01 | 3.07e-01 | 1.50e-01 | 3.48e-01 |
Killing mechanisms | 10 | 6.57e-01 | 7.05e-01 | 0.3240 | -0.237000 | -1.47e-01 | 0.098200 | 1.32e-01 | 1.94e-01 | 4.22e-01 | 5.91e-01 | 4.70e-01 |
WNT5:FZD7-mediated leishmania damping | 10 | 6.57e-01 | 7.05e-01 | 0.3240 | -0.237000 | -1.47e-01 | 0.098200 | 1.32e-01 | 1.94e-01 | 4.22e-01 | 5.91e-01 | 4.70e-01 |
Regulation of localization of FOXO transcription factors | 11 | 3.38e-01 | 4.22e-01 | 0.3240 | 0.126000 | 1.82e-02 | 0.011200 | -2.98e-01 | 4.69e-01 | 9.17e-01 | 9.49e-01 | 8.73e-02 |
Downstream signaling of activated FGFR1 | 21 | 1.22e-01 | 1.88e-01 | 0.3240 | 0.045900 | -1.96e-01 | -0.138000 | -2.12e-01 | 7.16e-01 | 1.19e-01 | 2.74e-01 | 9.24e-02 |
IL-6-type cytokine receptor ligand interactions | 12 | 2.70e-01 | 3.51e-01 | 0.3230 | 0.245000 | 7.09e-02 | -0.112000 | 1.64e-01 | 1.41e-01 | 6.71e-01 | 5.01e-01 | 3.27e-01 |
Mitochondrial biogenesis | 69 | 1.31e-03 | 4.33e-03 | 0.3230 | 0.010700 | -1.31e-01 | -0.144000 | -2.58e-01 | 8.78e-01 | 6.10e-02 | 3.82e-02 | 2.14e-04 |
Reduction of cytosolic Ca++ levels | 10 | 5.63e-01 | 6.27e-01 | 0.3230 | -0.119000 | -1.54e-01 | -0.258000 | -1.98e-02 | 5.15e-01 | 3.99e-01 | 1.58e-01 | 9.13e-01 |
SUMOylation | 149 | 1.28e-13 | 1.98e-12 | 0.3230 | 0.143000 | 3.51e-02 | 0.060300 | -2.81e-01 | 2.58e-03 | 4.61e-01 | 2.05e-01 | 3.36e-09 |
RHO GTPases Activate WASPs and WAVEs | 35 | 4.19e-02 | 7.97e-02 | 0.3230 | 0.208000 | 1.83e-01 | -0.086500 | 1.42e-01 | 3.33e-02 | 6.09e-02 | 3.76e-01 | 1.46e-01 |
Ovarian tumor domain proteases | 34 | 7.26e-02 | 1.23e-01 | 0.3230 | 0.051800 | 4.72e-02 | -0.159000 | -2.72e-01 | 6.01e-01 | 6.34e-01 | 1.08e-01 | 6.07e-03 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 36 | 9.47e-04 | 3.18e-03 | 0.3220 | 0.143000 | 3.56e-02 | 0.237000 | -1.61e-01 | 1.38e-01 | 7.12e-01 | 1.38e-02 | 9.55e-02 |
Diseases of mitotic cell cycle | 36 | 9.47e-04 | 3.18e-03 | 0.3220 | 0.143000 | 3.56e-02 | 0.237000 | -1.61e-01 | 1.38e-01 | 7.12e-01 | 1.38e-02 | 9.55e-02 |
Signaling by ERBB2 KD Mutants | 21 | 4.01e-01 | 4.85e-01 | 0.3220 | -0.203000 | -1.52e-01 | -0.146000 | -1.35e-01 | 1.07e-01 | 2.28e-01 | 2.48e-01 | 2.84e-01 |
Gastrin-CREB signalling pathway via PKC and MAPK | 16 | 4.81e-01 | 5.56e-01 | 0.3210 | -0.199000 | -1.08e-01 | -0.166000 | -1.56e-01 | 1.67e-01 | 4.56e-01 | 2.49e-01 | 2.81e-01 |
Adherens junctions interactions | 14 | 5.62e-01 | 6.27e-01 | 0.3210 | -0.154000 | -2.00e-01 | -0.187000 | -6.61e-02 | 3.19e-01 | 1.95e-01 | 2.26e-01 | 6.68e-01 |
Olfactory Signaling Pathway | 12 | 3.68e-01 | 4.54e-01 | 0.3210 | -0.101000 | -2.46e-02 | 0.302000 | 3.25e-02 | 5.46e-01 | 8.83e-01 | 7.01e-02 | 8.46e-01 |
Binding and Uptake of Ligands by Scavenger Receptors | 30 | 6.02e-02 | 1.07e-01 | 0.3200 | -0.171000 | 4.22e-04 | 0.135000 | 2.35e-01 | 1.06e-01 | 9.97e-01 | 2.02e-01 | 2.58e-02 |
SUMOylation of DNA damage response and repair proteins | 66 | 3.07e-07 | 1.62e-06 | 0.3200 | 0.120000 | 1.71e-03 | 0.178000 | -2.38e-01 | 9.35e-02 | 9.81e-01 | 1.24e-02 | 8.49e-04 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 9.75e-02 | 1.56e-01 | 0.3200 | 0.062400 | 1.13e-01 | 0.161000 | -2.44e-01 | 6.76e-01 | 4.49e-01 | 2.80e-01 | 1.02e-01 |
Branched-chain amino acid catabolism | 21 | 6.98e-02 | 1.20e-01 | 0.3190 | 0.085900 | -2.02e-01 | -0.184000 | -1.41e-01 | 4.96e-01 | 1.10e-01 | 1.45e-01 | 2.62e-01 |
Negative regulation of FGFR3 signaling | 19 | 6.76e-02 | 1.17e-01 | 0.3180 | -0.006180 | -3.02e-01 | 0.024200 | -9.67e-02 | 9.63e-01 | 2.26e-02 | 8.55e-01 | 4.66e-01 |
Downstream TCR signaling | 78 | 2.03e-04 | 7.69e-04 | 0.3180 | 0.183000 | 1.61e-01 | 0.202000 | -2.72e-02 | 5.15e-03 | 1.41e-02 | 2.07e-03 | 6.78e-01 |
Glutamate Neurotransmitter Release Cycle | 16 | 4.32e-01 | 5.13e-01 | 0.3180 | -0.024400 | 1.01e-02 | -0.271000 | -1.64e-01 | 8.66e-01 | 9.44e-01 | 6.11e-02 | 2.55e-01 |
Maturation of nucleoprotein | 10 | 5.35e-01 | 6.01e-01 | 0.3170 | 0.095800 | 2.16e-01 | -0.038000 | 2.07e-01 | 6.00e-01 | 2.36e-01 | 8.35e-01 | 2.56e-01 |
Ub-specific processing proteases | 165 | 1.20e-09 | 1.01e-08 | 0.3170 | 0.215000 | 1.46e-01 | 0.016500 | -1.81e-01 | 2.06e-06 | 1.25e-03 | 7.15e-01 | 6.42e-05 |
SARS-CoV-1 Infection | 41 | 1.31e-02 | 3.13e-02 | 0.3170 | -0.043800 | -1.34e-01 | 0.269000 | 9.00e-02 | 6.28e-01 | 1.38e-01 | 2.89e-03 | 3.19e-01 |
TCR signaling | 99 | 2.82e-04 | 1.03e-03 | 0.3160 | 0.195000 | 2.33e-01 | 0.081900 | -3.01e-02 | 8.14e-04 | 6.24e-05 | 1.60e-01 | 6.06e-01 |
WNT5A-dependent internalization of FZD4 | 15 | 2.42e-01 | 3.21e-01 | 0.3160 | -0.264000 | -8.46e-02 | 0.132000 | -7.44e-02 | 7.67e-02 | 5.71e-01 | 3.75e-01 | 6.18e-01 |
Constitutive Signaling by Overexpressed ERBB2 | 10 | 5.55e-01 | 6.21e-01 | 0.3160 | -0.023800 | -7.60e-02 | -0.054500 | -3.00e-01 | 8.96e-01 | 6.77e-01 | 7.65e-01 | 1.00e-01 |
Biosynthesis of DHA-derived SPMs | 11 | 3.60e-01 | 4.47e-01 | 0.3150 | 0.071500 | 2.22e-01 | -0.128000 | 1.69e-01 | 6.82e-01 | 2.02e-01 | 4.64e-01 | 3.32e-01 |
Regulation of PLK1 Activity at G2/M Transition | 84 | 2.51e-09 | 1.96e-08 | 0.3150 | 0.026200 | -3.64e-02 | 0.230000 | -2.10e-01 | 6.78e-01 | 5.65e-01 | 2.65e-04 | 9.02e-04 |
Processing of Capped Intronless Pre-mRNA | 26 | 1.74e-02 | 3.95e-02 | 0.3140 | 0.136000 | 3.78e-02 | 0.107000 | -2.59e-01 | 2.31e-01 | 7.39e-01 | 3.44e-01 | 2.23e-02 |
Glutathione conjugation | 28 | 3.89e-02 | 7.49e-02 | 0.3140 | 0.181000 | -2.77e-02 | 0.226000 | 1.18e-01 | 9.79e-02 | 8.00e-01 | 3.86e-02 | 2.81e-01 |
PKA-mediated phosphorylation of CREB | 18 | 1.34e-01 | 2.04e-01 | 0.3130 | -0.052500 | -3.09e-01 | -0.007790 | 1.04e-02 | 7.00e-01 | 2.34e-02 | 9.54e-01 | 9.39e-01 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) | 33 | 7.48e-02 | 1.26e-01 | 0.3130 | -0.123000 | -1.94e-01 | -0.000264 | -2.13e-01 | 2.23e-01 | 5.37e-02 | 9.98e-01 | 3.42e-02 |
Synthesis of substrates in N-glycan biosythesis | 54 | 9.88e-03 | 2.47e-02 | 0.3120 | -0.086300 | -1.46e-01 | 0.161000 | 2.07e-01 | 2.73e-01 | 6.34e-02 | 4.13e-02 | 8.58e-03 |
Iron uptake and transport | 48 | 1.78e-02 | 4.01e-02 | 0.3110 | 0.010300 | -7.74e-02 | 0.227000 | 1.98e-01 | 9.02e-01 | 3.54e-01 | 6.51e-03 | 1.78e-02 |
SUMOylation of chromatin organization proteins | 49 | 8.70e-05 | 3.41e-04 | 0.3110 | 0.021700 | -1.45e-01 | 0.123000 | -2.44e-01 | 7.93e-01 | 7.87e-02 | 1.36e-01 | 3.11e-03 |
Base-Excision Repair, AP Site Formation | 18 | 6.99e-02 | 1.20e-01 | 0.3100 | -0.029600 | 2.88e-01 | 0.107000 | 3.16e-02 | 8.28e-01 | 3.47e-02 | 4.30e-01 | 8.17e-01 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 27 | 7.44e-02 | 1.25e-01 | 0.3100 | 0.092000 | 1.05e-01 | -0.041400 | -2.73e-01 | 4.08e-01 | 3.44e-01 | 7.10e-01 | 1.40e-02 |
MAPK6/MAPK4 signaling | 77 | 1.48e-04 | 5.72e-04 | 0.3100 | 0.041900 | 9.85e-02 | 0.287000 | 4.54e-02 | 5.26e-01 | 1.35e-01 | 1.36e-05 | 4.92e-01 |
ER to Golgi Anterograde Transport | 120 | 1.76e-05 | 7.64e-05 | 0.3090 | -0.146000 | -2.05e-01 | 0.148000 | 1.03e-01 | 5.88e-03 | 1.09e-04 | 5.20e-03 | 5.18e-02 |
Amine ligand-binding receptors | 12 | 3.64e-01 | 4.49e-01 | 0.3090 | 0.113000 | -1.50e-01 | -0.155000 | -1.91e-01 | 4.99e-01 | 3.70e-01 | 3.54e-01 | 2.52e-01 |
Signaling by FGFR4 | 28 | 5.87e-02 | 1.05e-01 | 0.3090 | -0.005530 | -2.26e-01 | -0.058400 | -2.02e-01 | 9.60e-01 | 3.88e-02 | 5.93e-01 | 6.39e-02 |
Signaling by Hippo | 19 | 1.85e-01 | 2.60e-01 | 0.3090 | -0.052000 | -2.71e-01 | -0.133000 | -3.80e-02 | 6.95e-01 | 4.08e-02 | 3.16e-01 | 7.74e-01 |
Glucagon signaling in metabolic regulation | 25 | 1.45e-01 | 2.18e-01 | 0.3080 | -0.071100 | -1.37e-01 | 0.111000 | 2.43e-01 | 5.39e-01 | 2.35e-01 | 3.36e-01 | 3.58e-02 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 18 | 1.12e-02 | 2.76e-02 | 0.3080 | -0.203000 | 2.12e-01 | -0.086700 | 3.32e-02 | 1.36e-01 | 1.19e-01 | 5.24e-01 | 8.07e-01 |
Ion transport by P-type ATPases | 36 | 4.22e-02 | 8.02e-02 | 0.3070 | -0.152000 | -1.63e-01 | -0.209000 | 2.65e-02 | 1.14e-01 | 9.09e-02 | 2.97e-02 | 7.83e-01 |
DCC mediated attractive signaling | 13 | 3.92e-01 | 4.77e-01 | 0.3070 | 0.136000 | 1.64e-01 | -0.216000 | 4.65e-02 | 3.95e-01 | 3.07e-01 | 1.77e-01 | 7.72e-01 |
Tie2 Signaling | 16 | 4.05e-01 | 4.88e-01 | 0.3070 | 0.045000 | -1.29e-01 | -0.173000 | -2.13e-01 | 7.55e-01 | 3.72e-01 | 2.32e-01 | 1.40e-01 |
Downstream signaling events of B Cell Receptor (BCR) | 73 | 3.80e-04 | 1.36e-03 | 0.3070 | 0.153000 | 1.45e-01 | 0.221000 | -2.49e-02 | 2.36e-02 | 3.22e-02 | 1.12e-03 | 7.13e-01 |
Centrosome maturation | 80 | 2.07e-08 | 1.36e-07 | 0.3060 | 0.005620 | -5.50e-03 | 0.228000 | -2.04e-01 | 9.31e-01 | 9.32e-01 | 4.21e-04 | 1.61e-03 |
Recruitment of mitotic centrosome proteins and complexes | 80 | 2.07e-08 | 1.36e-07 | 0.3060 | 0.005620 | -5.50e-03 | 0.228000 | -2.04e-01 | 9.31e-01 | 9.32e-01 | 4.21e-04 | 1.61e-03 |
NCAM signaling for neurite out-growth | 46 | 3.36e-02 | 6.66e-02 | 0.3060 | -0.233000 | -1.47e-01 | -0.134000 | 4.59e-03 | 6.40e-03 | 8.52e-02 | 1.16e-01 | 9.57e-01 |
NGF-stimulated transcription | 34 | 1.40e-01 | 2.10e-01 | 0.3060 | -0.160000 | -2.49e-01 | -0.075600 | -7.26e-03 | 1.07e-01 | 1.19e-02 | 4.46e-01 | 9.42e-01 |
GRB2 events in EGFR signaling | 10 | 7.64e-01 | 8.04e-01 | 0.3060 | -0.201000 | -2.19e-01 | -0.070300 | 6.26e-03 | 2.71e-01 | 2.30e-01 | 7.00e-01 | 9.73e-01 |
Other interleukin signaling | 19 | 2.70e-01 | 3.51e-01 | 0.3060 | 0.060800 | 2.15e-01 | 0.028900 | 2.06e-01 | 6.46e-01 | 1.05e-01 | 8.27e-01 | 1.19e-01 |
Trafficking of GluR2-containing AMPA receptors | 13 | 4.76e-01 | 5.52e-01 | 0.3050 | -0.261000 | -1.01e-01 | -0.016100 | -1.21e-01 | 1.04e-01 | 5.30e-01 | 9.20e-01 | 4.49e-01 |
SHC1 events in ERBB2 signaling | 19 | 4.03e-01 | 4.86e-01 | 0.3050 | -0.207000 | -1.23e-01 | -0.175000 | -6.45e-02 | 1.18e-01 | 3.52e-01 | 1.87e-01 | 6.26e-01 |
Spry regulation of FGF signaling | 14 | 4.22e-01 | 5.03e-01 | 0.3050 | -0.114000 | -2.58e-01 | 0.115000 | -8.49e-03 | 4.62e-01 | 9.51e-02 | 4.55e-01 | 9.56e-01 |
Antiviral mechanism by IFN-stimulated genes | 70 | 1.54e-05 | 6.74e-05 | 0.3040 | 0.158000 | 7.93e-02 | 0.220000 | -1.13e-01 | 2.22e-02 | 2.52e-01 | 1.45e-03 | 1.03e-01 |
CD28 co-stimulation | 32 | 1.51e-01 | 2.23e-01 | 0.3040 | 0.230000 | 1.46e-01 | -0.111000 | -7.74e-02 | 2.45e-02 | 1.53e-01 | 2.76e-01 | 4.49e-01 |
Reproduction | 55 | 7.57e-04 | 2.59e-03 | 0.3040 | 0.131000 | 1.83e-01 | 0.147000 | -1.42e-01 | 9.19e-02 | 1.91e-02 | 5.92e-02 | 6.97e-02 |
MTOR signalling | 39 | 8.75e-03 | 2.23e-02 | 0.3040 | -0.066900 | -2.42e-01 | 0.094900 | -1.42e-01 | 4.70e-01 | 9.07e-03 | 3.05e-01 | 1.24e-01 |
Transport of Mature Transcript to Cytoplasm | 74 | 7.98e-07 | 4.06e-06 | 0.3030 | 0.086400 | 7.91e-02 | 0.151000 | -2.36e-01 | 1.99e-01 | 2.40e-01 | 2.52e-02 | 4.56e-04 |
Chemokine receptors bind chemokines | 26 | 5.86e-02 | 1.05e-01 | 0.3030 | 0.120000 | 1.47e-01 | -0.113000 | 2.08e-01 | 2.89e-01 | 1.96e-01 | 3.19e-01 | 6.65e-02 |
Cell junction organization | 50 | 4.81e-03 | 1.36e-02 | 0.3030 | -0.161000 | -5.23e-02 | -0.250000 | -2.92e-02 | 4.91e-02 | 5.23e-01 | 2.28e-03 | 7.21e-01 |
Activation of NMDA receptors and postsynaptic events | 58 | 1.90e-02 | 4.21e-02 | 0.3020 | -0.098800 | -1.86e-01 | -0.200000 | -8.47e-02 | 1.94e-01 | 1.45e-02 | 8.44e-03 | 2.65e-01 |
Extracellular matrix organization | 218 | 2.13e-19 | 5.59e-18 | 0.3020 | -0.200000 | -2.60e-02 | -0.184000 | 1.30e-01 | 4.15e-07 | 5.09e-01 | 3.02e-06 | 1.01e-03 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 22 | 2.57e-01 | 3.38e-01 | 0.3010 | -0.138000 | -1.18e-01 | 0.230000 | 7.17e-02 | 2.62e-01 | 3.40e-01 | 6.23e-02 | 5.60e-01 |
Downstream signal transduction | 28 | 2.84e-01 | 3.66e-01 | 0.3010 | -0.033900 | -4.89e-02 | -0.217000 | -2.00e-01 | 7.56e-01 | 6.54e-01 | 4.73e-02 | 6.67e-02 |
The NLRP3 inflammasome | 14 | 1.20e-01 | 1.86e-01 | 0.3000 | -0.165000 | 1.88e-01 | 0.069200 | 1.50e-01 | 2.85e-01 | 2.24e-01 | 6.54e-01 | 3.30e-01 |
Regulation of actin dynamics for phagocytic cup formation | 63 | 1.68e-02 | 3.84e-02 | 0.3000 | 0.138000 | 2.06e-01 | 0.033800 | 1.66e-01 | 5.93e-02 | 4.76e-03 | 6.43e-01 | 2.32e-02 |
Chondroitin sulfate/dermatan sulfate metabolism | 41 | 6.35e-03 | 1.72e-02 | 0.3000 | -0.131000 | 9.36e-02 | 0.073800 | 2.42e-01 | 1.46e-01 | 3.00e-01 | 4.14e-01 | 7.47e-03 |
Signaling by FGFR2 in disease | 31 | 4.88e-02 | 9.04e-02 | 0.2990 | -0.051700 | -2.57e-01 | 0.006100 | -1.44e-01 | 6.18e-01 | 1.34e-02 | 9.53e-01 | 1.66e-01 |
TNF signaling | 37 | 5.60e-02 | 1.01e-01 | 0.2990 | 0.038100 | 1.36e-01 | -0.218000 | -1.48e-01 | 6.88e-01 | 1.54e-01 | 2.17e-02 | 1.20e-01 |
Signaling by KIT in disease | 20 | 3.91e-01 | 4.76e-01 | 0.2980 | 0.109000 | 5.35e-02 | -0.221000 | -1.60e-01 | 3.97e-01 | 6.79e-01 | 8.76e-02 | 2.17e-01 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 20 | 3.91e-01 | 4.76e-01 | 0.2980 | 0.109000 | 5.35e-02 | -0.221000 | -1.60e-01 | 3.97e-01 | 6.79e-01 | 8.76e-02 | 2.17e-01 |
FCGR3A-mediated IL10 synthesis | 39 | 1.25e-01 | 1.92e-01 | 0.2980 | 0.013100 | 8.09e-02 | 0.167000 | 2.33e-01 | 8.87e-01 | 3.82e-01 | 7.14e-02 | 1.19e-02 |
Gap junction trafficking and regulation | 15 | 5.28e-01 | 5.95e-01 | 0.2970 | -0.038700 | -8.70e-02 | 0.203000 | 1.95e-01 | 7.95e-01 | 5.60e-01 | 1.73e-01 | 1.91e-01 |
Peptide ligand-binding receptors | 62 | 3.99e-04 | 1.41e-03 | 0.2970 | 0.021700 | 1.40e-01 | -0.023200 | 2.60e-01 | 7.68e-01 | 5.61e-02 | 7.53e-01 | 4.05e-04 |
Regulated proteolysis of p75NTR | 11 | 6.77e-01 | 7.23e-01 | 0.2970 | -0.131000 | -1.73e-01 | 0.126000 | 1.58e-01 | 4.51e-01 | 3.21e-01 | 4.70e-01 | 3.63e-01 |
Regulation of TP53 Activity through Acetylation | 29 | 1.29e-02 | 3.10e-02 | 0.2970 | -0.033400 | 1.20e-02 | 0.091000 | -2.80e-01 | 7.56e-01 | 9.11e-01 | 3.96e-01 | 9.07e-03 |
Molecules associated with elastic fibres | 27 | 5.37e-02 | 9.77e-02 | 0.2970 | -0.002580 | -3.40e-02 | -0.294000 | 1.16e-02 | 9.82e-01 | 7.60e-01 | 8.13e-03 | 9.17e-01 |
Elastic fibre formation | 37 | 1.24e-02 | 3.01e-02 | 0.2960 | -0.112000 | -8.42e-02 | -0.254000 | 5.77e-02 | 2.37e-01 | 3.76e-01 | 7.43e-03 | 5.44e-01 |
HIV Infection | 204 | 1.18e-13 | 1.87e-12 | 0.2950 | 0.067600 | 3.55e-02 | 0.285000 | -1.02e-02 | 9.72e-02 | 3.84e-01 | 2.64e-12 | 8.03e-01 |
RNA Polymerase III Chain Elongation | 18 | 5.36e-01 | 6.03e-01 | 0.2950 | 0.010600 | 6.16e-02 | 0.201000 | 2.07e-01 | 9.38e-01 | 6.51e-01 | 1.41e-01 | 1.29e-01 |
Nucleotide Excision Repair | 105 | 1.19e-06 | 5.91e-06 | 0.2950 | 0.125000 | 8.19e-02 | 0.252000 | -3.26e-02 | 2.69e-02 | 1.48e-01 | 8.52e-06 | 5.65e-01 |
Deubiquitination | 238 | 7.27e-13 | 9.93e-12 | 0.2950 | 0.184000 | 1.15e-01 | 0.002960 | -1.99e-01 | 1.11e-06 | 2.24e-03 | 9.37e-01 | 1.36e-07 |
Interconversion of nucleotide di- and triphosphates | 24 | 1.89e-01 | 2.65e-01 | 0.2950 | 0.073700 | 2.90e-02 | 0.275000 | 6.92e-02 | 5.32e-01 | 8.06e-01 | 1.97e-02 | 5.57e-01 |
Signaling by ERBB2 in Cancer | 22 | 4.86e-01 | 5.60e-01 | 0.2940 | -0.167000 | -1.36e-01 | -0.150000 | -1.31e-01 | 1.74e-01 | 2.69e-01 | 2.23e-01 | 2.86e-01 |
HCMV Infection | 73 | 2.18e-06 | 1.06e-05 | 0.2940 | 0.045400 | -8.78e-02 | 0.265000 | -7.83e-02 | 5.02e-01 | 1.95e-01 | 8.97e-05 | 2.48e-01 |
Costimulation by the CD28 family | 55 | 4.00e-02 | 7.68e-02 | 0.2940 | 0.214000 | 1.68e-01 | -0.080900 | -7.42e-02 | 5.98e-03 | 3.11e-02 | 3.00e-01 | 3.42e-01 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 20 | 5.06e-02 | 9.28e-02 | 0.2930 | 0.079400 | -1.29e-01 | 0.240000 | -7.17e-02 | 5.39e-01 | 3.19e-01 | 6.28e-02 | 5.79e-01 |
Insulin receptor recycling | 19 | 4.38e-01 | 5.15e-01 | 0.2920 | -0.112000 | -6.36e-02 | 0.154000 | 2.12e-01 | 3.98e-01 | 6.31e-01 | 2.44e-01 | 1.09e-01 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 18 | 4.22e-01 | 5.03e-01 | 0.2920 | 0.093800 | 1.05e-01 | 0.247000 | 6.95e-02 | 4.91e-01 | 4.43e-01 | 6.99e-02 | 6.10e-01 |
Ion channel transport | 103 | 8.87e-04 | 2.99e-03 | 0.2920 | -0.208000 | -1.72e-01 | -0.110000 | 4.21e-03 | 2.63e-04 | 2.62e-03 | 5.35e-02 | 9.41e-01 |
PRC2 methylates histones and DNA | 14 | 3.38e-01 | 4.22e-01 | 0.2920 | 0.257000 | 4.37e-02 | 0.002720 | -1.30e-01 | 9.54e-02 | 7.77e-01 | 9.86e-01 | 4.00e-01 |
Regulation of insulin secretion | 58 | 5.28e-02 | 9.65e-02 | 0.2910 | -0.160000 | -1.74e-01 | -0.156000 | -7.05e-02 | 3.56e-02 | 2.20e-02 | 4.07e-02 | 3.54e-01 |
Insulin receptor signalling cascade | 38 | 7.42e-02 | 1.25e-01 | 0.2910 | -0.003040 | -1.57e-01 | -0.116000 | -2.16e-01 | 9.74e-01 | 9.33e-02 | 2.18e-01 | 2.11e-02 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 11 | 4.17e-01 | 5.00e-01 | 0.2900 | -0.005910 | 2.00e-02 | 0.287000 | -3.62e-02 | 9.73e-01 | 9.09e-01 | 9.98e-02 | 8.35e-01 |
Frs2-mediated activation | 11 | 4.19e-01 | 5.01e-01 | 0.2890 | 0.005880 | -2.58e-01 | -0.031700 | -1.27e-01 | 9.73e-01 | 1.38e-01 | 8.56e-01 | 4.67e-01 |
MET activates RAP1 and RAC1 | 11 | 3.07e-01 | 3.89e-01 | 0.2890 | 0.116000 | -1.28e-01 | 0.056800 | 2.24e-01 | 5.07e-01 | 4.63e-01 | 7.45e-01 | 1.98e-01 |
Interleukin-17 signaling | 63 | 9.75e-03 | 2.45e-02 | 0.2890 | -0.049000 | -2.12e-01 | -0.111000 | -1.54e-01 | 5.02e-01 | 3.67e-03 | 1.29e-01 | 3.46e-02 |
RHO GTPases activate PAKs | 21 | 1.00e-01 | 1.60e-01 | 0.2880 | 0.027000 | 2.32e-01 | -0.160000 | 5.27e-02 | 8.31e-01 | 6.60e-02 | 2.04e-01 | 6.76e-01 |
Protein-protein interactions at synapses | 55 | 9.96e-04 | 3.31e-03 | 0.2880 | -0.123000 | -1.35e-01 | -0.183000 | 1.26e-01 | 1.14e-01 | 8.45e-02 | 1.89e-02 | 1.06e-01 |
G-protein beta:gamma signalling | 27 | 7.53e-02 | 1.27e-01 | 0.2870 | 0.035400 | 1.03e-01 | -0.031300 | 2.64e-01 | 7.50e-01 | 3.53e-01 | 7.78e-01 | 1.78e-02 |
Oncogene Induced Senescence | 29 | 3.34e-02 | 6.66e-02 | 0.2860 | -0.047300 | 4.63e-02 | 0.009180 | -2.79e-01 | 6.60e-01 | 6.66e-01 | 9.32e-01 | 9.46e-03 |
Inactivation, recovery and regulation of the phototransduction cascade | 19 | 5.72e-01 | 6.33e-01 | 0.2860 | -0.180000 | -1.62e-01 | -0.136000 | -6.72e-02 | 1.74e-01 | 2.22e-01 | 3.04e-01 | 6.12e-01 |
The phototransduction cascade | 19 | 5.72e-01 | 6.33e-01 | 0.2860 | -0.180000 | -1.62e-01 | -0.136000 | -6.72e-02 | 1.74e-01 | 2.22e-01 | 3.04e-01 | 6.12e-01 |
Transcriptional regulation by RUNX2 | 106 | 6.61e-04 | 2.27e-03 | 0.2860 | 0.110000 | 5.89e-02 | 0.224000 | 1.26e-01 | 5.17e-02 | 2.95e-01 | 6.92e-05 | 2.48e-02 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 38 | 1.06e-01 | 1.67e-01 | 0.2860 | -0.004990 | -1.35e-01 | -0.124000 | -2.19e-01 | 9.58e-01 | 1.50e-01 | 1.87e-01 | 1.96e-02 |
Transcriptional Regulation by MECP2 | 46 | 1.31e-01 | 2.00e-01 | 0.2850 | -0.069600 | -1.44e-01 | -0.162000 | -1.72e-01 | 4.15e-01 | 9.13e-02 | 5.77e-02 | 4.38e-02 |
Signaling by FGFR3 | 29 | 7.81e-02 | 1.31e-01 | 0.2850 | 0.027300 | -1.86e-01 | -0.068900 | -2.03e-01 | 7.99e-01 | 8.37e-02 | 5.21e-01 | 5.84e-02 |
Transport to the Golgi and subsequent modification | 145 | 6.08e-06 | 2.79e-05 | 0.2850 | -0.117000 | -1.94e-01 | 0.126000 | 1.18e-01 | 1.54e-02 | 5.67e-05 | 9.07e-03 | 1.42e-02 |
Regulation of TP53 Activity | 147 | 6.80e-13 | 9.39e-12 | 0.2850 | 0.057300 | -2.05e-02 | 0.142000 | -2.39e-01 | 2.31e-01 | 6.69e-01 | 3.13e-03 | 5.69e-07 |
ISG15 antiviral mechanism | 62 | 3.00e-05 | 1.27e-04 | 0.2840 | 0.112000 | 1.37e-02 | 0.210000 | -1.56e-01 | 1.29e-01 | 8.52e-01 | 4.28e-03 | 3.44e-02 |
IRS-related events triggered by IGF1R | 36 | 9.35e-02 | 1.52e-01 | 0.2840 | -0.000180 | -1.68e-01 | -0.118000 | -1.97e-01 | 9.99e-01 | 8.20e-02 | 2.21e-01 | 4.14e-02 |
Inhibition of DNA recombination at telomere | 20 | 2.57e-01 | 3.38e-01 | 0.2840 | 0.063000 | 1.69e-01 | 0.219000 | 2.70e-03 | 6.26e-01 | 1.91e-01 | 8.95e-02 | 9.83e-01 |
The role of Nef in HIV-1 replication and disease pathogenesis | 25 | 2.02e-01 | 2.78e-01 | 0.2830 | 0.079700 | 2.51e-01 | 0.101000 | 2.88e-02 | 4.91e-01 | 3.01e-02 | 3.83e-01 | 8.03e-01 |
EPH-ephrin mediated repulsion of cells | 41 | 6.70e-02 | 1.16e-01 | 0.2820 | -0.085200 | 4.88e-02 | 0.138000 | 2.26e-01 | 3.46e-01 | 5.89e-01 | 1.27e-01 | 1.22e-02 |
Negative regulation of MAPK pathway | 40 | 5.22e-02 | 9.55e-02 | 0.2820 | -0.047900 | -1.54e-01 | -0.028600 | -2.30e-01 | 6.01e-01 | 9.28e-02 | 7.55e-01 | 1.18e-02 |
Nonhomologous End-Joining (NHEJ) | 33 | 6.11e-02 | 1.08e-01 | 0.2810 | 0.213000 | 9.42e-02 | 0.132000 | -8.38e-02 | 3.41e-02 | 3.49e-01 | 1.90e-01 | 4.05e-01 |
RNA Polymerase III Transcription Termination | 23 | 4.97e-01 | 5.70e-01 | 0.2810 | 0.063900 | 1.06e-01 | 0.170000 | 1.86e-01 | 5.96e-01 | 3.81e-01 | 1.59e-01 | 1.22e-01 |
NOD1/2 Signaling Pathway | 29 | 2.83e-01 | 3.66e-01 | 0.2810 | -0.065600 | -3.53e-02 | -0.229000 | -1.44e-01 | 5.41e-01 | 7.42e-01 | 3.31e-02 | 1.78e-01 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 65 | 5.13e-05 | 2.08e-04 | 0.2800 | 0.082800 | 9.60e-02 | 0.153000 | -1.98e-01 | 2.49e-01 | 1.81e-01 | 3.34e-02 | 5.83e-03 |
mRNA 3'-end processing | 52 | 2.01e-02 | 4.44e-02 | 0.2800 | 0.150000 | 1.70e-01 | 0.002940 | -1.64e-01 | 6.19e-02 | 3.39e-02 | 9.71e-01 | 4.05e-02 |
Tight junction interactions | 10 | 4.77e-01 | 5.52e-01 | 0.2800 | -0.038900 | -1.27e-01 | -0.234000 | 7.71e-02 | 8.31e-01 | 4.88e-01 | 2.00e-01 | 6.73e-01 |
SUMOylation of transcription factors | 15 | 6.02e-01 | 6.59e-01 | 0.2800 | 0.079200 | -1.77e-02 | -0.199000 | -1.79e-01 | 5.96e-01 | 9.06e-01 | 1.83e-01 | 2.29e-01 |
RAF activation | 34 | 1.32e-01 | 2.02e-01 | 0.2790 | -0.006150 | -1.57e-01 | -0.105000 | -2.05e-01 | 9.51e-01 | 1.14e-01 | 2.89e-01 | 3.86e-02 |
Metabolism of nitric oxide: NOS3 activation and regulation | 15 | 5.48e-01 | 6.14e-01 | 0.2780 | 0.149000 | 1.55e-01 | -0.023500 | 1.75e-01 | 3.19e-01 | 2.99e-01 | 8.75e-01 | 2.41e-01 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 38 | 1.75e-02 | 3.95e-02 | 0.2770 | -0.105000 | -6.07e-02 | 0.245000 | -4.88e-02 | 2.62e-01 | 5.18e-01 | 9.10e-03 | 6.03e-01 |
HIV Transcription Elongation | 38 | 1.75e-02 | 3.95e-02 | 0.2770 | -0.105000 | -6.07e-02 | 0.245000 | -4.88e-02 | 2.62e-01 | 5.18e-01 | 9.10e-03 | 6.03e-01 |
Tat-mediated elongation of the HIV-1 transcript | 38 | 1.75e-02 | 3.95e-02 | 0.2770 | -0.105000 | -6.07e-02 | 0.245000 | -4.88e-02 | 2.62e-01 | 5.18e-01 | 9.10e-03 | 6.03e-01 |
Signaling by PDGFRA extracellular domain mutants | 12 | 4.55e-01 | 5.31e-01 | 0.2770 | 0.202000 | 8.09e-03 | -0.015700 | -1.89e-01 | 2.27e-01 | 9.61e-01 | 9.25e-01 | 2.58e-01 |
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | 12 | 4.55e-01 | 5.31e-01 | 0.2770 | 0.202000 | 8.09e-03 | -0.015700 | -1.89e-01 | 2.27e-01 | 9.61e-01 | 9.25e-01 | 2.58e-01 |
Amino acid transport across the plasma membrane | 21 | 1.90e-01 | 2.66e-01 | 0.2760 | 0.057000 | -1.67e-01 | -0.076300 | -1.99e-01 | 6.52e-01 | 1.85e-01 | 5.45e-01 | 1.15e-01 |
Late Phase of HIV Life Cycle | 120 | 1.24e-08 | 8.79e-08 | 0.2760 | -0.018000 | -9.65e-02 | 0.247000 | -7.57e-02 | 7.34e-01 | 6.85e-02 | 3.10e-06 | 1.53e-01 |
Fcgamma receptor (FCGR) dependent phagocytosis | 86 | 3.47e-03 | 1.02e-02 | 0.2760 | 0.091800 | 2.08e-01 | 0.040700 | 1.51e-01 | 1.42e-01 | 8.48e-04 | 5.15e-01 | 1.58e-02 |
Receptor Mediated Mitophagy | 11 | 6.78e-01 | 7.23e-01 | 0.2750 | -0.105000 | -2.33e-01 | 0.035800 | -9.62e-02 | 5.46e-01 | 1.81e-01 | 8.37e-01 | 5.81e-01 |
Biotin transport and metabolism | 11 | 8.28e-01 | 8.58e-01 | 0.2750 | -0.112000 | -1.42e-01 | -0.119000 | -1.69e-01 | 5.20e-01 | 4.15e-01 | 4.93e-01 | 3.33e-01 |
Formation of TC-NER Pre-Incision Complex | 50 | 2.53e-02 | 5.35e-02 | 0.2740 | 0.041700 | -2.96e-02 | 0.253000 | 9.25e-02 | 6.10e-01 | 7.18e-01 | 1.97e-03 | 2.58e-01 |
TGF-beta receptor signaling activates SMADs | 29 | 2.04e-02 | 4.47e-02 | 0.2740 | 0.063800 | -2.36e-01 | -0.024500 | -1.22e-01 | 5.52e-01 | 2.82e-02 | 8.19e-01 | 2.55e-01 |
Downregulation of TGF-beta receptor signaling | 24 | 3.54e-02 | 6.96e-02 | 0.2740 | 0.085800 | -2.27e-01 | -0.017100 | -1.25e-01 | 4.67e-01 | 5.39e-02 | 8.85e-01 | 2.89e-01 |
Activated NOTCH1 Transmits Signal to the Nucleus | 26 | 3.47e-02 | 6.84e-02 | 0.2730 | -0.232000 | 4.90e-02 | -0.129000 | -4.68e-02 | 4.09e-02 | 6.66e-01 | 2.57e-01 | 6.80e-01 |
Defective B3GALTL causes Peters-plus syndrome (PpS) | 29 | 2.76e-02 | 5.71e-02 | 0.2730 | -0.143000 | 3.74e-02 | -0.224000 | 4.96e-02 | 1.82e-01 | 7.28e-01 | 3.70e-02 | 6.44e-01 |
ER Quality Control Compartment (ERQC) | 18 | 4.35e-01 | 5.14e-01 | 0.2730 | -0.098600 | -2.12e-01 | 0.096900 | 1.03e-01 | 4.69e-01 | 1.20e-01 | 4.77e-01 | 4.51e-01 |
Negative regulators of DDX58/IFIH1 signaling | 30 | 1.63e-01 | 2.36e-01 | 0.2730 | 0.126000 | 1.33e-01 | -0.033500 | -1.99e-01 | 2.31e-01 | 2.09e-01 | 7.51e-01 | 5.92e-02 |
Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | 11 | 3.00e-01 | 3.83e-01 | 0.2720 | -0.088000 | 2.13e-01 | -0.038500 | 1.41e-01 | 6.13e-01 | 2.22e-01 | 8.25e-01 | 4.20e-01 |
COPI-mediated anterograde transport | 77 | 8.29e-03 | 2.17e-02 | 0.2720 | -0.118000 | -1.63e-01 | 0.154000 | 9.87e-02 | 7.41e-02 | 1.36e-02 | 1.99e-02 | 1.35e-01 |
Disorders of transmembrane transporters | 124 | 1.53e-06 | 7.51e-06 | 0.2710 | 0.062500 | 3.86e-02 | 0.261000 | 5.34e-03 | 2.31e-01 | 4.59e-01 | 5.29e-07 | 9.18e-01 |
MET receptor recycling | 10 | 7.85e-01 | 8.22e-01 | 0.2710 | -0.049800 | -1.42e-01 | -0.084100 | -2.08e-01 | 7.85e-01 | 4.35e-01 | 6.45e-01 | 2.54e-01 |
Respiratory electron transport | 97 | 2.69e-03 | 8.20e-03 | 0.2710 | 0.128000 | 1.85e-01 | 0.149000 | 2.29e-02 | 3.02e-02 | 1.71e-03 | 1.11e-02 | 6.97e-01 |
Lysosome Vesicle Biogenesis | 30 | 2.34e-01 | 3.13e-01 | 0.2690 | 0.007810 | 8.27e-02 | 0.236000 | 9.89e-02 | 9.41e-01 | 4.33e-01 | 2.50e-02 | 3.49e-01 |
Mitochondrial calcium ion transport | 20 | 2.53e-01 | 3.34e-01 | 0.2690 | 0.038100 | -1.01e-01 | 0.235000 | 7.58e-02 | 7.68e-01 | 4.35e-01 | 6.94e-02 | 5.58e-01 |
Caspase activation via Death Receptors in the presence of ligand | 15 | 1.59e-01 | 2.33e-01 | 0.2690 | -0.085900 | 1.35e-01 | -0.167000 | 1.37e-01 | 5.65e-01 | 3.65e-01 | 2.63e-01 | 3.59e-01 |
p38MAPK events | 12 | 6.58e-01 | 7.05e-01 | 0.2690 | 0.162000 | 3.26e-02 | -0.179000 | -1.14e-01 | 3.31e-01 | 8.45e-01 | 2.82e-01 | 4.96e-01 |
Metabolism of steroids | 109 | 9.76e-04 | 3.25e-03 | 0.2690 | -0.046300 | -1.75e-01 | -0.160000 | -1.18e-01 | 4.05e-01 | 1.62e-03 | 3.93e-03 | 3.39e-02 |
SUMOylation of intracellular receptors | 25 | 2.95e-01 | 3.77e-01 | 0.2690 | 0.133000 | -3.44e-03 | -0.147000 | -1.81e-01 | 2.49e-01 | 9.76e-01 | 2.05e-01 | 1.17e-01 |
WNT ligand biogenesis and trafficking | 13 | 6.26e-01 | 6.79e-01 | 0.2670 | -0.005590 | -5.94e-02 | 0.113000 | 2.34e-01 | 9.72e-01 | 7.11e-01 | 4.80e-01 | 1.44e-01 |
TP53 Regulates Transcription of DNA Repair Genes | 57 | 2.33e-04 | 8.72e-04 | 0.2670 | 0.016600 | 7.43e-02 | 0.212000 | -1.42e-01 | 8.29e-01 | 3.32e-01 | 5.57e-03 | 6.35e-02 |
Beta-oxidation of very long chain fatty acids | 10 | 6.37e-01 | 6.89e-01 | 0.2670 | -0.076400 | 1.36e-01 | 0.119000 | 1.81e-01 | 6.76e-01 | 4.55e-01 | 5.15e-01 | 3.23e-01 |
COPI-independent Golgi-to-ER retrograde traffic | 30 | 1.26e-01 | 1.92e-01 | 0.2670 | -0.070000 | -2.27e-01 | 0.115000 | 3.95e-02 | 5.07e-01 | 3.16e-02 | 2.77e-01 | 7.08e-01 |
MHC class II antigen presentation | 90 | 8.43e-03 | 2.19e-02 | 0.2660 | 0.052000 | 4.14e-02 | 0.218000 | 1.38e-01 | 3.95e-01 | 4.98e-01 | 3.58e-04 | 2.37e-02 |
Defective B4GALT7 causes EDS, progeroid type | 16 | 1.64e-01 | 2.37e-01 | 0.2660 | -0.223000 | 5.44e-02 | -0.134000 | 1.72e-02 | 1.23e-01 | 7.07e-01 | 3.52e-01 | 9.05e-01 |
TP53 Regulates Transcription of Cell Death Genes | 36 | 1.51e-01 | 2.23e-01 | 0.2660 | 0.038300 | 9.47e-02 | -0.214000 | -1.20e-01 | 6.91e-01 | 3.26e-01 | 2.65e-02 | 2.13e-01 |
Signaling by MET | 61 | 4.43e-02 | 8.34e-02 | 0.2650 | 0.026700 | -6.90e-02 | -0.200000 | -1.57e-01 | 7.19e-01 | 3.52e-01 | 6.82e-03 | 3.37e-02 |
MAP kinase activation | 60 | 1.15e-02 | 2.81e-02 | 0.2650 | -0.020900 | -2.07e-01 | -0.085800 | -1.41e-01 | 7.80e-01 | 5.62e-03 | 2.51e-01 | 5.95e-02 |
RNA Polymerase II Transcription Termination | 61 | 1.10e-02 | 2.70e-02 | 0.2650 | 0.142000 | 1.74e-01 | 0.058900 | -1.28e-01 | 5.58e-02 | 1.89e-02 | 4.27e-01 | 8.34e-02 |
Biological oxidations | 130 | 2.62e-04 | 9.66e-04 | 0.2650 | 0.206000 | 9.58e-02 | 0.103000 | 8.84e-02 | 4.95e-05 | 6.00e-02 | 4.27e-02 | 8.26e-02 |
Other semaphorin interactions | 19 | 1.43e-01 | 2.15e-01 | 0.2650 | 0.005150 | 1.06e-01 | -0.210000 | 1.22e-01 | 9.69e-01 | 4.22e-01 | 1.13e-01 | 3.59e-01 |
Signaling by NOTCH1 | 66 | 4.94e-02 | 9.09e-02 | 0.2650 | -0.117000 | -7.49e-02 | -0.186000 | -1.27e-01 | 1.01e-01 | 2.93e-01 | 8.91e-03 | 7.41e-02 |
ERKs are inactivated | 13 | 7.10e-01 | 7.52e-01 | 0.2650 | 0.034000 | 6.11e-02 | 0.232000 | 1.07e-01 | 8.32e-01 | 7.03e-01 | 1.48e-01 | 5.03e-01 |
Signaling by the B Cell Receptor (BCR) | 104 | 1.81e-03 | 5.76e-03 | 0.2650 | 0.178000 | 1.61e-01 | 0.106000 | -3.23e-02 | 1.70e-03 | 4.58e-03 | 6.26e-02 | 5.70e-01 |
Downregulation of ERBB2 signaling | 23 | 4.46e-01 | 5.23e-01 | 0.2650 | -0.204000 | -1.51e-01 | -0.034100 | 6.53e-02 | 9.03e-02 | 2.09e-01 | 7.77e-01 | 5.88e-01 |
Interleukin receptor SHC signaling | 21 | 3.13e-01 | 3.93e-01 | 0.2650 | 0.066400 | 1.42e-01 | -0.210000 | -3.39e-02 | 5.98e-01 | 2.60e-01 | 9.52e-02 | 7.88e-01 |
NOTCH4 Intracellular Domain Regulates Transcription | 18 | 4.65e-01 | 5.41e-01 | 0.2650 | -0.120000 | -4.84e-02 | -0.223000 | -5.97e-02 | 3.78e-01 | 7.22e-01 | 1.02e-01 | 6.61e-01 |
Oxidative Stress Induced Senescence | 60 | 3.40e-02 | 6.73e-02 | 0.2640 | -0.076200 | -1.39e-01 | -0.045700 | -2.06e-01 | 3.08e-01 | 6.19e-02 | 5.41e-01 | 5.75e-03 |
O-glycosylation of TSR domain-containing proteins | 30 | 3.12e-02 | 6.31e-02 | 0.2640 | -0.152000 | 2.92e-02 | -0.207000 | 5.45e-02 | 1.51e-01 | 7.82e-01 | 4.96e-02 | 6.06e-01 |
DARPP-32 events | 21 | 3.27e-02 | 6.56e-02 | 0.2640 | 0.171000 | -1.57e-01 | 0.118000 | -4.02e-02 | 1.75e-01 | 2.12e-01 | 3.49e-01 | 7.50e-01 |
IGF1R signaling cascade | 37 | 1.23e-01 | 1.90e-01 | 0.2630 | 0.011600 | -1.40e-01 | -0.101000 | -1.99e-01 | 9.03e-01 | 1.40e-01 | 2.90e-01 | 3.66e-02 |
Interleukin-6 family signaling | 18 | 2.61e-01 | 3.42e-01 | 0.2630 | 0.182000 | 5.69e-02 | -0.090000 | 1.58e-01 | 1.81e-01 | 6.76e-01 | 5.09e-01 | 2.47e-01 |
Cell-extracellular matrix interactions | 16 | 1.75e-01 | 2.49e-01 | 0.2630 | -0.171000 | 5.44e-02 | -0.103000 | 1.63e-01 | 2.38e-01 | 7.06e-01 | 4.77e-01 | 2.58e-01 |
FGFR1 mutant receptor activation | 24 | 2.44e-01 | 3.23e-01 | 0.2630 | 0.035900 | -1.56e-01 | -0.172000 | -1.20e-01 | 7.61e-01 | 1.87e-01 | 1.46e-01 | 3.11e-01 |
IKK complex recruitment mediated by RIP1 | 19 | 5.28e-01 | 5.95e-01 | 0.2630 | -0.052700 | -5.49e-02 | -0.233000 | -9.63e-02 | 6.91e-01 | 6.79e-01 | 7.94e-02 | 4.67e-01 |
Signaling by NOTCH2 | 27 | 9.52e-02 | 1.53e-01 | 0.2630 | -0.080900 | 1.16e-01 | -0.193000 | -1.09e-01 | 4.67e-01 | 2.97e-01 | 8.32e-02 | 3.26e-01 |
Platelet degranulation | 100 | 5.45e-05 | 2.21e-04 | 0.2620 | -0.001070 | 8.84e-02 | 0.001700 | 2.46e-01 | 9.85e-01 | 1.27e-01 | 9.77e-01 | 2.16e-05 |
Post-translational protein phosphorylation | 70 | 1.57e-03 | 5.08e-03 | 0.2610 | -0.160000 | -9.60e-02 | -0.066200 | 1.70e-01 | 2.07e-02 | 1.65e-01 | 3.39e-01 | 1.39e-02 |
DNA Damage Recognition in GG-NER | 35 | 7.88e-02 | 1.32e-01 | 0.2610 | 0.044000 | -2.03e-02 | 0.254000 | 3.55e-02 | 6.53e-01 | 8.36e-01 | 9.32e-03 | 7.16e-01 |
Heparan sulfate/heparin (HS-GAG) metabolism | 39 | 9.51e-02 | 1.53e-01 | 0.2610 | -0.167000 | -3.07e-02 | 0.086500 | 1.77e-01 | 7.06e-02 | 7.40e-01 | 3.50e-01 | 5.54e-02 |
DNA Double Strand Break Response | 38 | 8.35e-03 | 2.17e-02 | 0.2600 | 0.107000 | -6.95e-03 | 0.195000 | -1.35e-01 | 2.55e-01 | 9.41e-01 | 3.80e-02 | 1.50e-01 |
Fatty acyl-CoA biosynthesis | 23 | 3.68e-01 | 4.54e-01 | 0.2600 | -0.128000 | -7.02e-03 | -0.161000 | -1.59e-01 | 2.90e-01 | 9.54e-01 | 1.82e-01 | 1.86e-01 |
Anchoring of the basal body to the plasma membrane | 92 | 1.13e-06 | 5.64e-06 | 0.2600 | -0.006650 | -2.19e-02 | 0.219000 | -1.37e-01 | 9.12e-01 | 7.17e-01 | 2.81e-04 | 2.29e-02 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 103 | 3.48e-03 | 1.02e-02 | 0.2600 | 0.131000 | 1.82e-01 | 0.130000 | 1.36e-02 | 2.18e-02 | 1.43e-03 | 2.26e-02 | 8.12e-01 |
Signaling by RAF1 mutants | 34 | 5.11e-02 | 9.36e-02 | 0.2600 | 0.011700 | 3.51e-02 | -0.256000 | 2.19e-02 | 9.06e-01 | 7.23e-01 | 9.80e-03 | 8.26e-01 |
Chaperone Mediated Autophagy | 15 | 4.81e-01 | 5.56e-01 | 0.2590 | -0.076300 | -1.06e-01 | 0.224000 | 2.14e-03 | 6.09e-01 | 4.79e-01 | 1.34e-01 | 9.89e-01 |
mRNA Splicing - Major Pathway | 167 | 8.15e-09 | 5.91e-08 | 0.2590 | 0.120000 | 1.31e-01 | 0.137000 | -1.28e-01 | 7.66e-03 | 3.46e-03 | 2.25e-03 | 4.30e-03 |
SLBP independent Processing of Histone Pre-mRNAs | 10 | 6.92e-01 | 7.35e-01 | 0.2580 | -0.069200 | -4.57e-02 | 0.243000 | 2.77e-02 | 7.05e-01 | 8.02e-01 | 1.83e-01 | 8.79e-01 |
Response of Mtb to phagocytosis | 20 | 2.31e-01 | 3.11e-01 | 0.2580 | 0.084600 | 5.14e-02 | 0.042200 | -2.35e-01 | 5.12e-01 | 6.91e-01 | 7.44e-01 | 6.95e-02 |
Deadenylation-dependent mRNA decay | 54 | 1.77e-02 | 3.99e-02 | 0.2580 | 0.140000 | 6.88e-02 | -0.008040 | -2.05e-01 | 7.64e-02 | 3.82e-01 | 9.19e-01 | 9.19e-03 |
Kinesins | 35 | 8.00e-02 | 1.33e-01 | 0.2570 | 0.124000 | 1.22e-01 | 0.046000 | -1.84e-01 | 2.06e-01 | 2.13e-01 | 6.38e-01 | 5.96e-02 |
Interleukin-2 family signaling | 34 | 1.28e-01 | 1.96e-01 | 0.2570 | 0.133000 | 4.80e-02 | -0.211000 | -3.73e-02 | 1.79e-01 | 6.28e-01 | 3.33e-02 | 7.07e-01 |
p75NTR signals via NF-kB | 14 | 6.48e-01 | 6.98e-01 | 0.2560 | -0.229000 | -1.00e-01 | 0.005220 | -5.29e-02 | 1.37e-01 | 5.17e-01 | 9.73e-01 | 7.32e-01 |
Processing of Capped Intron-Containing Pre-mRNA | 220 | 6.31e-13 | 8.80e-12 | 0.2550 | 0.105000 | 9.84e-02 | 0.145000 | -1.53e-01 | 7.27e-03 | 1.22e-02 | 2.29e-04 | 1.00e-04 |
GAB1 signalosome | 14 | 6.45e-01 | 6.96e-01 | 0.2550 | -0.208000 | -1.15e-01 | -0.057700 | 7.06e-02 | 1.78e-01 | 4.56e-01 | 7.08e-01 | 6.47e-01 |
RHO GTPases activate IQGAPs | 10 | 6.00e-01 | 6.56e-01 | 0.2540 | 0.222000 | 3.02e-02 | 0.105000 | -5.84e-02 | 2.24e-01 | 8.69e-01 | 5.67e-01 | 7.49e-01 |
Chromatin modifying enzymes | 185 | 2.59e-07 | 1.38e-06 | 0.2530 | -0.019500 | -8.04e-02 | -0.035000 | -2.37e-01 | 6.48e-01 | 5.99e-02 | 4.13e-01 | 3.04e-08 |
Chromatin organization | 185 | 2.59e-07 | 1.38e-06 | 0.2530 | -0.019500 | -8.04e-02 | -0.035000 | -2.37e-01 | 6.48e-01 | 5.99e-02 | 4.13e-01 | 3.04e-08 |
HIV Life Cycle | 132 | 1.72e-08 | 1.16e-07 | 0.2530 | 0.009970 | -7.34e-02 | 0.227000 | -8.40e-02 | 8.44e-01 | 1.46e-01 | 7.02e-06 | 9.64e-02 |
The canonical retinoid cycle in rods (twilight vision) | 10 | 8.58e-01 | 8.84e-01 | 0.2530 | -0.128000 | -7.76e-02 | -0.117000 | -1.67e-01 | 4.84e-01 | 6.71e-01 | 5.21e-01 | 3.61e-01 |
Bile acid and bile salt metabolism | 25 | 1.95e-01 | 2.72e-01 | 0.2520 | 0.039900 | -9.88e-02 | 0.091300 | 2.10e-01 | 7.30e-01 | 3.93e-01 | 4.30e-01 | 6.94e-02 |
TBC/RABGAPs | 40 | 6.23e-02 | 1.10e-01 | 0.2520 | -0.065700 | -1.61e-01 | 0.052100 | -1.75e-01 | 4.73e-01 | 7.79e-02 | 5.69e-01 | 5.54e-02 |
Nuclear signaling by ERBB4 | 25 | 3.11e-01 | 3.92e-01 | 0.2520 | -0.074800 | -5.15e-02 | 0.059500 | 2.28e-01 | 5.17e-01 | 6.56e-01 | 6.07e-01 | 4.88e-02 |
CD28 dependent PI3K/Akt signaling | 21 | 4.17e-01 | 5.00e-01 | 0.2520 | 0.146000 | 4.21e-02 | -0.068000 | -1.89e-01 | 2.46e-01 | 7.38e-01 | 5.90e-01 | 1.34e-01 |
HIV Transcription Initiation | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
RNA Polymerase II HIV Promoter Escape | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
RNA Polymerase II Promoter Escape | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
RNA Polymerase II Transcription Initiation | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 45 | 7.24e-02 | 1.23e-01 | 0.2500 | -0.028700 | -9.83e-02 | 0.215000 | 7.37e-02 | 7.39e-01 | 2.54e-01 | 1.25e-02 | 3.93e-01 |
Complex I biogenesis | 54 | 9.32e-02 | 1.52e-01 | 0.2490 | 0.061600 | 1.65e-01 | 0.158000 | 7.80e-02 | 4.34e-01 | 3.64e-02 | 4.46e-02 | 3.22e-01 |
TNFR1-induced proapoptotic signaling | 13 | 3.79e-01 | 4.64e-01 | 0.2490 | -0.043500 | 1.92e-01 | -0.140000 | -5.88e-02 | 7.86e-01 | 2.30e-01 | 3.82e-01 | 7.14e-01 |
Neuronal System | 230 | 5.65e-07 | 2.91e-06 | 0.2480 | -0.102000 | -1.19e-01 | -0.188000 | -3.87e-02 | 7.94e-03 | 1.88e-03 | 9.28e-07 | 3.14e-01 |
Neurexins and neuroligins | 35 | 1.22e-01 | 1.88e-01 | 0.2480 | -0.137000 | -8.34e-02 | -0.187000 | 2.88e-02 | 1.60e-01 | 3.94e-01 | 5.57e-02 | 7.68e-01 |
Inositol phosphate metabolism | 40 | 3.33e-01 | 4.17e-01 | 0.2480 | -0.174000 | -1.51e-01 | -0.084100 | -3.88e-02 | 5.67e-02 | 9.97e-02 | 3.58e-01 | 6.71e-01 |
Formation of HIV elongation complex in the absence of HIV Tat | 40 | 2.20e-02 | 4.78e-02 | 0.2480 | -0.077300 | -4.22e-02 | 0.217000 | -8.15e-02 | 3.98e-01 | 6.44e-01 | 1.76e-02 | 3.73e-01 |
Regulation of RUNX1 Expression and Activity | 17 | 5.86e-01 | 6.45e-01 | 0.2480 | -0.061900 | 1.82e-02 | -0.208000 | -1.18e-01 | 6.59e-01 | 8.96e-01 | 1.37e-01 | 4.01e-01 |
Transmission across Chemical Synapses | 158 | 3.43e-04 | 1.24e-03 | 0.2480 | -0.081500 | -1.21e-01 | -0.184000 | -7.90e-02 | 7.80e-02 | 8.65e-03 | 6.96e-05 | 8.75e-02 |
mRNA Capping | 28 | 3.11e-01 | 3.92e-01 | 0.2470 | -0.124000 | -1.12e-01 | 0.179000 | 2.67e-02 | 2.55e-01 | 3.03e-01 | 1.00e-01 | 8.07e-01 |
MyD88 cascade initiated on plasma membrane | 77 | 3.36e-02 | 6.66e-02 | 0.2470 | -0.096000 | -2.03e-01 | -0.057000 | -8.34e-02 | 1.46e-01 | 2.05e-03 | 3.88e-01 | 2.07e-01 |
Toll Like Receptor 10 (TLR10) Cascade | 77 | 3.36e-02 | 6.66e-02 | 0.2470 | -0.096000 | -2.03e-01 | -0.057000 | -8.34e-02 | 1.46e-01 | 2.05e-03 | 3.88e-01 | 2.07e-01 |
Toll Like Receptor 5 (TLR5) Cascade | 77 | 3.36e-02 | 6.66e-02 | 0.2470 | -0.096000 | -2.03e-01 | -0.057000 | -8.34e-02 | 1.46e-01 | 2.05e-03 | 3.88e-01 | 2.07e-01 |
AKT phosphorylates targets in the cytosol | 14 | 5.56e-01 | 6.21e-01 | 0.2460 | -0.031000 | -1.64e-01 | 0.014400 | -1.80e-01 | 8.41e-01 | 2.88e-01 | 9.26e-01 | 2.43e-01 |
Cell-cell junction organization | 26 | 2.76e-01 | 3.58e-01 | 0.2460 | -0.060400 | -1.28e-01 | -0.201000 | -1.91e-03 | 5.94e-01 | 2.60e-01 | 7.56e-02 | 9.87e-01 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 76 | 1.49e-03 | 4.84e-03 | 0.2460 | -0.145000 | -8.42e-02 | -0.070800 | 1.65e-01 | 2.87e-02 | 2.05e-01 | 2.86e-01 | 1.31e-02 |
RNA Pol II CTD phosphorylation and interaction with CE | 26 | 3.75e-01 | 4.61e-01 | 0.2450 | -0.098700 | -6.21e-02 | 0.204000 | 7.20e-02 | 3.84e-01 | 5.84e-01 | 7.24e-02 | 5.25e-01 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 26 | 3.75e-01 | 4.61e-01 | 0.2450 | -0.098700 | -6.21e-02 | 0.204000 | 7.20e-02 | 3.84e-01 | 5.84e-01 | 7.24e-02 | 5.25e-01 |
Sema4D induced cell migration and growth-cone collapse | 20 | 1.60e-01 | 2.33e-01 | 0.2450 | -0.233000 | 2.66e-02 | -0.056800 | 4.56e-02 | 7.15e-02 | 8.37e-01 | 6.60e-01 | 7.24e-01 |
Formation of RNA Pol II elongation complex | 53 | 8.49e-03 | 2.19e-02 | 0.2450 | -0.081500 | -1.09e-01 | 0.172000 | -1.08e-01 | 3.05e-01 | 1.68e-01 | 3.02e-02 | 1.72e-01 |
RNA Polymerase II Transcription Elongation | 53 | 8.49e-03 | 2.19e-02 | 0.2450 | -0.081500 | -1.09e-01 | 0.172000 | -1.08e-01 | 3.05e-01 | 1.68e-01 | 3.02e-02 | 1.72e-01 |
Macroautophagy | 102 | 1.61e-03 | 5.18e-03 | 0.2440 | -0.109000 | -1.88e-01 | 0.094100 | -5.74e-02 | 5.66e-02 | 1.02e-03 | 1.01e-01 | 3.18e-01 |
Interleukin-6 signaling | 10 | 4.56e-01 | 5.31e-01 | 0.2430 | 0.158000 | -4.60e-02 | -0.132000 | 1.22e-01 | 3.88e-01 | 8.01e-01 | 4.70e-01 | 5.05e-01 |
mRNA decay by 5' to 3' exoribonuclease | 15 | 5.46e-01 | 6.13e-01 | 0.2430 | 0.078100 | -4.47e-02 | -0.047800 | -2.21e-01 | 6.00e-01 | 7.64e-01 | 7.49e-01 | 1.39e-01 |
Autophagy | 114 | 3.88e-04 | 1.39e-03 | 0.2430 | -0.096400 | -1.87e-01 | 0.117000 | -3.35e-02 | 7.58e-02 | 5.80e-04 | 3.10e-02 | 5.38e-01 |
MET activates RAS signaling | 10 | 8.06e-01 | 8.39e-01 | 0.2430 | -0.010600 | 4.38e-03 | -0.087100 | -2.27e-01 | 9.54e-01 | 9.81e-01 | 6.33e-01 | 2.15e-01 |
RIP-mediated NFkB activation via ZBP1 | 17 | 5.68e-01 | 6.30e-01 | 0.2430 | -0.228000 | -8.28e-02 | 0.011900 | -1.19e-02 | 1.04e-01 | 5.55e-01 | 9.32e-01 | 9.32e-01 |
Interleukin-1 signaling | 89 | 8.35e-03 | 2.17e-02 | 0.2420 | 0.029000 | 4.41e-02 | 0.224000 | 7.48e-02 | 6.37e-01 | 4.73e-01 | 2.69e-04 | 2.23e-01 |
Signaling by Hedgehog | 119 | 1.72e-03 | 5.50e-03 | 0.2420 | -0.006930 | -4.19e-02 | 0.206000 | 1.20e-01 | 8.96e-01 | 4.30e-01 | 1.09e-04 | 2.46e-02 |
Acyl chain remodelling of PC | 18 | 6.66e-01 | 7.13e-01 | 0.2420 | 0.106000 | 1.08e-01 | 0.180000 | 5.73e-02 | 4.38e-01 | 4.28e-01 | 1.87e-01 | 6.74e-01 |
Endogenous sterols | 17 | 2.69e-01 | 3.51e-01 | 0.2410 | -0.065300 | -3.93e-02 | -0.143000 | 1.79e-01 | 6.41e-01 | 7.79e-01 | 3.06e-01 | 2.02e-01 |
mRNA Splicing - Minor Pathway | 48 | 2.61e-02 | 5.49e-02 | 0.2410 | -0.021100 | -1.82e-02 | 0.239000 | -1.02e-02 | 8.01e-01 | 8.27e-01 | 4.12e-03 | 9.03e-01 |
Oncogenic MAPK signaling | 71 | 7.54e-02 | 1.27e-01 | 0.2410 | -0.095800 | -1.31e-01 | -0.163000 | -7.30e-02 | 1.63e-01 | 5.72e-02 | 1.76e-02 | 2.88e-01 |
Anti-inflammatory response favouring Leishmania parasite infection | 88 | 3.87e-03 | 1.12e-02 | 0.2410 | -0.001120 | 9.65e-02 | 0.047700 | 2.15e-01 | 9.86e-01 | 1.18e-01 | 4.40e-01 | 4.89e-04 |
Leishmania parasite growth and survival | 88 | 3.87e-03 | 1.12e-02 | 0.2410 | -0.001120 | 9.65e-02 | 0.047700 | 2.15e-01 | 9.86e-01 | 1.18e-01 | 4.40e-01 | 4.89e-04 |
Signaling by Retinoic Acid | 32 | 3.10e-01 | 3.92e-01 | 0.2410 | 0.090600 | -2.09e-02 | -0.139000 | -1.73e-01 | 3.76e-01 | 8.38e-01 | 1.74e-01 | 9.02e-02 |
Repression of WNT target genes | 11 | 5.83e-01 | 6.43e-01 | 0.2400 | -0.120000 | 2.57e-02 | -0.014300 | -2.06e-01 | 4.92e-01 | 8.83e-01 | 9.35e-01 | 2.37e-01 |
Synthesis of PIPs at the late endosome membrane | 11 | 7.82e-01 | 8.21e-01 | 0.2390 | 0.088200 | 5.91e-02 | -0.204000 | -6.60e-02 | 6.13e-01 | 7.34e-01 | 2.41e-01 | 7.05e-01 |
Class I peroxisomal membrane protein import | 19 | 5.26e-01 | 5.95e-01 | 0.2390 | 0.047500 | 6.80e-03 | 0.071100 | 2.23e-01 | 7.20e-01 | 9.59e-01 | 5.92e-01 | 9.19e-02 |
BBSome-mediated cargo-targeting to cilium | 20 | 9.15e-02 | 1.50e-01 | 0.2390 | 0.218000 | -8.93e-02 | -0.000621 | 4.03e-02 | 9.15e-02 | 4.89e-01 | 9.96e-01 | 7.55e-01 |
G alpha (12/13) signalling events | 70 | 1.06e-02 | 2.62e-02 | 0.2390 | -0.181000 | -9.24e-02 | -0.088900 | 8.90e-02 | 8.95e-03 | 1.82e-01 | 1.99e-01 | 1.99e-01 |
Innate Immune System | 746 | 2.00e-17 | 4.31e-16 | 0.2380 | 0.065100 | 1.34e-01 | 0.081900 | 1.66e-01 | 2.81e-03 | 6.57e-10 | 1.70e-04 | 2.26e-14 |
Diseases of metabolism | 174 | 5.57e-05 | 2.25e-04 | 0.2380 | -0.167000 | -1.03e-01 | 0.038300 | 1.29e-01 | 1.51e-04 | 1.98e-02 | 3.84e-01 | 3.48e-03 |
Integrin signaling | 24 | 2.85e-01 | 3.67e-01 | 0.2380 | 0.002660 | 1.42e-02 | -0.237000 | -8.95e-03 | 9.82e-01 | 9.04e-01 | 4.45e-02 | 9.40e-01 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 52 | 2.00e-01 | 2.76e-01 | 0.2370 | -0.090300 | -5.89e-02 | -0.172000 | -1.24e-01 | 2.60e-01 | 4.63e-01 | 3.24e-02 | 1.23e-01 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 52 | 2.00e-01 | 2.76e-01 | 0.2370 | -0.090300 | -5.89e-02 | -0.172000 | -1.24e-01 | 2.60e-01 | 4.63e-01 | 3.24e-02 | 1.23e-01 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 52 | 2.00e-01 | 2.76e-01 | 0.2370 | -0.090300 | -5.89e-02 | -0.172000 | -1.24e-01 | 2.60e-01 | 4.63e-01 | 3.24e-02 | 1.23e-01 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 52 | 2.00e-01 | 2.76e-01 | 0.2370 | -0.090300 | -5.89e-02 | -0.172000 | -1.24e-01 | 2.60e-01 | 4.63e-01 | 3.24e-02 | 1.23e-01 |
Signaling by NOTCH1 in Cancer | 52 | 2.00e-01 | 2.76e-01 | 0.2370 | -0.090300 | -5.89e-02 | -0.172000 | -1.24e-01 | 2.60e-01 | 4.63e-01 | 3.24e-02 | 1.23e-01 |
Class A/1 (Rhodopsin-like receptors) | 112 | 1.51e-05 | 6.65e-05 | 0.2370 | 0.065900 | 1.05e-01 | -0.116000 | 1.66e-01 | 2.29e-01 | 5.60e-02 | 3.41e-02 | 2.49e-03 |
A tetrasaccharide linker sequence is required for GAG synthesis | 20 | 1.68e-01 | 2.42e-01 | 0.2370 | -0.207000 | 4.99e-02 | -0.104000 | -1.20e-02 | 1.09e-01 | 6.99e-01 | 4.23e-01 | 9.26e-01 |
Signalling to ERKs | 30 | 1.60e-01 | 2.33e-01 | 0.2370 | 0.080500 | -1.29e-01 | -0.119000 | -1.37e-01 | 4.46e-01 | 2.23e-01 | 2.59e-01 | 1.94e-01 |
MET promotes cell motility | 28 | 1.63e-01 | 2.36e-01 | 0.2370 | -0.006180 | -4.38e-02 | -0.231000 | 2.67e-02 | 9.55e-01 | 6.88e-01 | 3.45e-02 | 8.07e-01 |
Activation of GABAB receptors | 30 | 1.02e-01 | 1.62e-01 | 0.2370 | 0.041400 | 2.21e-02 | -0.060000 | 2.24e-01 | 6.95e-01 | 8.34e-01 | 5.70e-01 | 3.38e-02 |
GABA B receptor activation | 30 | 1.02e-01 | 1.62e-01 | 0.2370 | 0.041400 | 2.21e-02 | -0.060000 | 2.24e-01 | 6.95e-01 | 8.34e-01 | 5.70e-01 | 3.38e-02 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 22 | 7.13e-02 | 1.22e-01 | 0.2360 | -0.173000 | 1.34e-01 | 0.087800 | 1.65e-02 | 1.60e-01 | 2.77e-01 | 4.76e-01 | 8.94e-01 |
Glycosaminoglycan metabolism | 93 | 5.98e-03 | 1.63e-02 | 0.2360 | -0.107000 | 3.18e-03 | 0.102000 | 1.84e-01 | 7.38e-02 | 9.58e-01 | 8.93e-02 | 2.19e-03 |
mRNA Splicing | 175 | 1.98e-07 | 1.07e-06 | 0.2360 | 0.116000 | 1.19e-01 | 0.128000 | -1.09e-01 | 8.56e-03 | 6.62e-03 | 3.52e-03 | 1.35e-02 |
Response to elevated platelet cytosolic Ca2+ | 105 | 6.38e-05 | 2.55e-04 | 0.2350 | -0.008600 | 9.23e-02 | -0.035000 | 2.14e-01 | 8.79e-01 | 1.03e-01 | 5.37e-01 | 1.59e-04 |
Signaling by FGFR1 | 36 | 1.03e-01 | 1.63e-01 | 0.2350 | 0.021200 | -1.71e-01 | -0.042900 | -1.54e-01 | 8.26e-01 | 7.63e-02 | 6.56e-01 | 1.10e-01 |
Metabolism of RNA | 598 | 5.00e-19 | 1.26e-17 | 0.2350 | 0.135000 | 1.32e-01 | 0.132000 | -4.54e-02 | 2.24e-08 | 5.27e-08 | 4.69e-08 | 6.03e-02 |
Retrograde transport at the Trans-Golgi-Network | 44 | 2.92e-01 | 3.75e-01 | 0.2350 | -0.080400 | -6.85e-02 | -0.178000 | -1.10e-01 | 3.57e-01 | 4.32e-01 | 4.06e-02 | 2.08e-01 |
eNOS activation | 11 | 6.05e-01 | 6.61e-01 | 0.2340 | 0.114000 | 5.42e-02 | -0.101000 | 1.69e-01 | 5.14e-01 | 7.56e-01 | 5.62e-01 | 3.31e-01 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 37 | 2.40e-02 | 5.13e-02 | 0.2340 | 0.082800 | -3.11e-02 | 0.174000 | -1.28e-01 | 3.84e-01 | 7.44e-01 | 6.73e-02 | 1.77e-01 |
Infection with Mycobacterium tuberculosis | 23 | 3.30e-01 | 4.14e-01 | 0.2340 | 0.130000 | 1.05e-01 | 0.133000 | -9.32e-02 | 2.79e-01 | 3.83e-01 | 2.69e-01 | 4.39e-01 |
Suppression of phagosomal maturation | 11 | 8.16e-01 | 8.47e-01 | 0.2330 | -0.077100 | -9.46e-02 | -0.035700 | -1.95e-01 | 6.58e-01 | 5.87e-01 | 8.38e-01 | 2.63e-01 |
Signaling by TGF-beta Receptor Complex | 67 | 2.14e-03 | 6.67e-03 | 0.2330 | 0.088800 | -1.20e-01 | -0.028800 | -1.76e-01 | 2.09e-01 | 9.04e-02 | 6.84e-01 | 1.28e-02 |
Synthesis of bile acids and bile salts | 22 | 1.74e-01 | 2.48e-01 | 0.2320 | 0.040600 | -1.73e-01 | 0.052900 | 1.40e-01 | 7.42e-01 | 1.60e-01 | 6.68e-01 | 2.56e-01 |
Keratan sulfate/keratin metabolism | 25 | 5.26e-01 | 5.95e-01 | 0.2320 | -0.162000 | -1.37e-01 | 0.001880 | 9.38e-02 | 1.62e-01 | 2.34e-01 | 9.87e-01 | 4.17e-01 |
Protein ubiquitination | 56 | 1.77e-03 | 5.65e-03 | 0.2320 | 0.081900 | -1.01e-01 | 0.086900 | -1.71e-01 | 2.90e-01 | 1.90e-01 | 2.61e-01 | 2.67e-02 |
Mitochondrial Fatty Acid Beta-Oxidation | 31 | 3.05e-01 | 3.87e-01 | 0.2320 | 0.093200 | 2.07e-01 | 0.021600 | -4.23e-02 | 3.70e-01 | 4.61e-02 | 8.35e-01 | 6.84e-01 |
Apoptotic cleavage of cellular proteins | 32 | 4.83e-01 | 5.56e-01 | 0.2310 | -0.057200 | -8.48e-02 | -0.104000 | -1.80e-01 | 5.75e-01 | 4.07e-01 | 3.11e-01 | 7.85e-02 |
HS-GAG biosynthesis | 22 | 6.17e-01 | 6.72e-01 | 0.2310 | -0.150000 | -1.02e-01 | 0.091700 | 1.09e-01 | 2.24e-01 | 4.06e-01 | 4.57e-01 | 3.76e-01 |
Transport of vitamins, nucleosides, and related molecules | 29 | 9.80e-02 | 1.57e-01 | 0.2300 | -0.032000 | 1.94e-01 | -0.021900 | 1.19e-01 | 7.66e-01 | 7.13e-02 | 8.38e-01 | 2.68e-01 |
Degradation of the extracellular matrix | 70 | 4.26e-03 | 1.23e-02 | 0.2300 | -0.174000 | -4.83e-02 | -0.107000 | 9.43e-02 | 1.20e-02 | 4.86e-01 | 1.21e-01 | 1.73e-01 |
SLC transporter disorders | 64 | 4.92e-03 | 1.38e-02 | 0.2300 | -0.018500 | -1.03e-01 | 0.068500 | -1.93e-01 | 7.98e-01 | 1.56e-01 | 3.44e-01 | 7.62e-03 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 38 | 1.38e-01 | 2.08e-01 | 0.2300 | -0.050400 | 1.05e-02 | -0.221000 | -3.30e-02 | 5.91e-01 | 9.11e-01 | 1.82e-02 | 7.25e-01 |
Signaling by RAS mutants | 38 | 1.38e-01 | 2.08e-01 | 0.2300 | -0.050400 | 1.05e-02 | -0.221000 | -3.30e-02 | 5.91e-01 | 9.11e-01 | 1.82e-02 | 7.25e-01 |
Signaling by moderate kinase activity BRAF mutants | 38 | 1.38e-01 | 2.08e-01 | 0.2300 | -0.050400 | 1.05e-02 | -0.221000 | -3.30e-02 | 5.91e-01 | 9.11e-01 | 1.82e-02 | 7.25e-01 |
Signaling downstream of RAS mutants | 38 | 1.38e-01 | 2.08e-01 | 0.2300 | -0.050400 | 1.05e-02 | -0.221000 | -3.30e-02 | 5.91e-01 | 9.11e-01 | 1.82e-02 | 7.25e-01 |
Synthesis of glycosylphosphatidylinositol (GPI) | 18 | 5.88e-01 | 6.46e-01 | 0.2280 | 0.009320 | -3.41e-02 | 0.076000 | 2.12e-01 | 9.45e-01 | 8.02e-01 | 5.77e-01 | 1.19e-01 |
Acyl chain remodelling of PE | 16 | 7.41e-01 | 7.82e-01 | 0.2270 | 0.157000 | 6.89e-02 | 0.084400 | 1.22e-01 | 2.76e-01 | 6.33e-01 | 5.59e-01 | 3.97e-01 |
Infectious disease | 563 | 2.76e-12 | 3.48e-11 | 0.2270 | 0.105000 | 8.87e-02 | 0.166000 | 7.09e-02 | 2.49e-05 | 3.63e-04 | 2.35e-11 | 4.42e-03 |
Glycerophospholipid biosynthesis | 95 | 3.10e-02 | 6.28e-02 | 0.2260 | -0.157000 | -8.68e-02 | -0.067400 | -1.20e-01 | 8.48e-03 | 1.44e-01 | 2.57e-01 | 4.38e-02 |
NRIF signals cell death from the nucleus | 14 | 7.77e-01 | 8.16e-01 | 0.2260 | 0.045700 | -1.55e-02 | 0.135000 | 1.74e-01 | 7.67e-01 | 9.20e-01 | 3.82e-01 | 2.59e-01 |
Platelet Aggregation (Plug Formation) | 25 | 2.95e-01 | 3.77e-01 | 0.2260 | 0.035000 | 5.10e-02 | -0.217000 | 8.33e-03 | 7.62e-01 | 6.59e-01 | 6.06e-02 | 9.43e-01 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 38 | 2.85e-01 | 3.67e-01 | 0.2250 | -0.023800 | -9.38e-03 | -0.208000 | -8.34e-02 | 8.00e-01 | 9.20e-01 | 2.68e-02 | 3.74e-01 |
Diseases associated with the TLR signaling cascade | 22 | 5.11e-01 | 5.82e-01 | 0.2250 | -0.178000 | -8.68e-02 | -0.015500 | 1.05e-01 | 1.49e-01 | 4.81e-01 | 9.00e-01 | 3.92e-01 |
Diseases of Immune System | 22 | 5.11e-01 | 5.82e-01 | 0.2250 | -0.178000 | -8.68e-02 | -0.015500 | 1.05e-01 | 1.49e-01 | 4.81e-01 | 9.00e-01 | 3.92e-01 |
Platelet sensitization by LDL | 15 | 5.18e-01 | 5.88e-01 | 0.2240 | -0.031900 | -1.26e-01 | 0.178000 | -4.35e-02 | 8.31e-01 | 3.99e-01 | 2.33e-01 | 7.71e-01 |
RHO GTPases activate CIT | 19 | 4.55e-01 | 5.31e-01 | 0.2240 | 0.035400 | 1.79e-01 | -0.057600 | -1.17e-01 | 7.89e-01 | 1.77e-01 | 6.64e-01 | 3.76e-01 |
Prefoldin mediated transfer of substrate to CCT/TriC | 24 | 1.82e-01 | 2.57e-01 | 0.2230 | 0.108000 | 2.35e-03 | 0.160000 | -1.12e-01 | 3.59e-01 | 9.84e-01 | 1.75e-01 | 3.42e-01 |
RAB geranylgeranylation | 46 | 4.73e-02 | 8.81e-02 | 0.2230 | 0.151000 | 2.65e-02 | -0.025200 | 1.61e-01 | 7.69e-02 | 7.56e-01 | 7.68e-01 | 5.97e-02 |
RUNX2 regulates osteoblast differentiation | 22 | 3.98e-01 | 4.82e-01 | 0.2230 | -0.054400 | -2.51e-02 | 0.005680 | 2.15e-01 | 6.59e-01 | 8.39e-01 | 9.63e-01 | 8.16e-02 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 47 | 3.29e-02 | 6.59e-02 | 0.2230 | -0.103000 | 7.67e-02 | -0.165000 | -7.65e-02 | 2.20e-01 | 3.63e-01 | 5.11e-02 | 3.64e-01 |
Apoptotic execution phase | 40 | 3.49e-01 | 4.35e-01 | 0.2220 | -0.010800 | -5.88e-02 | -0.102000 | -1.88e-01 | 9.06e-01 | 5.20e-01 | 2.67e-01 | 3.96e-02 |
RNA Polymerase II Pre-transcription Events | 75 | 2.37e-03 | 7.33e-03 | 0.2220 | -0.041500 | -1.18e-01 | 0.163000 | -8.45e-02 | 5.35e-01 | 7.78e-02 | 1.49e-02 | 2.06e-01 |
RHO GTPase Effectors | 219 | 1.39e-07 | 7.70e-07 | 0.2220 | 0.125000 | 1.09e-01 | 0.070000 | -1.30e-01 | 1.55e-03 | 5.48e-03 | 7.53e-02 | 9.75e-04 |
Platelet homeostasis | 69 | 2.60e-03 | 7.96e-03 | 0.2220 | -0.140000 | -2.05e-02 | -0.113000 | 1.28e-01 | 4.43e-02 | 7.69e-01 | 1.05e-01 | 6.68e-02 |
Intraflagellar transport | 36 | 2.68e-01 | 3.50e-01 | 0.2220 | 0.064700 | -3.40e-02 | 0.129000 | 1.65e-01 | 5.02e-01 | 7.24e-01 | 1.82e-01 | 8.70e-02 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 31 | 4.17e-01 | 5.00e-01 | 0.2210 | -0.169000 | -1.17e-01 | -0.050000 | 6.58e-02 | 1.04e-01 | 2.61e-01 | 6.30e-01 | 5.26e-01 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 26 | 1.36e-01 | 2.06e-01 | 0.2210 | 0.098200 | -1.94e-02 | 0.144000 | -1.34e-01 | 3.86e-01 | 8.64e-01 | 2.03e-01 | 2.38e-01 |
RMTs methylate histone arginines | 29 | 1.71e-01 | 2.45e-01 | 0.2210 | -0.058800 | -9.22e-02 | 0.164000 | -1.00e-01 | 5.84e-01 | 3.90e-01 | 1.28e-01 | 3.51e-01 |
SHC1 events in ERBB4 signaling | 11 | 8.51e-01 | 8.78e-01 | 0.2200 | -0.039900 | -1.15e-01 | -0.172000 | -6.22e-02 | 8.19e-01 | 5.09e-01 | 3.23e-01 | 7.21e-01 |
Interleukin-15 signaling | 14 | 4.01e-01 | 4.85e-01 | 0.2200 | 0.103000 | -1.61e-01 | -0.091500 | -6.06e-02 | 5.06e-01 | 2.98e-01 | 5.54e-01 | 6.95e-01 |
Cell surface interactions at the vascular wall | 95 | 1.16e-03 | 3.84e-03 | 0.2190 | 0.051200 | 1.59e-01 | -0.099300 | 1.02e-01 | 3.90e-01 | 7.44e-03 | 9.49e-02 | 8.74e-02 |
Transcriptional Regulation by TP53 | 332 | 1.12e-16 | 2.23e-15 | 0.2190 | 0.046500 | 3.09e-02 | 0.108000 | -1.82e-01 | 1.47e-01 | 3.35e-01 | 8.12e-04 | 1.30e-08 |
Toll Like Receptor 3 (TLR3) Cascade | 86 | 5.60e-02 | 1.01e-01 | 0.2190 | -0.039300 | -1.40e-01 | -0.111000 | -1.20e-01 | 5.30e-01 | 2.46e-02 | 7.48e-02 | 5.54e-02 |
Leishmania infection | 162 | 4.73e-05 | 1.95e-04 | 0.2190 | 0.024100 | 1.17e-01 | 0.009910 | 1.84e-01 | 5.97e-01 | 1.07e-02 | 8.28e-01 | 5.76e-05 |
Peroxisomal lipid metabolism | 25 | 6.49e-01 | 6.99e-01 | 0.2190 | 0.169000 | 1.25e-01 | -0.002610 | 6.01e-02 | 1.43e-01 | 2.80e-01 | 9.82e-01 | 6.03e-01 |
RNA Polymerase I Promoter Escape | 30 | 4.95e-01 | 5.68e-01 | 0.2190 | -0.044100 | -7.12e-02 | 0.151000 | 1.34e-01 | 6.76e-01 | 5.00e-01 | 1.52e-01 | 2.05e-01 |
Signaling by NTRKs | 121 | 9.31e-03 | 2.36e-02 | 0.2180 | -0.106000 | -1.90e-01 | -0.015900 | 2.95e-04 | 4.37e-02 | 3.11e-04 | 7.63e-01 | 9.96e-01 |
VxPx cargo-targeting to cilium | 18 | 4.55e-01 | 5.31e-01 | 0.2180 | -0.018500 | -1.69e-01 | 0.137000 | 1.10e-03 | 8.92e-01 | 2.16e-01 | 3.13e-01 | 9.94e-01 |
Diseases associated with O-glycosylation of proteins | 41 | 2.82e-02 | 5.81e-02 | 0.2180 | -0.109000 | 5.43e-02 | -0.171000 | 5.78e-02 | 2.26e-01 | 5.48e-01 | 5.78e-02 | 5.22e-01 |
Diseases of glycosylation | 107 | 1.33e-03 | 4.37e-03 | 0.2170 | -0.150000 | -4.02e-02 | 0.002160 | 1.52e-01 | 7.43e-03 | 4.73e-01 | 9.69e-01 | 6.62e-03 |
MyD88-independent TLR4 cascade | 90 | 7.29e-02 | 1.23e-01 | 0.2160 | -0.063800 | -1.45e-01 | -0.106000 | -1.01e-01 | 2.96e-01 | 1.74e-02 | 8.17e-02 | 9.88e-02 |
TRIF(TICAM1)-mediated TLR4 signaling | 90 | 7.29e-02 | 1.23e-01 | 0.2160 | -0.063800 | -1.45e-01 | -0.106000 | -1.01e-01 | 2.96e-01 | 1.74e-02 | 8.17e-02 | 9.88e-02 |
rRNA modification in the nucleus and cytosol | 53 | 1.72e-01 | 2.46e-01 | 0.2160 | 0.088900 | 1.24e-01 | -0.069600 | -1.36e-01 | 2.63e-01 | 1.19e-01 | 3.81e-01 | 8.72e-02 |
Pre-NOTCH Expression and Processing | 47 | 2.43e-01 | 3.22e-01 | 0.2160 | -0.167000 | -9.49e-02 | -0.002380 | -9.87e-02 | 4.83e-02 | 2.60e-01 | 9.77e-01 | 2.42e-01 |
RAF-independent MAPK1/3 activation | 21 | 4.18e-01 | 5.00e-01 | 0.2150 | 0.016300 | -1.79e-01 | -0.084600 | -8.31e-02 | 8.97e-01 | 1.56e-01 | 5.02e-01 | 5.10e-01 |
Neurotransmitter receptors and postsynaptic signal transmission | 118 | 7.27e-03 | 1.94e-02 | 0.2150 | -0.064300 | -1.14e-01 | -0.166000 | -3.75e-02 | 2.29e-01 | 3.23e-02 | 1.87e-03 | 4.82e-01 |
Myogenesis | 23 | 4.33e-01 | 5.13e-01 | 0.2150 | -0.011200 | -1.78e-01 | -0.109000 | -5.07e-02 | 9.26e-01 | 1.41e-01 | 3.65e-01 | 6.74e-01 |
Keratan sulfate biosynthesis | 20 | 8.01e-01 | 8.35e-01 | 0.2150 | -0.133000 | -1.46e-01 | -0.071000 | -4.39e-02 | 3.02e-01 | 2.59e-01 | 5.83e-01 | 7.34e-01 |
Regulation of signaling by CBL | 18 | 7.44e-01 | 7.84e-01 | 0.2150 | 0.113000 | 5.05e-02 | -0.119000 | -1.29e-01 | 4.08e-01 | 7.11e-01 | 3.81e-01 | 3.45e-01 |
Caspase activation via extrinsic apoptotic signalling pathway | 24 | 1.32e-01 | 2.02e-01 | 0.2140 | -0.170000 | 7.07e-02 | -0.070500 | 8.33e-02 | 1.49e-01 | 5.49e-01 | 5.50e-01 | 4.80e-01 |
Signaling by FGFR2 | 55 | 9.36e-02 | 1.52e-01 | 0.2140 | -0.052700 | -1.76e-01 | 0.011100 | -1.09e-01 | 5.00e-01 | 2.39e-02 | 8.87e-01 | 1.63e-01 |
Signaling by NTRK2 (TRKB) | 22 | 5.67e-01 | 6.29e-01 | 0.2130 | -0.022800 | -1.29e-01 | -0.160000 | -5.08e-02 | 8.54e-01 | 2.94e-01 | 1.94e-01 | 6.80e-01 |
Intra-Golgi traffic | 40 | 3.63e-01 | 4.49e-01 | 0.2130 | -0.145000 | -1.24e-01 | 0.009340 | 9.32e-02 | 1.13e-01 | 1.74e-01 | 9.19e-01 | 3.08e-01 |
Senescence-Associated Secretory Phenotype (SASP) | 44 | 4.17e-02 | 7.96e-02 | 0.2130 | -0.008640 | -4.62e-03 | 0.198000 | -7.74e-02 | 9.21e-01 | 9.58e-01 | 2.33e-02 | 3.75e-01 |
Nuclear Receptor transcription pathway | 41 | 3.87e-01 | 4.73e-01 | 0.2120 | -0.007720 | -8.07e-02 | -0.162000 | -1.11e-01 | 9.32e-01 | 3.71e-01 | 7.24e-02 | 2.21e-01 |
Interleukin-20 family signaling | 15 | 5.86e-01 | 6.45e-01 | 0.2120 | -0.049500 | -6.98e-03 | -0.023100 | 2.05e-01 | 7.40e-01 | 9.63e-01 | 8.77e-01 | 1.69e-01 |
Sphingolipid metabolism | 65 | 4.92e-02 | 9.09e-02 | 0.2120 | -0.099500 | -2.07e-02 | 0.035800 | 1.83e-01 | 1.66e-01 | 7.73e-01 | 6.18e-01 | 1.09e-02 |
Unfolded Protein Response (UPR) | 84 | 6.65e-03 | 1.80e-02 | 0.2120 | 0.013500 | -8.21e-02 | 0.192000 | 3.73e-02 | 8.31e-01 | 1.94e-01 | 2.43e-03 | 5.55e-01 |
Protein localization | 144 | 2.29e-03 | 7.10e-03 | 0.2110 | 0.073600 | 7.63e-02 | 0.178000 | 4.16e-02 | 1.28e-01 | 1.15e-01 | 2.31e-04 | 3.89e-01 |
Nicotinate metabolism | 24 | 3.76e-01 | 4.61e-01 | 0.2110 | 0.051400 | 1.49e-01 | -0.127000 | 6.05e-02 | 6.63e-01 | 2.08e-01 | 2.82e-01 | 6.08e-01 |
GPCR ligand binding | 157 | 1.05e-06 | 5.24e-06 | 0.2110 | -0.012500 | 5.31e-02 | -0.067900 | 1.92e-01 | 7.87e-01 | 2.52e-01 | 1.43e-01 | 3.43e-05 |
TRAF6 mediated NF-kB activation | 21 | 4.04e-01 | 4.87e-01 | 0.2110 | -0.166000 | 1.11e-02 | -0.068200 | -1.10e-01 | 1.88e-01 | 9.30e-01 | 5.89e-01 | 3.84e-01 |
Potassium Channels | 49 | 2.50e-02 | 5.31e-02 | 0.2110 | -0.083300 | -1.02e-02 | -0.164000 | 1.02e-01 | 3.14e-01 | 9.02e-01 | 4.72e-02 | 2.16e-01 |
MAP2K and MAPK activation | 33 | 1.40e-01 | 2.10e-01 | 0.2110 | -0.003330 | 1.38e-01 | -0.157000 | 2.30e-02 | 9.74e-01 | 1.70e-01 | 1.18e-01 | 8.20e-01 |
Defective B3GAT3 causes JDSSDHD | 16 | 3.99e-01 | 4.83e-01 | 0.2110 | -0.191000 | 3.86e-02 | -0.080400 | -2.92e-03 | 1.87e-01 | 7.89e-01 | 5.78e-01 | 9.84e-01 |
N-glycan antennae elongation in the medial/trans-Golgi | 20 | 4.35e-01 | 5.14e-01 | 0.2100 | 0.035900 | -8.03e-02 | 0.039500 | 1.87e-01 | 7.81e-01 | 5.34e-01 | 7.60e-01 | 1.48e-01 |
Cellular Senescence | 118 | 2.45e-04 | 9.08e-04 | 0.2100 | -0.043100 | -7.11e-02 | 0.053400 | -1.85e-01 | 4.20e-01 | 1.83e-01 | 3.17e-01 | 5.16e-04 |
ZBP1(DAI) mediated induction of type I IFNs | 20 | 5.64e-01 | 6.27e-01 | 0.2100 | -0.200000 | -5.05e-02 | -0.034900 | -2.17e-02 | 1.23e-01 | 6.96e-01 | 7.87e-01 | 8.67e-01 |
Signaling by BRAF and RAF fusions | 55 | 1.09e-01 | 1.71e-01 | 0.2090 | -0.094600 | -8.97e-02 | -0.163000 | 1.28e-02 | 2.25e-01 | 2.50e-01 | 3.62e-02 | 8.70e-01 |
G alpha (q) signalling events | 120 | 6.88e-05 | 2.74e-04 | 0.2090 | -0.057400 | 3.33e-02 | -0.196000 | 2.99e-02 | 2.79e-01 | 5.30e-01 | 2.10e-04 | 5.72e-01 |
Peptide hormone metabolism | 48 | 1.09e-01 | 1.71e-01 | 0.2090 | -0.113000 | -9.23e-02 | -0.134000 | 6.75e-02 | 1.74e-01 | 2.69e-01 | 1.10e-01 | 4.19e-01 |
Nuclear Events (kinase and transcription factor activation) | 56 | 1.90e-01 | 2.66e-01 | 0.2090 | -0.090300 | -1.87e-01 | -0.024800 | -8.09e-03 | 2.43e-01 | 1.57e-02 | 7.49e-01 | 9.17e-01 |
GABA receptor activation | 35 | 8.04e-02 | 1.34e-01 | 0.2090 | 0.044700 | -3.88e-02 | -0.072400 | 1.87e-01 | 6.48e-01 | 6.92e-01 | 4.59e-01 | 5.62e-02 |
EPH-Ephrin signaling | 81 | 1.25e-02 | 3.01e-02 | 0.2080 | -0.011500 | 1.23e-01 | 0.020500 | 1.66e-01 | 8.59e-01 | 5.59e-02 | 7.50e-01 | 9.84e-03 |
FGFR2 alternative splicing | 23 | 4.34e-01 | 5.14e-01 | 0.2080 | -0.086100 | -9.16e-02 | 0.157000 | -5.34e-02 | 4.75e-01 | 4.47e-01 | 1.93e-01 | 6.58e-01 |
RHO GTPases activate PKNs | 32 | 3.14e-01 | 3.95e-01 | 0.2080 | -0.021600 | 9.05e-02 | -0.160000 | -9.36e-02 | 8.33e-01 | 3.76e-01 | 1.16e-01 | 3.59e-01 |
Role of LAT2/NTAL/LAB on calcium mobilization | 14 | 8.41e-01 | 8.68e-01 | 0.2060 | 0.160000 | 1.09e-01 | 0.001100 | -7.03e-02 | 2.99e-01 | 4.79e-01 | 9.94e-01 | 6.49e-01 |
Cargo trafficking to the periciliary membrane | 45 | 3.24e-02 | 6.51e-02 | 0.2060 | 0.112000 | -9.49e-02 | 0.131000 | 6.06e-02 | 1.92e-01 | 2.71e-01 | 1.28e-01 | 4.82e-01 |
Negative epigenetic regulation of rRNA expression | 48 | 3.04e-01 | 3.87e-01 | 0.2060 | 0.093000 | 6.73e-02 | 0.161000 | 5.61e-02 | 2.65e-01 | 4.20e-01 | 5.33e-02 | 5.02e-01 |
Signaling by high-kinase activity BRAF mutants | 29 | 2.91e-01 | 3.74e-01 | 0.2060 | 0.029400 | 1.23e-01 | -0.162000 | 1.61e-02 | 7.84e-01 | 2.52e-01 | 1.32e-01 | 8.81e-01 |
Signaling by FGFR in disease | 50 | 1.59e-01 | 2.33e-01 | 0.2040 | -0.018000 | -1.63e-01 | -0.051200 | -1.11e-01 | 8.26e-01 | 4.69e-02 | 5.31e-01 | 1.76e-01 |
Transcription of the HIV genome | 64 | 1.22e-02 | 2.95e-02 | 0.2040 | -0.022200 | -7.84e-02 | 0.169000 | -7.94e-02 | 7.59e-01 | 2.78e-01 | 1.94e-02 | 2.73e-01 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 26 | 1.87e-01 | 2.63e-01 | 0.2030 | -0.053300 | 1.12e-01 | 0.006700 | -1.61e-01 | 6.38e-01 | 3.21e-01 | 9.53e-01 | 1.56e-01 |
Sema4D in semaphorin signaling | 24 | 2.33e-01 | 3.13e-01 | 0.2030 | -0.148000 | 7.83e-02 | 0.025100 | 1.13e-01 | 2.10e-01 | 5.07e-01 | 8.32e-01 | 3.40e-01 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 84 | 9.97e-02 | 1.59e-01 | 0.2030 | -0.089300 | -1.72e-01 | -0.020500 | -5.52e-02 | 1.58e-01 | 6.41e-03 | 7.45e-01 | 3.82e-01 |
RNA polymerase II transcribes snRNA genes | 70 | 1.53e-02 | 3.55e-02 | 0.2020 | -0.054200 | -9.49e-02 | 0.090400 | -1.44e-01 | 4.33e-01 | 1.70e-01 | 1.92e-01 | 3.69e-02 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 18 | 5.89e-01 | 6.47e-01 | 0.2020 | 0.031900 | 1.29e-01 | 0.151000 | -1.78e-02 | 8.15e-01 | 3.43e-01 | 2.66e-01 | 8.96e-01 |
Cellular responses to external stimuli | 426 | 1.56e-12 | 2.01e-11 | 0.2020 | 0.070200 | 4.78e-02 | 0.183000 | -1.17e-02 | 1.36e-02 | 9.32e-02 | 1.17e-10 | 6.81e-01 |
Signaling by TGFB family members | 84 | 2.88e-03 | 8.67e-03 | 0.2020 | 0.038400 | -1.66e-01 | -0.043000 | -9.93e-02 | 5.43e-01 | 8.50e-03 | 4.96e-01 | 1.16e-01 |
RNA Polymerase I Transcription Termination | 30 | 5.89e-01 | 6.47e-01 | 0.2020 | -0.056900 | -3.56e-02 | 0.110000 | 1.55e-01 | 5.90e-01 | 7.36e-01 | 2.98e-01 | 1.41e-01 |
Potential therapeutics for SARS | 34 | 5.10e-01 | 5.82e-01 | 0.2020 | 0.135000 | 1.32e-01 | 0.025200 | -6.57e-02 | 1.73e-01 | 1.82e-01 | 7.99e-01 | 5.07e-01 |
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases | 13 | 8.87e-01 | 9.05e-01 | 0.2000 | 0.119000 | 1.44e-01 | -0.039100 | -6.11e-02 | 4.59e-01 | 3.69e-01 | 8.07e-01 | 7.03e-01 |
Rho GTPase cycle | 128 | 3.33e-04 | 1.21e-03 | 0.2000 | -0.135000 | 7.82e-03 | -0.144000 | -3.04e-02 | 8.45e-03 | 8.79e-01 | 4.97e-03 | 5.54e-01 |
Neurotransmitter release cycle | 27 | 4.36e-01 | 5.14e-01 | 0.2000 | -0.019700 | -1.03e-01 | -0.170000 | -9.57e-03 | 8.59e-01 | 3.53e-01 | 1.27e-01 | 9.31e-01 |
Synthesis of PIPs at the Golgi membrane | 15 | 8.38e-01 | 8.67e-01 | 0.1980 | -0.026600 | -2.35e-02 | -0.080400 | -1.77e-01 | 8.58e-01 | 8.75e-01 | 5.90e-01 | 2.35e-01 |
SUMOylation of DNA methylation proteins | 16 | 7.77e-01 | 8.16e-01 | 0.1970 | -0.062900 | -1.51e-01 | -0.110000 | -9.25e-03 | 6.63e-01 | 2.97e-01 | 4.45e-01 | 9.49e-01 |
HDACs deacetylate histones | 30 | 2.16e-01 | 2.94e-01 | 0.1970 | 0.105000 | 5.61e-03 | 0.080000 | -1.46e-01 | 3.19e-01 | 9.58e-01 | 4.49e-01 | 1.66e-01 |
Cellular responses to stress | 422 | 1.24e-11 | 1.47e-10 | 0.1970 | 0.067200 | 4.38e-02 | 0.179000 | -7.97e-03 | 1.86e-02 | 1.25e-01 | 3.36e-10 | 7.80e-01 |
RA biosynthesis pathway | 13 | 7.08e-01 | 7.50e-01 | 0.1960 | 0.191000 | 1.67e-02 | 0.016100 | -3.44e-02 | 2.32e-01 | 9.17e-01 | 9.20e-01 | 8.30e-01 |
Semaphorin interactions | 63 | 4.56e-03 | 1.30e-02 | 0.1950 | -0.083400 | 9.26e-02 | -0.111000 | 1.02e-01 | 2.53e-01 | 2.04e-01 | 1.29e-01 | 1.62e-01 |
Interaction between L1 and Ankyrins | 21 | 6.90e-01 | 7.34e-01 | 0.1950 | -0.167000 | -7.97e-02 | -0.051800 | 3.39e-02 | 1.84e-01 | 5.27e-01 | 6.81e-01 | 7.88e-01 |
MAPK targets/ Nuclear events mediated by MAP kinases | 31 | 1.76e-01 | 2.50e-01 | 0.1950 | 0.052300 | -1.63e-01 | -0.025900 | -8.91e-02 | 6.14e-01 | 1.16e-01 | 8.03e-01 | 3.91e-01 |
Transcriptional Regulation by VENTX | 35 | 4.97e-01 | 5.70e-01 | 0.1950 | -0.129000 | -1.15e-01 | 0.084400 | -2.88e-02 | 1.87e-01 | 2.38e-01 | 3.88e-01 | 7.68e-01 |
Metabolism of fat-soluble vitamins | 30 | 5.90e-01 | 6.47e-01 | 0.1940 | -0.056500 | 3.07e-02 | 0.123000 | 1.36e-01 | 5.93e-01 | 7.71e-01 | 2.45e-01 | 1.97e-01 |
Glutathione synthesis and recycling | 10 | 8.25e-01 | 8.56e-01 | 0.1940 | 0.091600 | -3.86e-02 | 0.157000 | 5.63e-02 | 6.16e-01 | 8.33e-01 | 3.90e-01 | 7.58e-01 |
NoRC negatively regulates rRNA expression | 45 | 4.30e-01 | 5.11e-01 | 0.1940 | 0.056700 | 3.84e-02 | 0.161000 | 8.43e-02 | 5.11e-01 | 6.56e-01 | 6.20e-02 | 3.28e-01 |
Mitophagy | 25 | 5.33e-01 | 6.00e-01 | 0.1940 | -0.072200 | -1.42e-01 | 0.100000 | -4.86e-02 | 5.32e-01 | 2.20e-01 | 3.87e-01 | 6.74e-01 |
Cell death signalling via NRAGE, NRIF and NADE | 68 | 1.20e-01 | 1.86e-01 | 0.1940 | -0.156000 | -7.50e-02 | -0.086000 | 1.71e-02 | 2.63e-02 | 2.86e-01 | 2.21e-01 | 8.07e-01 |
Signaling by PDGFR in disease | 20 | 6.30e-01 | 6.82e-01 | 0.1920 | 0.039800 | -1.02e-01 | -0.063700 | -1.45e-01 | 7.58e-01 | 4.32e-01 | 6.22e-01 | 2.61e-01 |
Cell-Cell communication | 80 | 6.26e-03 | 1.70e-02 | 0.1920 | -0.085000 | 3.61e-02 | -0.167000 | 2.02e-02 | 1.89e-01 | 5.77e-01 | 9.92e-03 | 7.55e-01 |
Visual phototransduction | 54 | 2.69e-01 | 3.51e-01 | 0.1920 | -0.162000 | -8.71e-02 | -0.037400 | 3.88e-02 | 3.95e-02 | 2.68e-01 | 6.35e-01 | 6.23e-01 |
Signalling to RAS | 17 | 7.89e-01 | 8.26e-01 | 0.1920 | 0.100000 | 1.95e-03 | -0.120000 | -1.11e-01 | 4.75e-01 | 9.89e-01 | 3.91e-01 | 4.30e-01 |
CLEC7A (Dectin-1) signaling | 89 | 4.09e-02 | 7.81e-02 | 0.1920 | 0.074800 | 5.86e-02 | 0.166000 | 1.21e-02 | 2.23e-01 | 3.40e-01 | 6.89e-03 | 8.44e-01 |
NOTCH3 Intracellular Domain Regulates Transcription | 22 | 7.16e-01 | 7.57e-01 | 0.1910 | -0.111000 | -6.25e-02 | -0.139000 | -2.97e-02 | 3.68e-01 | 6.12e-01 | 2.61e-01 | 8.09e-01 |
SHC1 events in EGFR signaling | 11 | 9.46e-01 | 9.57e-01 | 0.1900 | -0.143000 | -1.23e-01 | -0.016200 | -1.90e-02 | 4.10e-01 | 4.81e-01 | 9.26e-01 | 9.13e-01 |
ABC transporters in lipid homeostasis | 14 | 5.05e-01 | 5.78e-01 | 0.1900 | 0.064100 | -1.71e-01 | 0.021700 | -4.73e-02 | 6.78e-01 | 2.67e-01 | 8.88e-01 | 7.59e-01 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 50 | 2.13e-01 | 2.91e-01 | 0.1890 | 0.018900 | -1.22e-01 | -0.107000 | -9.50e-02 | 8.17e-01 | 1.34e-01 | 1.91e-01 | 2.45e-01 |
Estrogen-dependent gene expression | 81 | 6.78e-02 | 1.17e-01 | 0.1890 | -0.057300 | -7.97e-02 | -0.002770 | -1.61e-01 | 3.74e-01 | 2.16e-01 | 9.66e-01 | 1.23e-02 |
Signaling by NTRK1 (TRKA) | 105 | 5.86e-02 | 1.05e-01 | 0.1880 | -0.074000 | -1.65e-01 | -0.019300 | -4.91e-02 | 1.91e-01 | 3.52e-03 | 7.33e-01 | 3.86e-01 |
Synthesis of PIPs at the plasma membrane | 51 | 2.20e-01 | 3.00e-01 | 0.1880 | 0.062000 | -2.77e-02 | -0.166000 | -5.86e-02 | 4.44e-01 | 7.33e-01 | 4.09e-02 | 4.70e-01 |
CTLA4 inhibitory signaling | 21 | 5.99e-01 | 6.56e-01 | 0.1880 | 0.112000 | -8.79e-03 | 0.142000 | 5.16e-02 | 3.75e-01 | 9.44e-01 | 2.60e-01 | 6.83e-01 |
The citric acid (TCA) cycle and respiratory electron transport | 149 | 2.55e-04 | 9.43e-04 | 0.1870 | 0.114000 | 4.71e-02 | 0.062200 | -1.26e-01 | 1.61e-02 | 3.23e-01 | 1.91e-01 | 8.09e-03 |
N-Glycan antennae elongation | 13 | 7.59e-01 | 8.00e-01 | 0.1870 | 0.060100 | -5.81e-02 | 0.061300 | 1.56e-01 | 7.07e-01 | 7.17e-01 | 7.02e-01 | 3.31e-01 |
Signaling by SCF-KIT | 42 | 2.79e-01 | 3.61e-01 | 0.1870 | 0.016600 | 3.31e-02 | -0.182000 | -2.04e-02 | 8.52e-01 | 7.11e-01 | 4.12e-02 | 8.19e-01 |
Metabolism of carbohydrates | 227 | 5.12e-04 | 1.79e-03 | 0.1860 | -0.124000 | -9.40e-02 | 0.101000 | 4.43e-03 | 1.30e-03 | 1.50e-02 | 8.78e-03 | 9.09e-01 |
Pre-NOTCH Transcription and Translation | 32 | 5.41e-01 | 6.07e-01 | 0.1860 | -0.119000 | -3.33e-02 | -0.063800 | -1.24e-01 | 2.46e-01 | 7.44e-01 | 5.33e-01 | 2.26e-01 |
Growth hormone receptor signaling | 19 | 8.12e-01 | 8.45e-01 | 0.1860 | -0.068100 | -1.52e-01 | -0.074100 | -3.48e-02 | 6.08e-01 | 2.51e-01 | 5.76e-01 | 7.93e-01 |
Regulation of lipid metabolism by PPARalpha | 109 | 5.91e-03 | 1.62e-02 | 0.1860 | 0.011600 | -1.14e-02 | 0.003720 | -1.85e-01 | 8.35e-01 | 8.37e-01 | 9.47e-01 | 8.71e-04 |
Sema3A PAK dependent Axon repulsion | 16 | 6.26e-01 | 6.79e-01 | 0.1860 | -0.129000 | -1.26e-02 | -0.067900 | 1.14e-01 | 3.73e-01 | 9.31e-01 | 6.38e-01 | 4.28e-01 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 13 | 8.95e-01 | 9.13e-01 | 0.1840 | -0.129000 | -1.12e-01 | -0.042900 | 5.39e-02 | 4.20e-01 | 4.85e-01 | 7.89e-01 | 7.36e-01 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 55 | 2.28e-01 | 3.09e-01 | 0.1840 | -0.028200 | 4.45e-02 | -0.091400 | -1.51e-01 | 7.17e-01 | 5.69e-01 | 2.42e-01 | 5.32e-02 |
TCF dependent signaling in response to WNT | 143 | 3.94e-04 | 1.40e-03 | 0.1840 | -0.064900 | -8.15e-02 | 0.118000 | -9.41e-02 | 1.81e-01 | 9.34e-02 | 1.49e-02 | 5.27e-02 |
Retinoid metabolism and transport | 27 | 5.05e-01 | 5.78e-01 | 0.1830 | -0.110000 | 2.74e-02 | 0.063100 | 1.30e-01 | 3.25e-01 | 8.05e-01 | 5.71e-01 | 2.42e-01 |
Signaling by ERBB2 | 42 | 6.46e-01 | 6.96e-01 | 0.1830 | -0.107000 | -1.01e-01 | -0.088200 | -6.42e-02 | 2.32e-01 | 2.56e-01 | 3.23e-01 | 4.72e-01 |
CD209 (DC-SIGN) signaling | 19 | 7.99e-01 | 8.34e-01 | 0.1830 | -0.033300 | 2.67e-02 | -0.133000 | -1.18e-01 | 8.02e-01 | 8.40e-01 | 3.15e-01 | 3.73e-01 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 28 | 6.87e-01 | 7.31e-01 | 0.1830 | 0.044000 | 1.26e-02 | 0.156000 | 8.37e-02 | 6.87e-01 | 9.08e-01 | 1.53e-01 | 4.44e-01 |
MyD88 dependent cascade initiated on endosome | 85 | 1.53e-01 | 2.26e-01 | 0.1820 | -0.078500 | -1.59e-01 | -0.008710 | -4.29e-02 | 2.12e-01 | 1.16e-02 | 8.90e-01 | 4.95e-01 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 85 | 1.53e-01 | 2.26e-01 | 0.1820 | -0.078500 | -1.59e-01 | -0.008710 | -4.29e-02 | 2.12e-01 | 1.16e-02 | 8.90e-01 | 4.95e-01 |
G alpha (z) signalling events | 36 | 1.85e-01 | 2.61e-01 | 0.1820 | -0.079400 | -7.62e-03 | -0.099100 | 1.30e-01 | 4.10e-01 | 9.37e-01 | 3.04e-01 | 1.77e-01 |
Beta-catenin independent WNT signaling | 128 | 1.82e-02 | 4.10e-02 | 0.1820 | -0.061600 | 2.90e-02 | 0.146000 | 8.50e-02 | 2.30e-01 | 5.72e-01 | 4.51e-03 | 9.74e-02 |
Platelet activation, signaling and aggregation | 208 | 5.97e-07 | 3.06e-06 | 0.1810 | -0.022800 | 8.87e-02 | -0.064700 | 1.42e-01 | 5.73e-01 | 2.79e-02 | 1.09e-01 | 4.15e-04 |
Ephrin signaling | 19 | 4.85e-01 | 5.58e-01 | 0.1810 | -0.125000 | 3.46e-02 | -0.121000 | 3.54e-02 | 3.46e-01 | 7.94e-01 | 3.61e-01 | 7.89e-01 |
Cilium Assembly | 171 | 3.62e-05 | 1.52e-04 | 0.1800 | 0.026200 | -4.91e-02 | 0.169000 | -2.72e-02 | 5.56e-01 | 2.69e-01 | 1.41e-04 | 5.40e-01 |
Golgi-to-ER retrograde transport | 103 | 1.43e-02 | 3.35e-02 | 0.1800 | 0.008290 | -8.73e-02 | 0.151000 | 4.50e-02 | 8.85e-01 | 1.26e-01 | 8.40e-03 | 4.31e-01 |
PPARA activates gene expression | 107 | 7.75e-03 | 2.04e-02 | 0.1800 | 0.012800 | -2.04e-02 | 0.012400 | -1.78e-01 | 8.19e-01 | 7.16e-01 | 8.24e-01 | 1.52e-03 |
Metalloprotease DUBs | 18 | 8.82e-01 | 9.03e-01 | 0.1790 | 0.142000 | 9.86e-02 | 0.045300 | 1.56e-02 | 2.97e-01 | 4.69e-01 | 7.40e-01 | 9.09e-01 |
Programmed Cell Death | 151 | 6.36e-03 | 1.72e-02 | 0.1790 | 0.023600 | 7.22e-02 | 0.159000 | 3.06e-02 | 6.18e-01 | 1.27e-01 | 7.60e-04 | 5.17e-01 |
Apoptosis | 148 | 5.35e-03 | 1.49e-02 | 0.1790 | 0.023900 | 6.84e-02 | 0.162000 | 2.24e-02 | 6.17e-01 | 1.52e-01 | 6.97e-04 | 6.39e-01 |
COPI-dependent Golgi-to-ER retrograde traffic | 73 | 9.73e-02 | 1.56e-01 | 0.1780 | 0.040500 | -2.94e-02 | 0.165000 | 4.70e-02 | 5.50e-01 | 6.65e-01 | 1.52e-02 | 4.88e-01 |
Interleukin-4 and Interleukin-13 signaling | 85 | 1.18e-02 | 2.87e-02 | 0.1780 | -0.009210 | 2.89e-02 | -0.056700 | 1.66e-01 | 8.83e-01 | 6.46e-01 | 3.67e-01 | 8.32e-03 |
Adrenaline,noradrenaline inhibits insulin secretion | 21 | 5.79e-01 | 6.39e-01 | 0.1770 | -0.007520 | 2.91e-02 | -0.030500 | 1.72e-01 | 9.52e-01 | 8.18e-01 | 8.09e-01 | 1.72e-01 |
VEGFA-VEGFR2 Pathway | 90 | 1.22e-01 | 1.88e-01 | 0.1770 | 0.047000 | 6.34e-02 | -0.143000 | -6.83e-02 | 4.42e-01 | 2.99e-01 | 1.91e-02 | 2.63e-01 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 16 | 8.85e-01 | 9.04e-01 | 0.1760 | -0.025200 | 1.00e-02 | -0.113000 | -1.32e-01 | 8.62e-01 | 9.45e-01 | 4.35e-01 | 3.60e-01 |
Interleukin-37 signaling | 18 | 5.50e-01 | 6.16e-01 | 0.1750 | -0.101000 | 2.45e-02 | -0.125000 | 6.54e-02 | 4.60e-01 | 8.57e-01 | 3.57e-01 | 6.31e-01 |
Positive epigenetic regulation of rRNA expression | 45 | 1.49e-01 | 2.22e-01 | 0.1750 | 0.082600 | 2.61e-02 | 0.092800 | -1.21e-01 | 3.38e-01 | 7.62e-01 | 2.82e-01 | 1.61e-01 |
Keratinization | 20 | 6.96e-01 | 7.39e-01 | 0.1750 | -0.023500 | -1.09e-01 | -0.134000 | 5.18e-04 | 8.56e-01 | 3.98e-01 | 2.98e-01 | 9.97e-01 |
C-type lectin receptors (CLRs) | 109 | 6.45e-02 | 1.13e-01 | 0.1750 | 0.081500 | 8.63e-02 | 0.128000 | 7.46e-03 | 1.42e-01 | 1.20e-01 | 2.12e-02 | 8.93e-01 |
Aggrephagy | 17 | 8.39e-01 | 8.67e-01 | 0.1740 | -0.101000 | -1.10e-01 | 0.081600 | -3.86e-02 | 4.72e-01 | 4.33e-01 | 5.60e-01 | 7.83e-01 |
Cargo recognition for clathrin-mediated endocytosis | 85 | 6.38e-02 | 1.12e-01 | 0.1740 | -0.048200 | -1.48e-01 | 0.077500 | -1.10e-02 | 4.44e-01 | 1.86e-02 | 2.18e-01 | 8.61e-01 |
Toll Like Receptor 9 (TLR9) Cascade | 88 | 1.68e-01 | 2.42e-01 | 0.1730 | -0.072300 | -1.52e-01 | -0.007390 | -3.96e-02 | 2.42e-01 | 1.36e-02 | 9.05e-01 | 5.22e-01 |
ADORA2B mediated anti-inflammatory cytokines production | 54 | 1.37e-01 | 2.08e-01 | 0.1730 | 0.013100 | 3.39e-03 | -0.022400 | 1.71e-01 | 8.68e-01 | 9.66e-01 | 7.76e-01 | 2.95e-02 |
Sphingolipid de novo biosynthesis | 32 | 3.98e-01 | 4.82e-01 | 0.1720 | -0.056400 | -9.89e-02 | -0.073500 | 1.06e-01 | 5.81e-01 | 3.33e-01 | 4.72e-01 | 3.01e-01 |
Transcriptional regulation by RUNX3 | 88 | 8.35e-02 | 1.38e-01 | 0.1710 | 0.041200 | 1.14e-01 | 0.121000 | 2.20e-03 | 5.04e-01 | 6.60e-02 | 5.02e-02 | 9.72e-01 |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | 16 | 6.12e-01 | 6.67e-01 | 0.1700 | -0.146000 | 2.98e-02 | -0.060100 | 5.69e-02 | 3.13e-01 | 8.36e-01 | 6.78e-01 | 6.94e-01 |
RUNX2 regulates bone development | 28 | 5.58e-01 | 6.24e-01 | 0.1690 | -0.069900 | -9.32e-02 | -0.034300 | 1.18e-01 | 5.23e-01 | 3.94e-01 | 7.54e-01 | 2.80e-01 |
FCERI mediated MAPK activation | 30 | 6.58e-01 | 7.05e-01 | 0.1690 | 0.063200 | 3.12e-02 | -0.147000 | -4.66e-02 | 5.50e-01 | 7.68e-01 | 1.65e-01 | 6.59e-01 |
p75NTR recruits signalling complexes | 11 | 8.69e-01 | 8.93e-01 | 0.1690 | -0.159000 | -1.92e-02 | -0.052300 | -1.49e-02 | 3.62e-01 | 9.12e-01 | 7.64e-01 | 9.32e-01 |
trans-Golgi Network Vesicle Budding | 65 | 3.80e-01 | 4.65e-01 | 0.1690 | -0.030200 | -4.01e-02 | 0.120000 | 1.08e-01 | 6.74e-01 | 5.77e-01 | 9.46e-02 | 1.34e-01 |
PTEN Regulation | 131 | 2.80e-03 | 8.52e-03 | 0.1690 | 0.017500 | -2.89e-03 | 0.166000 | -2.66e-02 | 7.30e-01 | 9.55e-01 | 1.08e-03 | 5.99e-01 |
Intrinsic Pathway for Apoptosis | 44 | 4.24e-01 | 5.05e-01 | 0.1680 | 0.013000 | 8.02e-02 | 0.144000 | 2.95e-02 | 8.82e-01 | 3.58e-01 | 9.86e-02 | 7.35e-01 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 88 | 2.39e-01 | 3.19e-01 | 0.1670 | -0.072100 | -1.40e-01 | -0.045900 | -3.06e-02 | 2.43e-01 | 2.30e-02 | 4.58e-01 | 6.20e-01 |
Toll Like Receptor 2 (TLR2) Cascade | 88 | 2.39e-01 | 3.19e-01 | 0.1670 | -0.072100 | -1.40e-01 | -0.045900 | -3.06e-02 | 2.43e-01 | 2.30e-02 | 4.58e-01 | 6.20e-01 |
Toll Like Receptor TLR1:TLR2 Cascade | 88 | 2.39e-01 | 3.19e-01 | 0.1670 | -0.072100 | -1.40e-01 | -0.045900 | -3.06e-02 | 2.43e-01 | 2.30e-02 | 4.58e-01 | 6.20e-01 |
Toll Like Receptor TLR6:TLR2 Cascade | 88 | 2.39e-01 | 3.19e-01 | 0.1670 | -0.072100 | -1.40e-01 | -0.045900 | -3.06e-02 | 2.43e-01 | 2.30e-02 | 4.58e-01 | 6.20e-01 |
Fc epsilon receptor (FCERI) signaling | 121 | 5.63e-02 | 1.02e-01 | 0.1670 | 0.110000 | 9.11e-02 | 0.079100 | -3.43e-02 | 3.71e-02 | 8.40e-02 | 1.34e-01 | 5.15e-01 |
Adaptive Immune System | 577 | 5.91e-06 | 2.72e-05 | 0.1660 | 0.129000 | 9.00e-02 | 0.038900 | 3.53e-02 | 1.59e-07 | 2.55e-04 | 1.14e-01 | 1.51e-01 |
SARS-CoV Infections | 75 | 1.17e-01 | 1.82e-01 | 0.1650 | 0.037400 | -1.32e-02 | 0.159000 | 1.94e-02 | 5.76e-01 | 8.44e-01 | 1.74e-02 | 7.71e-01 |
RNA Polymerase I Promoter Clearance | 48 | 3.40e-01 | 4.25e-01 | 0.1630 | -0.006470 | -2.26e-02 | 0.160000 | 1.40e-02 | 9.38e-01 | 7.87e-01 | 5.48e-02 | 8.67e-01 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 30 | 6.78e-01 | 7.23e-01 | 0.1620 | -0.101000 | -1.10e-02 | 0.104000 | 7.17e-02 | 3.38e-01 | 9.17e-01 | 3.26e-01 | 4.97e-01 |
Opioid Signalling | 74 | 7.30e-02 | 1.23e-01 | 0.1620 | -0.011200 | -1.29e-01 | -0.093700 | 2.22e-02 | 8.68e-01 | 5.47e-02 | 1.64e-01 | 7.41e-01 |
Golgi Associated Vesicle Biogenesis | 51 | 4.75e-01 | 5.51e-01 | 0.1590 | -0.054900 | -1.12e-01 | 0.070700 | 6.96e-02 | 4.98e-01 | 1.69e-01 | 3.83e-01 | 3.90e-01 |
Signaling by VEGF | 98 | 1.21e-01 | 1.86e-01 | 0.1590 | 0.014800 | 6.06e-02 | -0.135000 | -5.60e-02 | 8.00e-01 | 3.01e-01 | 2.12e-02 | 3.39e-01 |
Phospholipid metabolism | 173 | 6.42e-02 | 1.12e-01 | 0.1590 | -0.070900 | -3.84e-02 | -0.097000 | -9.65e-02 | 1.09e-01 | 3.85e-01 | 2.81e-02 | 2.90e-02 |
E3 ubiquitin ligases ubiquitinate target proteins | 39 | 2.63e-01 | 3.45e-01 | 0.1590 | 0.080900 | -7.33e-02 | 0.002320 | -1.15e-01 | 3.82e-01 | 4.28e-01 | 9.80e-01 | 2.14e-01 |
Transcriptional regulation of white adipocyte differentiation | 75 | 5.83e-02 | 1.05e-01 | 0.1580 | 0.028100 | -1.39e-02 | 0.049400 | -1.47e-01 | 6.74e-01 | 8.36e-01 | 4.60e-01 | 2.78e-02 |
Immune System | 1518 | 7.59e-15 | 1.36e-13 | 0.1580 | 0.060600 | 9.05e-02 | 0.035100 | 1.09e-01 | 1.26e-04 | 9.91e-09 | 2.61e-02 | 4.60e-12 |
Carboxyterminal post-translational modifications of tubulin | 26 | 6.82e-01 | 7.27e-01 | 0.1570 | -0.085900 | 2.13e-05 | 0.128000 | 2.92e-02 | 4.48e-01 | 1.00e+00 | 2.57e-01 | 7.96e-01 |
Interleukin-1 family signaling | 114 | 1.92e-01 | 2.67e-01 | 0.1570 | 0.002900 | 2.91e-02 | 0.130000 | 8.31e-02 | 9.57e-01 | 5.92e-01 | 1.65e-02 | 1.26e-01 |
Signaling by Insulin receptor | 56 | 4.44e-01 | 5.21e-01 | 0.1560 | -0.045500 | -1.30e-01 | -0.012700 | -7.29e-02 | 5.57e-01 | 9.32e-02 | 8.70e-01 | 3.46e-01 |
Caspase-mediated cleavage of cytoskeletal proteins | 12 | 8.87e-01 | 9.05e-01 | 0.1550 | -0.146000 | -2.48e-02 | 0.007460 | -4.65e-02 | 3.81e-01 | 8.82e-01 | 9.64e-01 | 7.80e-01 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 21 | 6.69e-01 | 7.15e-01 | 0.1550 | 0.038400 | -1.17e-01 | -0.079400 | -5.08e-02 | 7.61e-01 | 3.52e-01 | 5.29e-01 | 6.87e-01 |
Signaling by FGFR | 63 | 1.77e-01 | 2.51e-01 | 0.1550 | -0.008010 | -1.29e-01 | 0.018900 | -8.29e-02 | 9.13e-01 | 7.59e-02 | 7.95e-01 | 2.56e-01 |
Basigin interactions | 20 | 5.81e-01 | 6.41e-01 | 0.1550 | -0.022400 | 1.50e-01 | 0.014000 | -2.98e-02 | 8.62e-01 | 2.47e-01 | 9.14e-01 | 8.18e-01 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 14 | 8.59e-01 | 8.85e-01 | 0.1550 | -0.152000 | -2.39e-02 | -0.011100 | -7.91e-03 | 3.24e-01 | 8.77e-01 | 9.43e-01 | 9.59e-01 |
Signaling by NOTCH3 | 43 | 2.03e-01 | 2.79e-01 | 0.1540 | -0.140000 | 3.29e-02 | -0.047900 | -2.75e-02 | 1.11e-01 | 7.09e-01 | 5.87e-01 | 7.55e-01 |
GPCR downstream signalling | 381 | 1.23e-07 | 6.89e-07 | 0.1540 | -0.064100 | -1.34e-02 | -0.137000 | 2.68e-02 | 3.29e-02 | 6.57e-01 | 4.93e-06 | 3.73e-01 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 27 | 7.89e-01 | 8.26e-01 | 0.1530 | 0.015100 | -1.95e-02 | 0.136000 | 6.62e-02 | 8.92e-01 | 8.61e-01 | 2.22e-01 | 5.52e-01 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 8.98e-01 | 9.14e-01 | 0.1530 | -0.087600 | -9.48e-05 | 0.015500 | -1.24e-01 | 6.32e-01 | 1.00e+00 | 9.32e-01 | 4.97e-01 |
alpha-linolenic acid (ALA) metabolism | 10 | 8.98e-01 | 9.14e-01 | 0.1530 | -0.087600 | -9.48e-05 | 0.015500 | -1.24e-01 | 6.32e-01 | 1.00e+00 | 9.32e-01 | 4.97e-01 |
PI Metabolism | 79 | 3.63e-01 | 4.49e-01 | 0.1510 | 0.043200 | 2.83e-02 | -0.124000 | -6.89e-02 | 5.08e-01 | 6.64e-01 | 5.71e-02 | 2.91e-01 |
TICAM1-dependent activation of IRF3/IRF7 | 10 | 9.34e-01 | 9.46e-01 | 0.1500 | 0.021900 | 6.44e-02 | -0.016200 | -1.32e-01 | 9.04e-01 | 7.24e-01 | 9.29e-01 | 4.69e-01 |
Factors involved in megakaryocyte development and platelet production | 101 | 4.26e-02 | 8.08e-02 | 0.1490 | 0.011700 | 3.96e-02 | 0.016600 | -1.43e-01 | 8.39e-01 | 4.93e-01 | 7.74e-01 | 1.34e-02 |
Gene expression (Transcription) | 1084 | 8.65e-20 | 2.47e-18 | 0.1490 | 0.044100 | 1.16e-03 | 0.021100 | -1.41e-01 | 1.62e-02 | 9.50e-01 | 2.51e-01 | 1.44e-14 |
Peroxisomal protein import | 54 | 6.26e-01 | 6.79e-01 | 0.1490 | 0.125000 | 7.85e-02 | -0.012600 | 1.86e-03 | 1.11e-01 | 3.19e-01 | 8.72e-01 | 9.81e-01 |
Signaling by GPCR | 411 | 3.17e-07 | 1.67e-06 | 0.1480 | -0.080600 | -3.50e-02 | -0.112000 | 4.08e-02 | 5.36e-03 | 2.27e-01 | 1.08e-04 | 1.59e-01 |
Phase I - Functionalization of compounds | 60 | 3.75e-01 | 4.61e-01 | 0.1480 | 0.133000 | 3.65e-02 | 0.050600 | 1.62e-02 | 7.44e-02 | 6.25e-01 | 4.99e-01 | 8.28e-01 |
Death Receptor Signalling | 122 | 3.56e-02 | 6.97e-02 | 0.1480 | -0.043500 | 3.18e-02 | -0.135000 | -2.54e-02 | 4.08e-01 | 5.46e-01 | 1.02e-02 | 6.29e-01 |
B-WICH complex positively regulates rRNA expression | 32 | 5.27e-01 | 5.95e-01 | 0.1470 | 0.099300 | 1.58e-02 | 0.052900 | -9.40e-02 | 3.31e-01 | 8.77e-01 | 6.05e-01 | 3.57e-01 |
RNA Polymerase II Transcription | 968 | 1.32e-16 | 2.51e-15 | 0.1470 | 0.050100 | 6.56e-03 | 0.015800 | -1.37e-01 | 9.52e-03 | 7.34e-01 | 4.13e-01 | 1.34e-12 |
Neddylation | 205 | 5.55e-04 | 1.93e-03 | 0.1460 | 0.112000 | -7.26e-03 | 0.092100 | 4.22e-03 | 5.71e-03 | 8.58e-01 | 2.34e-02 | 9.17e-01 |
HATs acetylate histones | 74 | 1.11e-01 | 1.74e-01 | 0.1450 | -0.004540 | -1.75e-02 | 0.047900 | -1.36e-01 | 9.46e-01 | 7.94e-01 | 4.76e-01 | 4.35e-02 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 30 | 8.37e-01 | 8.67e-01 | 0.1450 | -0.092800 | -9.34e-02 | 0.060900 | 5.49e-03 | 3.79e-01 | 3.76e-01 | 5.64e-01 | 9.58e-01 |
Organelle biogenesis and maintenance | 240 | 1.46e-05 | 6.46e-05 | 0.1450 | 0.021900 | -7.33e-02 | 0.079100 | -9.47e-02 | 5.61e-01 | 5.15e-02 | 3.56e-02 | 1.18e-02 |
Signal transduction by L1 | 21 | 7.32e-01 | 7.73e-01 | 0.1450 | 0.051000 | 1.36e-02 | -0.035600 | 1.30e-01 | 6.86e-01 | 9.14e-01 | 7.78e-01 | 3.02e-01 |
RNA Polymerase I Transcription | 49 | 4.48e-01 | 5.25e-01 | 0.1450 | -0.014000 | -8.92e-03 | 0.143000 | 8.16e-03 | 8.66e-01 | 9.14e-01 | 8.27e-02 | 9.21e-01 |
Activation of HOX genes during differentiation | 54 | 2.29e-01 | 3.09e-01 | 0.1440 | 0.000317 | -6.03e-02 | 0.121000 | -5.00e-02 | 9.97e-01 | 4.44e-01 | 1.23e-01 | 5.25e-01 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 54 | 2.29e-01 | 3.09e-01 | 0.1440 | 0.000317 | -6.03e-02 | 0.121000 | -5.00e-02 | 9.97e-01 | 4.44e-01 | 1.23e-01 | 5.25e-01 |
Protein folding | 84 | 4.13e-01 | 4.96e-01 | 0.1440 | 0.019900 | -6.31e-03 | 0.106000 | 9.58e-02 | 7.53e-01 | 9.21e-01 | 9.46e-02 | 1.30e-01 |
G alpha (s) signalling events | 76 | 1.08e-01 | 1.70e-01 | 0.1440 | -0.030700 | -1.18e-02 | -0.045800 | 1.33e-01 | 6.44e-01 | 8.59e-01 | 4.91e-01 | 4.59e-02 |
p75 NTR receptor-mediated signalling | 84 | 1.46e-01 | 2.18e-01 | 0.1440 | -0.115000 | -2.89e-02 | -0.073600 | 3.57e-02 | 6.94e-02 | 6.48e-01 | 2.44e-01 | 5.73e-01 |
Fatty acid metabolism | 129 | 5.42e-02 | 9.84e-02 | 0.1440 | 0.036700 | 1.30e-01 | -0.049400 | 3.44e-03 | 4.72e-01 | 1.12e-02 | 3.33e-01 | 9.46e-01 |
Regulation of PTEN gene transcription | 58 | 4.74e-01 | 5.50e-01 | 0.1430 | -0.053900 | -8.38e-02 | 0.013500 | -1.02e-01 | 4.78e-01 | 2.70e-01 | 8.59e-01 | 1.79e-01 |
mTORC1-mediated signalling | 23 | 7.98e-01 | 8.34e-01 | 0.1430 | 0.026500 | -3.37e-02 | 0.132000 | 3.62e-02 | 8.26e-01 | 7.79e-01 | 2.74e-01 | 7.64e-01 |
Diseases associated with glycosaminoglycan metabolism | 33 | 5.50e-01 | 6.16e-01 | 0.1430 | -0.125000 | -1.11e-02 | -0.055500 | 4.12e-02 | 2.15e-01 | 9.12e-01 | 5.81e-01 | 6.82e-01 |
RHO GTPases Activate ROCKs | 19 | 6.55e-01 | 7.05e-01 | 0.1430 | -0.064600 | 6.51e-02 | -0.077900 | 7.72e-02 | 6.26e-01 | 6.23e-01 | 5.57e-01 | 5.60e-01 |
Class I MHC mediated antigen processing & presentation | 318 | 1.76e-04 | 6.74e-04 | 0.1430 | 0.119000 | 1.91e-02 | 0.069000 | 3.11e-02 | 2.72e-04 | 5.61e-01 | 3.53e-02 | 3.42e-01 |
RAS processing | 19 | 7.19e-01 | 7.60e-01 | 0.1420 | 0.089000 | -1.67e-02 | 0.096800 | -5.15e-02 | 5.02e-01 | 9.00e-01 | 4.65e-01 | 6.98e-01 |
Generic Transcription Pathway | 854 | 1.98e-13 | 2.99e-12 | 0.1410 | 0.050600 | 7.17e-03 | 0.012300 | -1.31e-01 | 1.34e-02 | 7.26e-01 | 5.48e-01 | 1.34e-10 |
TP53 Regulates Metabolic Genes | 82 | 3.33e-01 | 4.17e-01 | 0.1390 | -0.071200 | -7.41e-02 | 0.021200 | -9.10e-02 | 2.66e-01 | 2.47e-01 | 7.41e-01 | 1.55e-01 |
PINK1-PRKN Mediated Mitophagy | 18 | 8.78e-01 | 8.99e-01 | 0.1390 | -0.061800 | -7.74e-02 | 0.090900 | -3.47e-02 | 6.50e-01 | 5.70e-01 | 5.05e-01 | 7.99e-01 |
Formation of Incision Complex in GG-NER | 40 | 4.42e-01 | 5.19e-01 | 0.1380 | 0.109000 | -9.39e-03 | 0.083900 | -7.94e-03 | 2.32e-01 | 9.18e-01 | 3.59e-01 | 9.31e-01 |
SUMOylation of immune response proteins | 11 | 9.80e-01 | 9.84e-01 | 0.1380 | -0.020300 | -1.68e-02 | -0.085500 | -1.05e-01 | 9.07e-01 | 9.23e-01 | 6.24e-01 | 5.47e-01 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 16 | 8.66e-01 | 8.90e-01 | 0.1380 | 0.066800 | -3.39e-02 | 0.053800 | 1.02e-01 | 6.44e-01 | 8.14e-01 | 7.10e-01 | 4.79e-01 |
Amyloid fiber formation | 35 | 8.71e-01 | 8.94e-01 | 0.1370 | 0.029800 | 5.69e-02 | 0.089700 | 8.15e-02 | 7.60e-01 | 5.60e-01 | 3.58e-01 | 4.04e-01 |
RNA Polymerase I Transcription Initiation | 45 | 6.34e-01 | 6.86e-01 | 0.1360 | -0.024400 | -3.22e-02 | 0.126000 | 2.79e-02 | 7.77e-01 | 7.08e-01 | 1.43e-01 | 7.46e-01 |
Vitamin B5 (pantothenate) metabolism | 15 | 9.13e-01 | 9.28e-01 | 0.1360 | 0.097500 | 5.84e-03 | -0.087400 | -3.45e-02 | 5.13e-01 | 9.69e-01 | 5.58e-01 | 8.17e-01 |
Acyl chain remodelling of PG | 11 | 8.85e-01 | 9.04e-01 | 0.1340 | -0.106000 | 3.80e-02 | -0.071900 | -9.26e-03 | 5.42e-01 | 8.27e-01 | 6.80e-01 | 9.58e-01 |
O-linked glycosylation | 66 | 3.61e-01 | 4.48e-01 | 0.1330 | -0.095500 | -4.36e-02 | -0.052100 | 6.38e-02 | 1.80e-01 | 5.40e-01 | 4.65e-01 | 3.70e-01 |
Signaling by Receptor Tyrosine Kinases | 412 | 9.58e-04 | 3.20e-03 | 0.1320 | -0.080600 | -7.22e-02 | -0.075300 | 1.24e-02 | 5.29e-03 | 1.25e-02 | 9.21e-03 | 6.68e-01 |
Metabolism of proteins | 1541 | 9.03e-18 | 2.11e-16 | 0.1320 | 0.051400 | -1.91e-02 | 0.114000 | 3.57e-02 | 1.05e-03 | 2.23e-01 | 2.83e-13 | 2.30e-02 |
NR1H2 and NR1H3-mediated signaling | 37 | 6.85e-01 | 7.29e-01 | 0.1320 | -0.125000 | -2.81e-02 | -0.028600 | -1.31e-03 | 1.87e-01 | 7.68e-01 | 7.64e-01 | 9.89e-01 |
G alpha (i) signalling events | 196 | 2.76e-03 | 8.40e-03 | 0.1300 | -0.038900 | -2.26e-02 | -0.107000 | 5.98e-02 | 3.50e-01 | 5.86e-01 | 1.02e-02 | 1.50e-01 |
Amino acids regulate mTORC1 | 48 | 7.36e-01 | 7.77e-01 | 0.1290 | -0.067100 | -7.73e-02 | 0.029600 | 7.35e-02 | 4.22e-01 | 3.55e-01 | 7.23e-01 | 3.79e-01 |
Signaling by Rho GTPases | 337 | 8.17e-04 | 2.78e-03 | 0.1290 | 0.033500 | 6.77e-02 | -0.015500 | -1.04e-01 | 2.93e-01 | 3.37e-02 | 6.26e-01 | 1.16e-03 |
Toll Like Receptor 4 (TLR4) Cascade | 116 | 3.01e-01 | 3.83e-01 | 0.1290 | -0.056300 | -7.46e-02 | -0.088200 | -8.44e-03 | 2.96e-01 | 1.66e-01 | 1.01e-01 | 8.75e-01 |
Transcriptional regulation by RUNX1 | 154 | 4.46e-02 | 8.39e-02 | 0.1280 | 0.052700 | 5.07e-02 | 0.099600 | -3.47e-02 | 2.60e-01 | 2.79e-01 | 3.33e-02 | 4.59e-01 |
O-linked glycosylation of mucins | 31 | 8.62e-01 | 8.87e-01 | 0.1250 | -0.043000 | -6.11e-02 | 0.044700 | 9.01e-02 | 6.79e-01 | 5.56e-01 | 6.67e-01 | 3.86e-01 |
Association of TriC/CCT with target proteins during biosynthesis | 36 | 5.99e-01 | 6.56e-01 | 0.1250 | 0.072900 | -2.13e-02 | 0.099500 | -3.18e-03 | 4.50e-01 | 8.25e-01 | 3.02e-01 | 9.74e-01 |
Post-translational modification: synthesis of GPI-anchored proteins | 54 | 5.62e-01 | 6.27e-01 | 0.1250 | -0.040500 | -3.86e-02 | 0.004400 | 1.12e-01 | 6.07e-01 | 6.24e-01 | 9.55e-01 | 1.57e-01 |
SLC-mediated transmembrane transport | 150 | 1.56e-01 | 2.30e-01 | 0.1240 | 0.017700 | 2.37e-02 | -0.115000 | -3.48e-02 | 7.09e-01 | 6.17e-01 | 1.51e-02 | 4.63e-01 |
tRNA processing | 106 | 6.04e-02 | 1.07e-01 | 0.1240 | -0.002160 | 3.49e-03 | 0.088500 | -8.66e-02 | 9.69e-01 | 9.51e-01 | 1.16e-01 | 1.24e-01 |
Activation of BH3-only proteins | 27 | 9.06e-01 | 9.21e-01 | 0.1240 | 0.073900 | 7.77e-02 | -0.009540 | -6.10e-02 | 5.06e-01 | 4.85e-01 | 9.32e-01 | 5.84e-01 |
Signaling by Interleukins | 347 | 1.47e-02 | 3.44e-02 | 0.1230 | 0.059400 | 6.15e-02 | 0.010300 | 8.74e-02 | 5.87e-02 | 5.04e-02 | 7.42e-01 | 5.43e-03 |
Acyl chain remodelling of PS | 14 | 8.72e-01 | 8.94e-01 | 0.1220 | 0.018300 | -3.14e-02 | -0.077000 | 8.78e-02 | 9.06e-01 | 8.39e-01 | 6.18e-01 | 5.69e-01 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 32 | 6.30e-01 | 6.82e-01 | 0.1210 | 0.071600 | -1.31e-02 | -0.032200 | 9.10e-02 | 4.84e-01 | 8.98e-01 | 7.53e-01 | 3.73e-01 |
Metabolism of water-soluble vitamins and cofactors | 101 | 5.28e-01 | 5.95e-01 | 0.1210 | -0.081100 | -7.96e-02 | 0.040000 | -2.49e-03 | 1.60e-01 | 1.67e-01 | 4.88e-01 | 9.66e-01 |
Hemostasis | 444 | 5.08e-07 | 2.64e-06 | 0.1200 | -0.017600 | 7.06e-02 | -0.065000 | 7.07e-02 | 5.28e-01 | 1.14e-02 | 1.98e-02 | 1.13e-02 |
Vesicle-mediated transport | 557 | 3.60e-04 | 1.30e-03 | 0.1190 | -0.047800 | -9.89e-02 | 0.036600 | 2.60e-02 | 5.61e-02 | 7.67e-05 | 1.44e-01 | 2.99e-01 |
Antigen processing: Ubiquitination & Proteasome degradation | 268 | 6.55e-04 | 2.26e-03 | 0.1180 | 0.098500 | -9.58e-03 | 0.054100 | -3.40e-02 | 5.74e-03 | 7.88e-01 | 1.29e-01 | 3.41e-01 |
Membrane Trafficking | 528 | 2.38e-04 | 8.85e-04 | 0.1170 | -0.039000 | -1.05e-01 | 0.032400 | 1.37e-02 | 1.29e-01 | 4.49e-05 | 2.07e-01 | 5.93e-01 |
Rab regulation of trafficking | 113 | 3.08e-01 | 3.90e-01 | 0.1170 | -0.020100 | -9.18e-02 | -0.008320 | -6.85e-02 | 7.13e-01 | 9.23e-02 | 8.79e-01 | 2.09e-01 |
Signaling by WNT | 221 | 6.54e-02 | 1.14e-01 | 0.1150 | -0.066700 | -6.51e-02 | 0.056900 | -3.63e-02 | 8.86e-02 | 9.65e-02 | 1.46e-01 | 3.54e-01 |
Axon guidance | 426 | 5.62e-03 | 1.56e-02 | 0.1130 | 0.016200 | 7.33e-02 | 0.024400 | 8.12e-02 | 5.68e-01 | 1.00e-02 | 3.92e-01 | 4.32e-03 |
Cytochrome P450 - arranged by substrate type | 30 | 8.07e-01 | 8.39e-01 | 0.1130 | 0.038300 | 2.86e-02 | -0.029900 | 9.78e-02 | 7.16e-01 | 7.87e-01 | 7.77e-01 | 3.54e-01 |
Recycling pathway of L1 | 27 | 8.46e-01 | 8.73e-01 | 0.1130 | -0.035000 | -3.45e-02 | 0.027900 | -9.74e-02 | 7.53e-01 | 7.56e-01 | 8.02e-01 | 3.81e-01 |
Adenylate cyclase inhibitory pathway | 12 | 9.25e-01 | 9.39e-01 | 0.1120 | 0.014300 | -1.05e-01 | -0.008840 | 3.52e-02 | 9.32e-01 | 5.28e-01 | 9.58e-01 | 8.33e-01 |
ESR-mediated signaling | 140 | 4.08e-01 | 4.92e-01 | 0.1120 | -0.021100 | -3.83e-02 | -0.040600 | -9.49e-02 | 6.67e-01 | 4.35e-01 | 4.08e-01 | 5.32e-02 |
Extra-nuclear estrogen signaling | 63 | 6.58e-01 | 7.05e-01 | 0.1110 | 0.032000 | 3.12e-02 | -0.100000 | -1.69e-02 | 6.60e-01 | 6.69e-01 | 1.69e-01 | 8.16e-01 |
Epigenetic regulation of gene expression | 84 | 3.34e-01 | 4.18e-01 | 0.1090 | 0.060100 | 1.20e-02 | 0.034900 | -8.34e-02 | 3.42e-01 | 8.50e-01 | 5.81e-01 | 1.87e-01 |
Metabolism of vitamins and cofactors | 148 | 4.37e-01 | 5.15e-01 | 0.1090 | -0.069800 | -6.06e-02 | 0.047800 | 3.15e-02 | 1.43e-01 | 2.04e-01 | 3.17e-01 | 5.09e-01 |
Signaling by NOTCH | 159 | 4.60e-02 | 8.62e-02 | 0.1080 | -0.042700 | 3.82e-02 | 0.091300 | -1.21e-02 | 3.54e-01 | 4.07e-01 | 4.76e-02 | 7.93e-01 |
ERK/MAPK targets | 22 | 7.95e-01 | 8.31e-01 | 0.1070 | 0.042900 | -8.17e-02 | 0.035500 | -4.06e-02 | 7.28e-01 | 5.07e-01 | 7.73e-01 | 7.42e-01 |
Constitutive Signaling by Aberrant PI3K in Cancer | 53 | 5.09e-01 | 5.82e-01 | 0.1070 | -0.019200 | 7.65e-03 | -0.085000 | 6.13e-02 | 8.09e-01 | 9.23e-01 | 2.85e-01 | 4.41e-01 |
Chaperonin-mediated protein folding | 78 | 6.30e-01 | 6.82e-01 | 0.1050 | 0.037400 | -1.46e-02 | 0.071700 | 6.59e-02 | 5.68e-01 | 8.24e-01 | 2.74e-01 | 3.15e-01 |
PI3K/AKT Signaling in Cancer | 79 | 7.81e-01 | 8.20e-01 | 0.1050 | -0.016100 | -4.84e-02 | -0.069200 | -6.04e-02 | 8.05e-01 | 4.57e-01 | 2.88e-01 | 3.54e-01 |
Cytokine Signaling in Immune system | 647 | 3.82e-03 | 1.11e-02 | 0.1050 | 0.048100 | 6.46e-02 | 0.008360 | 6.67e-02 | 3.92e-02 | 5.58e-03 | 7.20e-01 | 4.22e-03 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 165 | 1.81e-01 | 2.56e-01 | 0.1040 | -0.011900 | -7.44e-02 | 0.058100 | 4.18e-02 | 7.93e-01 | 1.00e-01 | 1.99e-01 | 3.55e-01 |
Downregulation of ERBB2:ERBB3 signaling | 11 | 9.95e-01 | 9.96e-01 | 0.1030 | -0.060200 | -7.63e-02 | -0.024100 | -2.24e-02 | 7.30e-01 | 6.62e-01 | 8.90e-01 | 8.98e-01 |
Transport of small molecules | 477 | 2.29e-02 | 4.93e-02 | 0.1020 | -0.042300 | -5.41e-02 | 0.053400 | 5.41e-02 | 1.17e-01 | 4.47e-02 | 4.76e-02 | 4.48e-02 |
Diseases of signal transduction by growth factor receptors and second messengers | 330 | 1.45e-01 | 2.18e-01 | 0.1020 | -0.047200 | -7.26e-02 | -0.017400 | -5.19e-02 | 1.43e-01 | 2.43e-02 | 5.90e-01 | 1.07e-01 |
Signaling by ERBB4 | 43 | 8.06e-01 | 8.39e-01 | 0.1020 | -0.034300 | -7.82e-02 | -0.047600 | 2.96e-02 | 6.98e-01 | 3.75e-01 | 5.89e-01 | 7.37e-01 |
Intracellular signaling by second messengers | 269 | 3.52e-02 | 6.93e-02 | 0.1010 | -0.029100 | -5.88e-02 | 0.034500 | -6.88e-02 | 4.14e-01 | 9.83e-02 | 3.33e-01 | 5.32e-02 |
PIP3 activates AKT signaling | 232 | 1.85e-02 | 4.16e-02 | 0.0995 | -0.000397 | -2.54e-02 | 0.083200 | -4.83e-02 | 9.92e-01 | 5.07e-01 | 2.97e-02 | 2.07e-01 |
Metabolic disorders of biological oxidation enzymes | 19 | 9.69e-01 | 9.77e-01 | 0.0995 | -0.027100 | -9.01e-02 | -0.013500 | -2.91e-02 | 8.38e-01 | 4.97e-01 | 9.19e-01 | 8.26e-01 |
Signal Transduction | 1705 | 9.55e-06 | 4.32e-05 | 0.0960 | -0.053500 | -3.53e-02 | -0.062500 | -3.48e-02 | 3.73e-04 | 1.90e-02 | 3.19e-05 | 2.08e-02 |
L1CAM interactions | 84 | 6.10e-01 | 6.65e-01 | 0.0957 | -0.065400 | -2.13e-02 | -0.066400 | 5.58e-03 | 3.01e-01 | 7.36e-01 | 2.94e-01 | 9.30e-01 |
Metabolism of cofactors | 18 | 9.30e-01 | 9.43e-01 | 0.0940 | 0.007290 | -8.38e-02 | 0.010400 | 4.06e-02 | 9.57e-01 | 5.38e-01 | 9.39e-01 | 7.65e-01 |
Metabolism of lipids | 566 | 3.55e-02 | 6.97e-02 | 0.0937 | -0.028900 | -1.09e-02 | -0.067700 | -5.69e-02 | 2.44e-01 | 6.59e-01 | 6.39e-03 | 2.19e-02 |
Toll-like Receptor Cascades | 132 | 3.23e-01 | 4.06e-01 | 0.0925 | -0.031600 | -5.67e-02 | -0.043000 | 5.00e-02 | 5.32e-01 | 2.61e-01 | 3.94e-01 | 3.23e-01 |
Cytosolic sensors of pathogen-associated DNA | 57 | 5.65e-01 | 6.28e-01 | 0.0924 | -0.034000 | 7.72e-02 | 0.033500 | 1.70e-02 | 6.57e-01 | 3.14e-01 | 6.62e-01 | 8.24e-01 |
Metabolism | 1569 | 5.59e-08 | 3.32e-07 | 0.0902 | 0.024400 | 1.89e-02 | 0.084700 | 3.50e-04 | 1.17e-01 | 2.25e-01 | 5.18e-08 | 9.82e-01 |
Signaling by Nuclear Receptors | 195 | 4.67e-01 | 5.43e-01 | 0.0884 | 0.000120 | -9.06e-03 | -0.039600 | -7.85e-02 | 9.98e-01 | 8.28e-01 | 3.42e-01 | 5.97e-02 |
tRNA modification in the nucleus and cytosol | 38 | 9.34e-01 | 9.46e-01 | 0.0877 | 0.015700 | 4.03e-02 | 0.012200 | 7.54e-02 | 8.67e-01 | 6.67e-01 | 8.97e-01 | 4.22e-01 |
Clathrin-mediated endocytosis | 122 | 4.82e-01 | 5.56e-01 | 0.0869 | -0.014100 | -7.00e-02 | 0.048600 | 1.02e-02 | 7.89e-01 | 1.83e-01 | 3.55e-01 | 8.46e-01 |
VEGFR2 mediated vascular permeability | 27 | 9.27e-01 | 9.41e-01 | 0.0862 | -0.001510 | -7.88e-02 | 0.004130 | -3.48e-02 | 9.89e-01 | 4.79e-01 | 9.70e-01 | 7.55e-01 |
Nervous system development | 444 | 3.22e-02 | 6.49e-02 | 0.0846 | 0.003590 | 5.68e-02 | 0.008110 | 6.21e-02 | 8.98e-01 | 4.16e-02 | 7.71e-01 | 2.61e-02 |
Disease | 1107 | 2.10e-03 | 6.56e-03 | 0.0802 | 0.007730 | -7.40e-04 | 0.073000 | 3.23e-02 | 6.71e-01 | 9.68e-01 | 5.88e-05 | 7.53e-02 |
RNA Polymerase III Abortive And Retractive Initiation | 41 | 9.75e-01 | 9.81e-01 | 0.0783 | 0.021300 | 3.49e-02 | 0.054200 | 3.91e-02 | 8.14e-01 | 6.99e-01 | 5.48e-01 | 6.65e-01 |
RNA Polymerase III Transcription | 41 | 9.75e-01 | 9.81e-01 | 0.0783 | 0.021300 | 3.49e-02 | 0.054200 | 3.91e-02 | 8.14e-01 | 6.99e-01 | 5.48e-01 | 6.65e-01 |
Post-translational protein modification | 1100 | 5.24e-08 | 3.13e-07 | 0.0768 | 0.038200 | -4.36e-02 | 0.041600 | -2.84e-02 | 3.61e-02 | 1.67e-02 | 2.23e-02 | 1.19e-01 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 16 | 9.63e-01 | 9.73e-01 | 0.0768 | 0.061500 | -2.10e-02 | -0.007720 | 4.02e-02 | 6.70e-01 | 8.85e-01 | 9.57e-01 | 7.81e-01 |
RAB GEFs exchange GTP for GDP on RABs | 83 | 7.05e-01 | 7.48e-01 | 0.0751 | 0.016400 | -5.97e-02 | -0.021000 | -3.69e-02 | 7.97e-01 | 3.48e-01 | 7.41e-01 | 5.62e-01 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 28 | 9.82e-01 | 9.86e-01 | 0.0741 | -0.009120 | 2.60e-02 | 0.032300 | 6.08e-02 | 9.33e-01 | 8.12e-01 | 7.68e-01 | 5.78e-01 |
Signaling by Non-Receptor Tyrosine Kinases | 48 | 9.69e-01 | 9.77e-01 | 0.0623 | -0.045400 | -3.00e-02 | -0.013900 | 2.69e-02 | 5.86e-01 | 7.19e-01 | 8.68e-01 | 7.47e-01 |
Signaling by PTK6 | 48 | 9.69e-01 | 9.77e-01 | 0.0623 | -0.045400 | -3.00e-02 | -0.013900 | 2.69e-02 | 5.86e-01 | 7.19e-01 | 8.68e-01 | 7.47e-01 |
RNA Polymerase III Transcription Initiation | 36 | 9.87e-01 | 9.90e-01 | 0.0620 | -0.011400 | 3.12e-03 | 0.053500 | 2.89e-02 | 9.06e-01 | 9.74e-01 | 5.79e-01 | 7.64e-01 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 80 | 9.56e-01 | 9.67e-01 | 0.0561 | -0.027700 | -4.38e-02 | 0.002630 | 2.12e-02 | 6.68e-01 | 4.99e-01 | 9.68e-01 | 7.43e-01 |
MAPK family signaling cascades | 261 | 8.77e-01 | 8.98e-01 | 0.0444 | -0.035500 | -1.64e-02 | -0.013900 | -1.60e-02 | 3.26e-01 | 6.51e-01 | 7.00e-01 | 6.58e-01 |
Negative regulation of the PI3K/AKT network | 87 | 9.92e-01 | 9.94e-01 | 0.0326 | -0.009560 | -2.97e-02 | -0.007010 | -6.62e-03 | 8.78e-01 | 6.33e-01 | 9.10e-01 | 9.15e-01 |
FLT3 Signaling | 237 | 9.78e-01 | 9.84e-01 | 0.0309 | -0.024800 | -1.77e-02 | -0.000691 | -4.97e-03 | 5.12e-01 | 6.41e-01 | 9.85e-01 | 8.96e-01 |
Developmental Biology | 665 | 8.15e-01 | 8.46e-01 | 0.0293 | -0.003530 | 1.45e-02 | 0.012900 | 2.16e-02 | 8.78e-01 | 5.27e-01 | 5.74e-01 | 3.48e-01 |
RAF/MAP kinase cascade | 223 | 9.93e-01 | 9.95e-01 | 0.0166 | -0.014400 | -8.62e-04 | 0.001380 | 8.14e-03 | 7.13e-01 | 9.82e-01 | 9.72e-01 | 8.35e-01 |
MAPK1/MAPK3 signaling | 228 | 9.96e-01 | 9.96e-01 | 0.0131 | -0.009940 | 2.14e-03 | 0.000839 | 8.28e-03 | 7.97e-01 | 9.56e-01 | 9.83e-01 | 8.30e-01 |
Classical antibody-mediated complement activation
metric | value |
---|---|
setSize | 10 |
pMANOVA | 6.32e-09 |
p.adjustMANOVA | 4.74e-08 |
s.dist | 1.5 |
s.heart_ctrl_vs_acetate | 0.256 |
s.heart_ctrl_vs_hifibre | 0.684 |
s.spleen_ctrl_vs_acetate | 0.896 |
s.spleen_ctrl_vs_hifibre | 0.948 |
p.heart_ctrl_vs_acetate | 0.161 |
p.heart_ctrl_vs_hifibre | 0.000178 |
p.spleen_ctrl_vs_acetate | 9.16e-07 |
p.spleen_ctrl_vs_hifibre | 2.05e-07 |
Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
---|---|---|
C1QA | 5529.0 | 6718.0 |
IGHG1 | 5439.5 | 6828.5 |
IGHG2 | 5439.5 | 6828.5 |
IGHG3 | 5439.5 | 6828.5 |
IGHG4 | 5439.5 | 6828.5 |
C1QB | 5474.0 | 6768.0 |
C1QC | 5471.0 | 6725.0 |
IGKC | 5401.0 | 6413.0 |
C1R | 5561.0 | 4906.0 |
C1S | 5522.0 | 2996.0 |
heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
---|---|---|---|---|
C1QA | 5552.0 | 6352.0 | 6718.0 | 5529.0 |
C1QB | 2397.0 | 5852.0 | 6768.0 | 5474.0 |
C1QC | 1827.0 | 5700.0 | 6725.0 | 5471.0 |
C1R | -599.0 | 5446.0 | 4906.0 | 5561.0 |
C1S | -3242.0 | -911.0 | 2996.0 | 5522.0 |
IGHG1 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG2 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG3 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG4 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGKC | 5754.0 | 3132.0 | 6413.0 | 5401.0 |
Unwinding of DNA
metric | value |
---|---|
setSize | 12 |
pMANOVA | 1.21e-13 |
p.adjustMANOVA | 1.89e-12 |
s.dist | 1.34 |
s.heart_ctrl_vs_acetate | 0.705 |
s.heart_ctrl_vs_hifibre | 0.705 |
s.spleen_ctrl_vs_acetate | 0.864 |
s.spleen_ctrl_vs_hifibre | -0.231 |
p.heart_ctrl_vs_acetate | 2.32e-05 |
p.heart_ctrl_vs_hifibre | 2.32e-05 |
p.spleen_ctrl_vs_acetate | 2.19e-07 |
p.spleen_ctrl_vs_hifibre | 0.166 |
Gene | spleen_ctrl_vs_acetate | heart_ctrl_vs_acetate |
---|---|---|
MCM6 | 5952 | 6208 |
CDC45 | 6388 | 5622 |
MCM5 | 6405 | 5469 |
MCM4 | 5931 | 5542 |
GINS4 | 5503 | 5839 |
MCM7 | 6212 | 4960 |
GINS1 | 5387 | 5291 |
MCM2 | 6383 | 4410 |
MCM3 | 6061 | 3878 |
GINS2 | 6307 | 3700 |
MCM8 | 6611 | 2589 |
GINS3 | 4591 | 1957 |
heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
---|---|---|---|---|
CDC45 | 5622 | 2870 | 6388 | -751 |
GINS1 | 5291 | 5451 | 5387 | -3714 |
GINS2 | 3700 | 4767 | 6307 | -3352 |
GINS3 | 1957 | 415 | 4591 | -2614 |
GINS4 | 5839 | 3985 | 5503 | -1900 |
MCM2 | 4410 | 5869 | 6383 | -3749 |
MCM3 | 3878 | 5525 | 6061 | -2721 |
MCM4 | 5542 | 6361 | 5931 | -3055 |
MCM5 | 5469 | 6300 | 6405 | -2703 |
MCM6 | 6208 | 6082 | 5952 | -1760 |
MCM7 | 4960 | 5693 | 6212 | -2230 |
MCM8 | 2589 | 2131 | 6611 | 4651 |
Creation of C4 and C2 activators
metric | value |
---|---|
setSize | 11 |
pMANOVA | 7.68e-08 |
p.adjustMANOVA | 4.5e-07 |
s.dist | 1.32 |
s.heart_ctrl_vs_acetate | 0.265 |
s.heart_ctrl_vs_hifibre | 0.71 |
s.spleen_ctrl_vs_acetate | 0.742 |
s.spleen_ctrl_vs_hifibre | 0.794 |
p.heart_ctrl_vs_acetate | 0.128 |
p.heart_ctrl_vs_hifibre | 4.55e-05 |
p.spleen_ctrl_vs_acetate | 2.02e-05 |
p.spleen_ctrl_vs_hifibre | 5.13e-06 |
Gene | spleen_ctrl_vs_hifibre | spleen_ctrl_vs_acetate |
---|---|---|
C1QA | 5529.0 | 6718.0 |
IGHG1 | 5439.5 | 6828.5 |
IGHG2 | 5439.5 | 6828.5 |
IGHG3 | 5439.5 | 6828.5 |
IGHG4 | 5439.5 | 6828.5 |
C1QB | 5474.0 | 6768.0 |
C1QC | 5471.0 | 6725.0 |
IGKC | 5401.0 | 6413.0 |
C1R | 5561.0 | 4906.0 |
C1S | 5522.0 | 2996.0 |
heart_ctrl_vs_acetate | heart_ctrl_vs_hifibre | spleen_ctrl_vs_acetate | spleen_ctrl_vs_hifibre | |
---|---|---|---|---|
C1QA | 5552.0 | 6352.0 | 6718.0 | 5529.0 |
C1QB | 2397.0 | 5852.0 | 6768.0 | 5474.0 |
C1QC | 1827.0 | 5700.0 | 6725.0 | 5471.0 |
C1R | -599.0 | 5446.0 | 4906.0 | 5561.0 |
C1S | -3242.0 | -911.0 | 2996.0 | 5522.0 |
COLEC11 | 2402.0 | 6262.0 | -4551.0 | -5290.0 |
IGHG1 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG2 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG3 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGHG4 | 1522.5 | 4829.5 | 6828.5 | 5439.5 |
IGKC | 5754.0 | 3132.0 | 6413.0 | 5401.0 |
Initial triggering of complement
metric | value |
---|---|
setSize | 18 |
pMANOVA | 3.07e-11 |
p.adjustMANOVA | 3.35e-10 |
s.dist | 1.27 |
s.heart_ctrl_vs_acetate | 0.349 |
s.heart_ctrl_vs_hifibre | 0.692 |
s.spleen_ctrl_vs_acetate | 0.673 |
s.spleen_ctrl_vs_hifibre | 0.747 |
p.heart_ctrl_vs_acetate | 0.0103 |
p.heart_ctrl_vs_hifibre | 3.71e-07 |
p.spleen_ctrl_vs_acetate | 7.58e-07 |
p.spleen_ctrl_vs_hifibre | 4.01e-08 |